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Defining and controlling the subtype identity of human stem cell-derived motor neurons 
Gist F. Croft 
One cardinal promise of stem cell research is that many intractable, common, and poorly 
understood diseases may be studied in an entirely new way: in vitro in the specific human cell 
types affected in vivo.  Embryonic stem (ES) cells have the pluripotency to generate all somatic 
cells types, and the invention of somatic cell reprogramming techniques has allowed the creation 
of cell lines with both ES-cell grade pluripotency—induced pluripotent stem (iPS) cells—and the 
genetic determinants of diseases.  If iPS cells derived from patients with genetic disease are to 
enable studying the affected human cell types in vitro then it is necessary to: first, precisely 
define the appropriate cellular phenotypes in vivo; second, selectively generate those cell types 
in vitro; and third, demonstrate that iPS cells retain similarly predictable and tractable cellular 
potential as ES cells.  In the motor neuron degenerative disease Amyotrophic Lateral Sclerosis 
(ALS) spinal motor neurons innervating different types of muscles and individual muscle groups 
show selective vulnerability or resistance to disease.  We therefore set out to define the subtypes 
of human motor neurons in vivo and to generate these in vitro.  Here we report that human motor 
neurons in vivo share with mouse the molecular markers of motor neuron column, division, and 
pool organization, as well as positional expression of HOX proteins which regulate this diversity 
in chick and mouse.  We then used combinations of these markers to classify motor neuron 
subtypes derived from human ES cells in vitro under standard differentiation conditions.  These 
human ES cell-derived motor neurons expressed marker combinations appropriate to each motor 
 
 
column, but were strongly biased to cervical phenotypes.  In order to access a greater diversity of 
motor neuron subtypes, including some with differential responses to ALS in vivo, we defined a 
developmental strategy to generate more caudal ES-cell derived motor neurons.  We show that 
FGF treatment, in a patterning window we defined, generated human ES-cell derived motor 
neurons with more caudal (brachial, thoracic, and lumbar) phenotypes.  We then participated in a 
long term collaboration to generate iPS cell lines from donors with ALS-genotypes (familial 
ALS), and no clinical motor dysfunction (controls).  We first showed that ALS and control iPS 
cells from patients of advanced age could generate motor neurons in vitro (Dimos, Rodolfa et al. 
2008).  To address questions about the variability of iPS cells, and their comparability to ES cells 
for making defined neuronal subtypes, we generated a panel of iPS lines from donors of varying 
demography, thoroughly characterized these cells by standard assays for pluripotent cells, and 
assessed their ability to generate functional motor neurons in comparison to a panel of ES cell 
lines.  We showed that iPS cells were equivalent to ES cells, and that human genetic diversity 
may influence the efficiency of motor neuron generation (Boulting, Kiskinis et al. 2011).  Next, 
we used these lines to show that iPS cells could generate the same diversity of motor neurons in 
vitro, and that the rostrocaudal output of this diversity was rationally manipulable.  Finally, since 
ALS is an adult onset disease, we anticipated that if ES and iPS cell-derived motor neurons could 
reach significant landmarks of functional maturation in vitro, then the chances of manifesting 
disease phenotypes would be increased.  Therefore we developed methods for long term cultures 
in which ES and iPS cell-derived motor neurons showed progressive molecular, morphological, 
and electrophysiological maturation.  Together these results enable future studies to ask if ALS-
patient iPS cell-derived motor neurons will show pan-motor neuron or subtype-specific ALS 
 
 
phenotypes in vitro.  In turn these which may help elucidate mechanisms of disease resistance 
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Chapter 1. General Introduction 
 
Part I. INTRODUCTION 
The function of the central nervous system is predicated on the specific connectivity of billions 
of distinct neuronal subtypes that form trillions of plastic synapses.  At the founding of the 
modern discipline of neuroscience Ramon y Cajal described thousands of these distinct neuronal 
types by their morphologies (Fig. 1.1).  Thus even at the beginning Cajal‘s studies clearly 
articulated two fundamental questions for understanding brain function, although this was highly 
controversial at the time.  First, distinctive morphologies suggested distinct neuronal subtypes.  
Second, the axonal and dendritic morphologies that distinguished neuronal subtypes, as Cajal 
argued, were themselves the myriad specific connections formed from one neuron to another.  As 
molecular and genetic methods have replaced silver staining and camera lucida our appreciation 
for neuronal diversity and our knowledge of the circuits formed by specific connections between 
them have expanded like the Purkinje cell arbors Cajal depicted.  From a reductionist standpoint 
however his basic questions remain:  What are the different neuronal actors and what makes 
them distinct?  And how do they connect to each other in functional circuits to produce 
behavior? 
Because of its concrete behavioral output, the motor system has been an attractive target for 
studies seeking to define specific neuronal subtypes and the logic and development of functional 
circuit connections between them.  We now understand a great deal about the hierarchy of motor 
neuron subtypes at the molecular, genetic, and circuit levels.  A distinct group of motor neurons 




contractions of each of several hundred skeletal muscles. Motor pools in turn are organized in 
rostrocaudal columns, termed motor columns, according to the type of target muscle they 
innervate (Fig. 1.2).  During development motor columns and their constituent motor pools are 
generated in rostrocaudal register with their target muscle by pattering factors and genes which 
articulate the rostrocaudal body plan of the embryo.  
The result is that individual motor neurons possess distinct transcriptional identities, accumulated 
from rostrocaudal and columnar identities, and finally specific to the individual motor pools to 
which they belong.  Functional identities are downstream of these transcriptional identities.  For 
example, the axons of a leg muscle innervating motor neurons must make a series of directional 
choices in order to arrive successfully at the muscle that they are destined to control.  Centrally 
they must also choose to participate in forming hundreds or thousands of specific synapses with 
sensory afferents, descending cortical inputs and local interneurons, and spinal central pattern 
generators in order to mediate motor behavior.   
The human motor system conforms to of the same basic functional and anatomic categories that 
have been described in vertebrate model systems.  However, almost all of the genetic and 
molecular information about of the development of the motor system and motor neuron subtypes 
is based on studies in animal models, since human motor neurons were available only in 
postmortem samples.  This scarcity, and the lack of living motor neurons for experimental 
studies, was compounded by the diversity of motor neuron subtypes and pools requiring study.  
With the establishment of human embryonic stem (ES) cells as a research tool, and the 
demonstration that they could be directed to differentiate into spinal motor neurons, this 




directly, and attempt to understand the development and function of human motor neuron 
subtypes. 
Spinal motor neurons are of intellectual interest, but they are also the target of several diseases.  
The motor neuron disease Amyotrophic Lateral Sclerosis (ALS) becomes symptomatic as the 
spinal motor neurons which innervate muscles die, leading to progressive paralysis and 
ultimately death.  The mechanisms of motor neuron-selective degeneration are not well 
understood and there are no effective therapies.  The derivation of induced pluripotent stem (iPS) 
cells from ALS-patients brings together the genotypes which determine familial forms of the 
disease with the pluripotency to generate the affected cells in vitro.  However, reproducing 
degenerative cellular phenotypes in vitro will be a major challenge using ES/iPS-derived cells.  
While ALS is not believed to have a developmental component, developmental biology could 
provide leverage on this problem in two ways.  First, motor neurons show differential 
susceptibility depending on their motor column or motor pool subtypes, therefore these subtypes 
may offer novel and specific ways to understand the mechanisms of motor neuron degeneration 
in ALS.  However, human motor neuron subtypes have not been molecularly defined in vivo, 
and rational means to generate them in vitro have not been described.   Second, it is likely that in 
order to model an adult-onset neurodegenerative disease like ALS, ES/iPS cell-derived motor 
neurons should at the minimum adopt coherent in vivo-like identities and progress to states of 
maturity as indicated by changes at the molecular, morphological, and electrophysiological 







The aim of the this thesis was to lay the groundwork for the study of ALS using motor neurons, 
and their specific subtypes, derived from ALS-patient iPS cell lines.  First, we needed to 
establish that the molecular markers of vertebrate motor neurons and their subtypes were 
conserved in humans in vivo.  Second, we sought to characterize the subtype diversity of motor 
neurons differentiated from ES cells (ES-MNs) and to develop assays under which to test the 
maturation of motor neurons.  Third, in order to generate ALS-motor neurons, we participated in 
collaborative efforts to generate iPS cell lines from familial ALS patients and control donors, and 
to compare these lines to each other and to ES cells for their capacity to generate motor neurons 
and the functional phenotypes of those cells.  Fourth, we designed a strategy, based on 
developmental mechanisms, to control the rostrocaudal subtype of ES and iPS cell-derived motor 
neurons, and asked if coherent subtype identities could be rationally orchestrated. 
Summary of research background 
In order to set the stage for the studies described in Chapters 2-5, it is necessary to review the 
literature which forms the background for this work.  First, we review the molecular markers that 
distinguish motor column subtypes as defined in vertebrate models.  Then we review the 
developmental mechanisms which generate motor column subtype identity (Part II).  Next, we 
review the evidence that motor neurons can be differentiated from mouse ES cells, and describe 
the molecular and functional diversity of mouse ES cell-derived motor neurons (ES-MNs) (Part 
III).  Then, we describe the generation of human ES cells, their differentiation to motor neurons, 




the development of iPS cells which allow patient-specific ALS-genotypes to be captured in cells 
with the properties of ES cells (Part V).   
Part II.  SPINAL MOTOR NEURON DIVERSITY AND ONTOGENY IN 
VERTEBRATES 
Categories of motor neuron diversity: motor columns, divisions, and pools 
Motor neurons control muscle contraction and motor behavior 
Motor neurons are the sole means of behavioral output from the nervous system.  Their cell 
bodies are located in rostrocaudal columns in the ventral horns of the spinal cord and in the 
dorsal hindbrain, and their axons synapse on muscles controlling contractions.  Central control of 
motor neuron/muscle activity is governed by descending cortical inputs which synapse on local 
interneurons and on some motor neurons directly as well as on central pattern generators.  Motor 
neurons are also integrated into spinal reflex circuits which modulate the activity of motor 
neurons based on sensory feedback from homonymous and antagonistic muscles.  Finally, 
central pattern generators are complex local circuits which coordinate the activity of many 
muscle groups acting in concert to effect locomotion and other stereotyped motor behaviors. 
Motor neurons with similar muscle targets are grouped into motor columns 
The organization of spinal motor neurons is described by a series of hierarchical categories 
which are defined by their peripheral targets, and these are reflected by characteristic anatomical 
positions in the spinal cord and the expression of definitive molecular markers  (Fig. 1.2A-C) 




 are somatic motor neurons, which project directly to muscle targets, and second are visceral 
preganglionic motor neurons, which synapse on sympathetic ganglia.  The visceral preganglionic 
motor neurons are grouped into a dorsal column termed the preganglionic motor column (PGC, 
or Column of Terni in chick) and are found at thoracic levels (Prasad and Hollyday 1991).  
Somatic motor neurons can then be subdivided into three columnar categories.  First,  median 
motor column (MMC) cells constitute a continuous column in a medial and ventral position 
throughout the rostrocaudal length of the spinal cord, and innervate dorsal epaxial muscles of the 
back (Fetcho 1987; Gutman, Ajmera et al. 1993).  Second, hypaxial motor column (HMC) motor 
neurons, which are restricted primarily to the thoracic spinal  cord, are located just lateral to the 
MMC, and innervate intercostal and abdominal muscles (Gutman, Ajmera et al. 1993). Third, the 
lateral motor columns (LMCs), which are located dorsal and lateral to the MMC, are found only 
at the level of the fore- and hind-limbs that contain their muscle targets.  The LMC is further 
subdivided into medial and lateral divisions which innervate muscles derived from the ventral or 
dorsal primordial muscle masses of the limb (Landmesser 1978).   
Molecular markers of motor column subtype identity  
At the molecular level all motor neurons can all be identified by expression of the acetylcholine 
synthetic enzyme choline acetyltransferase (ChAT), since this is the neurotransmitter by which 
they communicate with muscles, and the transcription factors HB9 (Arber, Han et al. 1999) and 
or ISLET1 (ISL1) (Ericson, Thor et al. 1992).  Motor column and division subtypes can be 
identified by their combinatorial expression of specific molecular markers (Fig. 1.2D). The 
MMC expresses transcription factor LHX3, which is initially expressed by all nascent motor 
neurons but rapidly downregulated in all motor columns except the MMC.  At brachial and 




FOXP1, and the retinoid synthetic enzyme RALDH2, which serve as specific molecular markers 
of LMC identity among motor neurons (Dasen, De Camilli et al. 2008).  The LMC divisions can 
be identified based on their combinatorial expression of LIM homeodomain proteins and HB9: 
medial division (LMCM: ISL1 and ISLET2 (ISL2)) and lateral division (LMCL: HB9 and LIM1, 
ISL2).  At thoracic levels, the HMC is marked by expression of HB9 and ISL1/2, the absence of 
both FOXP1 and LHX3 and the expression of ER81 (Dasen, Liu et al. 2003), while PGC motor 
neurons express ISL1, low levels of FOXP1, nNOS, and phosphorylated SMAD (pSMAD) 
proteins (Dasen and Jessell 2009).  
Motor pools innervate individual muscles 
The last level of specificity is the motor pool: the group of motor neurons which are dedicated to 
synapse on one specific muscle (Romanes 1942).  Axonal retrograde transport of horse radish 
peroxidase, and later fluorescent dyes, allowed the nerves innervating individual muscle to be 
traced to their origin at spinal motor neurons.  This allowed a one-to-one map to be established 
between individual limb muscles and the motor pools which innervate them (Romanes 1964; 
Landmesser 1978; Landmesser 1978; Hollyday 1980). 
While motor pool identity is defined by muscle target, many pools can be identified centrally by 
a distinct profile of transcription factor expression.  For example, in the rostral brachial chick 
LMCL the deltoid (DL) motor pool expresses high level ISL2 and LIM1, the extensor metacarpi 
radialis/ulnaris (EMR) motor pool expresses low levels of ISL2 and LIM1, and the rhomboideus 
(RB) motor pool, not part of the LMC, expresses ISL1, ISL2, and LHX3 (Ensini, Tsuchida et al. 
1998).   Additionally, dozens of HOX genes and HOX cofactors (MEIS and PBX proteins) are 




identity of many motor pools (Dasen, Tice et al. 2005).  Some motor pools can be identified by 
expression of specific transcription factors (PEA3, ER81, RUNX1, SCIP, and Nkx6 proteins) 
which can serve as pool markers (Lin, Saito et al. 1998; Arber, Ladle et al. 2000; Haase, Dessaud 
et al. 2002; Livet, Sigrist et al. 2002; Dasen, Tice et al. 2005). 
In some cases pool markers have been shown to respond to peripheral signals and drive motor 
pool specific connectivity phenotypes.  For example, intermediate target- and muscle-derived 
GDNF induces the expression of the ETS protein PEA3 in cutaneous maximus (CM) and 
latissumus dorsi (LD) motor pools (Haase, Dessaud et al. 2002). PEA3 and GDNF knockout 
mice showed defects in cell body settling position and terminal arborization pattern of these 
motor pools pools (Haase, Dessaud et al. 2002; Livet, Sigrist et al. 2002).  Thus selective 
expression of transcription factors not only marks motor pool identities, but can result from 
interaction with muscle targets and determine functional motor pool phenotypes. 
Anatomy and molecular markers of human motor neurons and their subtypes 
Human spinal motor neurons are arranged in the same broad categories as mouse, medial motor 
neurons (MMC, HMC), intermediolateral motor neurons (PGC),and lateral column motor 
neurons ( LMCM/L) as described by histological criteria (Rath, Gopinath et al. 1982; Altman and 
Bayer 2001; Bayer and Altman 2002).  However, molecular tools and tracing studies have not 
been used to definitively establish a distinction between the MMC and HMC, the divisions of the 
LMC, or specific motor pools.  At the molecular level, in situ probes for the motor neuron 
marker HB9 identified motor neurons in the anterior horn of the spinal cord at Carnegie stage 
(CS) 15 (35-38 days of development) (Ross, Ruiz-Perez et al. 1998; Hagan, Ross et al. 2000), 




shown), however by CS19 (day 48-51) only more caudal regions showed subventricular staining 
(Fig. 1.4C, D) and by CS21 (day 53-54, data not shown in publication, the sacral subventricular 
signal was no longer detected).  The authors also report but do not show that anterior horn and 
subventricular signal was seen at CS14 (31-35 days) but not at CS12 (26-30 days).  These data 
validate the use of HB9 as a selective marker for embryonic human motor neurons and they 
appear at day 35-38 and perhaps as early as day 31-35. 
If the subventricular expression pattern is interpreted as HB9  expression in motor neuron 
progenitors, this suggests that human motor neurons initiate HB9 at an earlier stage than do chick 
(Tanabe, William et al. 1998) but similar to mouse (Arber, Han et al. 1999).  Whether HB9 is 
expressed in motor neuron progenitors or in immediately post-mitotic motor neurons, the 
rostrocaudal progression of signal loss strongly suggests it is correlated with motor neurogenesis.  
The period of human motor neurogenesis is thus likely to occur in vivo over a period of almost 3 
weeks: embryonic days 31 to 51. 
Histological analysis offers another perspective on the period of motor neurogenesis, suggesting 
essentially the same start but perhaps an earlier conclusion.  Incipient motor neurons were 
recognized by Ramon y Cajal in the human spinal cord at  ―week 4‖ as early as 1909 (Fig 1.4A)   
(Altman and Bayer 2001).  More recently a detailed analysis of dozens of archival embryos was 
used to construct a comprehensive histological account of spinal development from GW 4 to 
gestational month 4 (Bayer and Altman 2002) of which the first trimester data is most relevant 
here (Fig. 1.4A).  These authors clearly identify motor neurons which have migrated out of the 
subventricular germinal zone by GW 4.5, and interpret a subsequent thinning of the 
subventricualr neuroepithelium at GW 5.5—the presumed human motor neuron progenitor 




estimate however, derives from the cervical spinal cord only, and is only a few days in advance 
of the loss of subventricualr HB9 expression described above, and they do not present a full 
rostrocaudal account of spinal cords samples before GW 8.5.    In summary the period of human 
motor neurogenesis cannot be definitively established with these tools alone, but the histological 
and molecular evidence supports the idea that human motor neurons are born between about 
embryonic day 30 and 50. 
Motor columns begin to separate from a histologically undifferentiated mass of motor neurons 
by GW 6.5 and are quite well segregated into columns by GW 7, however cell group movements 
and further separation of motor columns and pools occurs well into the second trimester (Bayer 
and Altman 2002).  Between GW7.5 and GW17 motor neurons express increasingly distinctive 
levels of non-phosphorylated neurofilaments relative to immediately surrounding cells, and at 
late embryonic stages (GW10-14) they express EphA4 with relative uniformity (Clowry, Moss et 
al. 2005).  Chromatolytic reactions in the cell bodies of motor neurons degenerated through 
injury or disease (poliomyelitis) allowed identification of some motor pools, although in the 
absence of tracing studies in human, the current hypotheses about motor pool-muscle maps are 
based mostly on analogy to precise retrograde tracing in experimental vertebrates (Sharrard 
1955; Romanes 1964; Altman and Bayer 2001; Bayer and Altman 2002).   
None of the molecular markers which delineate specific columnar or motor pool subtypes in 
chick or mouse have been investigated in human, with the exception of ER81.  ER81 expression 
was not associated with the HMC in this study, but the timepoint of analysis was long after the 
period of columnar diversification (Clowry, Moss et al. 2005).  ER81 was, however, observed in 
some unidentified LMC pools at GW14, suggesting that it functions in human as a pool marker.  




Since these reports numerous new antibodies against proteins expressed in a motor neuron 
subtype-specific manner were generated.  Therefore, new, detailed studies of the molecular 
markers and determinants of motor column, division, and pool identities in first trimester human 
embryos are needed to confirm the relevance of the markers of rostrocaudal and columnar 
identity, and validate their use in assigning in vitro derived cells to cognate in vivo categories. 
 
Rostrocaudal patterning generates motor column diversity 
Motor neurons are grouped into columns, divisions and pools, and many of these subtypes can be 
identified by transcriptional codes.  We next ask how generic motor neurons acquire these 
subtype identities in vivo.  A detailed understanding of the processes governing motor neuron 
diversification has been adduced in chick and mouse.  These mechanisms can be reduced to the 
idea that the embryo deploys developmental morphogens along the dorsoventral and rostrocaudal 
axes, to generate unique positional identities defined by the concentration, timing and 
combination of these cues.  Interactive genetic mechanisms then interpret these positional 
identities, resolving a series of unique cellular motor neuron columnar identities.  A classic 
example of this principle is found in the dorsoventral patterning which generates cellular 
diversity, including pan-motor neuron identity, in the ventral spinal cord. 
Dorso-ventral patterning and the specification of motor neuron progenitors 
Motor neuron progenitors (pMNs) are induced in a specific ventral domain of the spinal cord by 
high levels of sonic hedgehog (SHH) protein and are then marked by the expression of OLIG2 
(Roelink, Porter et al. 1995).  The most ventral neural tube cells, floorplate cells secrete that then 




induces expression of Class II homeodomain (HD) proteins Nkx2.2 and Nkx6.1, and represses 
expression of Class I HD proteins Pax7, Dbx1, Dbx2, Irx3, and Pax6 at staggered threshold 
concentrations (Fig. 1.6).  Cross repressive interactions between Class I and II HD proteins then 
resolve the SHH gradient into a set of 5 unique progenitor cell identities—(p0, p1, p2, pMN, and 
p3) located in serial dorsoventral domains in the spinal cord.  In this fashion, a morphogen 
gradient is interpreted by cross repressive genetic mechanisms, and positional information is 
translated into a array of unique cellular identities 
HOXC genes determine motor column subtype identities 
Since all motor neurons arise from a single dorsoventral progenitor domain, generated by high 
levels of SHH signaling, how is the columnar diversity of motor neurons orchestrated?  The 
interaction of HOX genes underpins the diversification of generic motor neurons into columnar 
subtypes and links their diversity to rostrocaudal topography in register with their muscle targets.  
HOX genes are induced in the neural tube, and later are expressed by postmitotic motor neurons 
in a rostrocaudal sequence which is collinear to their 3‘-5‘ position in HOX clusters in the 
genome (Deschamps and van Nes 2005). Cross repressive activity of many HOXC genes helps 
resolve initial graded expression patterns into sequential regions where cells express unique 
combinations of HOX genes.  The result is that motor neurons at brachial limb-innervating levels 
express HOXC6, those at thoracic non-limb innervating levels express HOXC9, and those at 
lumbar limb-innervating levels express  HOXC10 (Liu, Laufer et al. 2001) (Fig. 1.2).  In these 
domains HOXC genes determine the elaboration of level appropriate columnar identities: 
HOXC6 and HOXC10 are required for the specification of the LMCs and repress thoracic motor 
columns, whereas HOXC9 suppresses LMC fate in thoracic spinal cord and supports the 




2010).  Finally dozens of HOX genes, including HOXA5 and HOXC8, work in combination to 
generate the diversity of forelimb innervating motor pools (Dasen, Tice et al. 2005).  HOX genes 
are thus both instrumental in the diversification of motor neurons and serve as specific markers 
of motor neuron rostrocaudal subtype identity. 
Wnt and FGF induce CDX genes to determine caudal neural identity in primitive streak and 
neural plate stage embryos 
While HOXC genes appear to control the columnar identity of postmitotic motor neurons, in 
order to manipulate these identities it is necessary to work backwards in development to 
understand how HOXC genes are induced in this pattern in the spinal cord in the first place.  The 
emerging model for this process again conforms to the principle of developmental morphogens 
inducing positional identities interpreted by interactive gene expression programs.  However, in 
this case the axis is rostrocaudal, the process unfolds in several temporal waves, each sculpting 
more refined positional zones, and progenitor cells must integrate information from several 
overlapped morphogen signaling pathways.  Caudal neural identity is first induced in chick in 
vivo in response to morphogens secreted from two anatomical sources.  First, at the beginning of 
gastrulation through the 1-4 somite stage (Hamburger and Hamilton (HH) stage 3
+
-8) gradients 
of Wnt, from the paraxial mesoderm, and FGFs from the primitive streak induce caudal neural 
identity in cells which will form the spinal cord (Bel-Vialar, Itasaki et al. 2002; Nordstrom, 
Jessell et al. 2002; Nordstrom, Maier et al. 2006).  This primitive caudal identity is encoded by 
the expression of CDX genes in the caudal neural plate by the 1-4 somite stage (HH 8) (Fig. 1.7). 
This first caudal determining period of Wnt and FGF signaling begins coincident with primary 




specified—as shown by fate mapping studies—however it does not yet express the first 
identified definitive marker of neural plate identity in chick and mouse (SOX1). 
Spinal identity is subdivided and diversified by FGF and RA in neural plate and neural tube: 
HOXB genes 
Next, from the 4-17 somite stages (HH8-12) FGF from the regressing Hensen‘s node exposes 
progressively more caudal spinal regions to higher levels of FGF for longer time periods: it is 
adjacent to the presumptive cervical region at HH8, brachial region at HH10, and lumbar region 
at HH15 (Liu, Laufer et al. 2001).  Meanwhile the somites are formed from paraxial mesoderm 
in the anterior wake of the node, and expose brachial progenitors to a rostral to caudal gradient of 
Retinoic Acid (RA) (Fig. 1.8). The generic caudal identity of prospective spinal cord cells, 
encoded by CDX genes, is then refined into rostral and caudal zones by the activity of RA, acting 
directly on 3‘ HOX genes (HOXB1, HOXB3-5), and FGF acting through CDX genes as well as 
on 5‘ HOX genes (HOXB6-9) more directly (Bel-Vialar, Itasaki et al. 2002).  These morphogens 
refine HOX expression such that by HH stage 17 the hindbrain and spinal cord can be subdivided 
into three progenitor zones based upon their expression of HOXB/C genes: caudal hindbrain, 
rostral and caudal spinal cord can be prospectively identified by their combinatorial expression 
of HOXB4, HOXB8, and HOXC9 (Nordstrom, Maier et al. 2006).  Importantly, these authors 
showed that this entire spectrum of specific regional identities, at the CDX and then HOX levels, 
can be rationally reconstructed by exposing prospective forebrain explants to combination of 
Wnt, FGF, and RA signals.  As described previously, by the time motor neurons have exited the 
cell cycle (~HH24), they have been imbued with positional identities marked by HOXC6 




2003).  Finally the most caudal identities—lumbar: HOXC10—depend on additional node-
derived GDF signals  (Liu, Laufer et al. 2001) (Fig. 1.8). 
Many HOX genes interact to diversify limb innervating motor pools 
After specifying columnar identities, many other HOX genes act at a tertiary level to diversify 
the generic identity of forelimb innervating LMC motor neurons into the multiple pool identities 
required for targeted innervation of limb muscles (Dasen, Tice et al. 2005).  HOXA5 is 
expressed in the rostral, and HOXC8 in the caudal brachial LMC and the respective motor pools 
therein.  HOXA5 is required for the scapulohumeralis posterior (SCA ) which is marked by 
RUNX1 expression, and HOXC8 is required for the specification of the flexor carpi ulnaris 
(FCU, SCIP
+
), pectoralis (PEC, PEA3
+
), and anterior latissimus dorsi (ALD, PEA3
+
) motor 
pools.  Cross-repressive actions between HOXA5 and HOXC8, with HOXC8 in a dominant 
position, establish the boundary of HOX expression and pool location, and positive or negative 
perturbations of HOXC8 expression result in shifts in pool identity as measured by molecular 
profile of motor pools and axonal target selection.  A second tier of interactions between other 
HOX genes and the HOX-cofactor MEIS1 sculpts a series of motor pool identities at the same 
intrasegmental (HOXC8
+
) level.  These include MEIS repression of HOX4, HOX7 repression of 
HOX4, and HOX4 activation of Pec-, ALD-, and FCU-motor pool-specific expression of their 
respective pool-markers PEA3 and SCIP. 
 FOXP1 gates limb level HOX diversification of motor pools 
FOXP1, as previously described, is a marker for LMC motor neurons, however it is also a 
required determinant of LMC functional identity.  The FOXP1 knockout mouse showed a loss of 




coordinated limb muscle control (Dasen, De Camilli et al. 2008).  All motor neurons reverted to 
an axial innervating character (MMC/HMC), an atavistic phenotype characteristic of 
evolutionarily basal aquatic vertebrates without limbs or sympathetic nervous systems, relying 
on axial, sinusoidal locomotion: which was the striking locomotor phenotype of these animals.  
In limbed vertebrates, high-level FOXP1 expression, in the context of HOXC6 or HOXC10, 
directs limb-level LMC motor neuron diversification by enabling the productive interaction of 
the dozens of HOX genes to determine motor pool identities.   At thoracic levels however, in the 
context of HOXC9 expression, low-level FOXP1 expression direct motor neurons to adopt PGC 
motor neuron identities (Fig. 1.9).   
Relationship to human development 
No direct evidence is available on the expression of any of the rostrocaudal morphogens, CDX or 
HOX genes in the human spinal cord.  However the human embryo generates the same 
anatomical structures—primitive streak, node and somites—that produce these morphogens in 
the chick and mouse. While molecular studies on human or primate embryos would be extremely 
useful in this regard, it is unlikely that relevant staged samples could be procured at all and if so 
intact at an early enough timepoint in development to be useful.  Moreover, an experimental 
system in which perturbations could be introduced and their effects tested is not conceivable in 
human.  Therefore it would be highly desirable to develop the ability to investigate these 







Motor neuron degeneration in ALS 
ALS is an adult onset neurodegenerative disease that was first described by Jean-Martin Charcot 
(Charcot and Joffroy 1869) and is characterized by the selective death of spinal motor neurons 
and upper motor neurons of the motor cortex.  Axonal degeneration and cell loss spreads, from 
an from an initiating motor pool, to nearly all others causing muscle weakness, spasticity and 
paralysis leading to death within a few years of diagnosis (Ravits and La Spada 2009).   90% of 
ALS is sporadic—without known genetic cause—however 10% is familial.  Mutations in several 
genes have been linked to ALS:  beginning with SOD1 (Rosen, Siddique et al. 1993), and now 
including many others (Boillee, Vande Velde et al. 2006).  Most recent and exciting was the 
identification of TDP-43 in several reports in both familial (Gitcho, Baloh et al. 2008; Van 
Deerlin, Leverenz et al. 2008) and sporadic (Kabashi, Valdmanis et al. 2008; Sreedharan, Blair et 
al. 2008) ALS, which therefore links the familial and sporadic and by implicating a new 
molecule may give new clues to mechanisms.  Mutations in the SOD1 gene have formed the 
basis for rodent models which have provided important insights into the sequence and specifics 
of pathology—axonal dieback, misfolded SOD1 and protein aggregation, axonal transport 
defects, mitochondrial dysfunction, and glutamate excitoxicity, for example—pointing towards 
key players but not identifying upstream mechanisms which could serve as therapeutic targets.  
Animal models have also generated some groundbreaking insights, for example, the importance 
of non motor neurons to disease progression: astrocytes and microglia (Clement, Nguyen et al. 
2003; Boillee, Yamanaka et al. 2006).  Despite this progress disease mechanism are not well 





Motor neuron subtype-selective disease phenotypes 
The motor neuron selectivity of cell loss in ALS has historically, and with good reason, occupied 
much attention.  However, while almost all motor neurons degenerate in ALS, certain classes 
and motor pools show enhanced susceptibility or resistance to degeneration (Kanning, Kaplan et 
al. 2010).  
Distal limb projecting, or facial motor muscles in bulbar forms, are typically affected first, 
compared to thoracic muscles (Ravits, Paul et al. 2007).  These clinical findings suggest that 
limb innervating motor neurons of the LMC are more susceptible to the onset or triggers of ALS 
than are the axial muscle innervating MMC or HMC motor neurons of the trunk.  Whether this 
susceptibility is due to intrinsic properties of these motor neurons, their interactions with glia, or 
circuit and activity characteristics is not known.  Sympathetic motor function and motor neurons 
may be relatively less affected in ALS, suggesting that PGC motor neurons are resistant to 
degeneration.  This strength of this subtype-phenotype is less clear and is complicated by a less 
direct understanding of the neural substrates of sympathetic nervous system function and less 
direct measures.  Bunina bodies, characteristic of degenerating motor neurons in ALS, have been 
identified in PGC (intermediolateral column) motor neurons suggesting that they are affected, 
although depending on the spinal level the density of deposits was less than compared to somatic 
motor neurons (Takahashi, Oyanagi et al. 1993).  The number of PGC motor neurons with NF-H 
accumulations was higher in ALS patients compared to controls, but not as frequent as in ALS-
patient ventral motor column (MMC/HMC/LMC) motor neurons (Itoh, Sobue et al. 1992).  To 
address this controversy a series of functional tests on human patients determined that 
sympathetic nervous system function was somewhat tonically increased in ALS patients, 




subtle involvement of the sympathetic nervous system in ALS (Oey, Vos et al. 2002).  In 
conclusion it seems clear that PGC motor neurons are affected in ALS, but perhaps less 
pervasively than somatic muscle motor neurons.  If LMC and PGC motor neurons can be studied 
in vitro, it will be intriguing to determine if they indeed are relatively susceptible and relatively 
resistant, respectively. 
One clear subtype-selective phenotype in ALS is the relative order of degeneration of fast 
fatigable (FF), followed by fatigue-resistant (FR), and finally slow (S) motor units (Kanning, 
Kaplan et al. 2010).  This sequence is evident in the muscle morphology of  mutant-SOD1 mice 
(Frey, Schneider et al. 2000; Pun, Santos et al. 2006), early loss of large diameter (FF) axons in 
ventral roots (Fischer, Culver et al. 2004), and calcitonin gene related peptide
+
 (FF) cell bodies in 
the spinal cord (Kong and Xu 1998).  Loss of FF and FR motor units may be compensated for by 
sprouting from FR and S motor units with resulting EMG and fiber type changes (Kanning, 
Kaplan et al. 2010).  Data from human patients supports this sequence of events: early signs of 
deinnervation in muscles, electromyelograms consistent with deinnervation/reinnervation, and 
twitch force studies (Dengler, Konstanzer et al. 1990; Fischer, Culver et al. 2004; de Carvalho, 
Pinto et al. 2008).  Despite these intriguing differences, the developmental mechanisms leading 
to FF, FR, or S motor unit motor neurons are not known.  Furthermore these motor neurons can 
be distinguished in situ by differences in cell soma size and axon caliber, but are not 
unambiguously distinguished by any molecular or any genetic markers. 
Two motor pools however show remarkable resilience even at end stages of disease.  In ALS 
patients‘ eyes muscle and pelvic sphincter functions are well preserved even at end stages 
(Mitsumoto, Przedborski et al. 2006).  ALS patient autopsy samples showed significance 




2002) and Onuf‘s nuclei (Mannen, Iwata et al. 1977; Schroder and Reske-Nielsen 1984; Mannen 
2000).  Furthermore these phenotypes translate robustly to ALS mice, where several eye muscle-
innervating nuclei, including the oculomotor (Ferrucci, Spalloni et al. 2010), as well as Onuf‘s 
(Artem Kaplan and Christopher E. Henderson, unpublished results) are also robustly preserved.  
These strong motor pool-specific ALS-resistance phenotypes suggest that studying these motor 




Chick and mouse motor neuron subtypes are defined at the level of motor column, division, and 
pool, and can be identified by molecular markers.  These functional subtypes are conserved in 
human, but will these molecular markers be conserved as well?  The developmental mechanisms 
which produce the diversity of motor neuron subtypes in chick are early embryonic rostrocaudal 
patterning, initiated by morphogens secreted from discrete embryological structures over several 
developmental time periods. We know that the human embryo generates the same structures as 
the chick and mouse (see Chapter 6) but we do not know if the same cues are deployed.  In 
models systems these morphogenetic cues are translated into positional identity and motor 
neuron subtype diversity by CDX and HOX genes.  While human embryonic stem cells can 
respond to two of these morphogens, RA and SHH (see Chapter 1, Part IV), will Wnt, FGF, and 
RA in combination have similar activities as in model systems?  
ALS is a disease with poorly understood mechanism which selectively targets motor neurons, but 




motor neuron subtypes can be defined at the molecular level in vivo, and developmental 
mechanisms controlled in vitro, it may be possible to generate motor neurons from human stem 
cells with identifiable subtype identities which match those showing differential responses to 
ALS in vivo.  Comparing the disease-response phenotype of these outlying subtypes to more 
classically affected, or especially to more susceptible motor neurons may reduce the noise of 
gene expression, cell-biological, or phenotypic changes which distinguish ALS motor neurons 
from non-motor neurons, and produce a novel range of mechanistic insights. 
 
Part III. MOUSE EMBRYONIC STEM CELL-DERIVED MOTOR NEURONS  
Introduction 
The development of the mouse embryonic stem (ES) cells in the 1980s revolutionized mouse 
genetics but also opened several possible avenues for in vitro investigation.  Because of the 
pluripotency of stem cells developmental biologists could imagine studying lineage development 
in a highly reduced but highly tractable system.  Those interested in diseases could also imagine 
generating the affected cell types in vitro and using these to build new models to understand 
disease mechanisms.  Finally, many were excited by the prospect of generating differentiated 
cells in vitro to be used in transplantation approaches to replace damaged or dead cells.  Since 
research on mouse ES cells and ES-derived motor neurons frame much of the work on the 
human system, it is important to review these precedents.  Here we review the origins and 
defining characteristics of mouse stem cells and their application to the problem of mouse motor 





Mouse embryonic stem cells 
In 1981 mouse ES cells were derived from the blastocysts of the preimplantation mouse embryo 
(Evans and Kaufman 1981; Martin 1981).  These cells provided the functional in vitro definition 
of ES cells: unlimited proliferation (self-renewal) with retention of the ability to differentiate into 
cells from each of the three embryonic germ layers: ectoderm, mesoderm, and endoderm 
(pluripotency).  25 years of concerted effort have defined a core network of transcription factors 
(OCT4, SOX2, NANOG, TCF3) that determine the self-renewing pluripotent state and maintain 
it through mutual transcriptional positive feedback (Loh, Wu et al. 2006).  Not least this work 
provided the groundwork for reprogramming approaches to induce the state of pluripotency (iPS, 
see below) using defined genetic factors. 
In vivo tests of pluripotency 
The formal test of ES cell pluripotency was provided by the ability to contribute significantly to 
all tissues in the morula aggregation assay (Bradley, Evans et al. 1984).  This advance provided a 
technical means to manipulate the mouse germline, and formally demonstrated that ES cells, in 
the context of implantation development, were able to give rise to all cells of the embryo .  A 
more direct test of pluripotency is the tetraploid embryo complementation assay (Eggan and 
Jaenisch 2003).  In this assay a fertilized egg at the two-cell stage is fused to create a tetraploid 
cell.  The result is normal development only up to the morula stage, and a normal trophoblast, 
but a complete failure of embryonic development.  If diploid ES cells are inserted into this 
blastocyst, only these cells contribute to development of the embryo.  Therefore when embryos 
do develop, they are constituted of cells differentiated exclusively from the ES cells inserted, 




In vitro and in situ tests of pluripotency  
Several in vitro or transplantation assays are commonly used shortcuts to the more complete 
demonstrations of pluripotency described above.  First, ES cells can be allowed to undergo 
spontaneous differentiation by removing the factors (leukemia inhibitory factor (LIF) and or 
fibroblast conditioned medium) which actively maintain an undifferentiated state in vitro (Smith, 
Heath et al. 1988).  Transcriptional or protein endpoints can then be used to look for the 
elaboration of cellular identities characteristic of the 3 embryonic germ layers.  Alternatively the 
teratoma formation assay is interpreted as slightly stronger evidence of pluripotency.  In this 
assay, spontaneous differentiation occurs when ES cells are transplanted into immune deficient 
(SCID) mouse kidney capsule, where pluripotent cells elaborate not only cellular and molecular 
markers of 3 germ layers, but develop tissue patterns characteristic of the 3 germ layers.   
 
ES-cell derived motor neurons 
Motor neurons can be generated from stem cells in vitro using developmental mechanisms 
Pluripotency implies than any given somatic cell can be generated from ES cells.  A new 
subfield of motor neuron and stem cell biology was inaugurated by the finding that 
developmental mechanisms could be used to robustly direct mouse ES cells to differentiate to a 
specific post-mitotic fate: the spinal motor neuron (Wichterle, Lieberam et al. 2002).  Mouse ES 
cells were removed from pluripotency-maintaining culture conditions, cultured as free floating 
aggregates termed embryoid bodies (EBs) and allowed to differentiate spontaneously for several 
days.  Then, since RA is synthesized by anterior (cervical) somites in early somite stage embryos 




Liu, Laufer et al. 2001) it was used to impose a caudal, spinal identity on neuroectodermal cells 
with a default anterior identity.  Again following developmental principles SHH was used to 
induce the ventral identity and gene expression programs required for motor neuron 





ChAT-expressing cells which met the molecular characteristics of spinal motor neurons and were 
defined as ES-derived motor neurons (ES-MNs).  When transplanted to chick embryonic neural 
tube these ES-MNs were able to settle in the ventral horn and projects axons to muscle targets 
(Fig. 1.10).  It is important to note that the timecourse of motor neuron lineage elaboration in 
these experiments precisely paralleled that found in vivo, and this allowed the morphogenetic 
cues RA and SHH to be presented in a logical and defined temporal window in vitro. 
ES-MN diversity in mouse 
The subtype diversity of ES-MN was later found to be almost exclusively of a rostral, cervical 
phenotype under these RA-based differentiation conditions, as assessed by expression of 
HOXA5 (Wichterle, Lieberam et al. 2002; Soundararajan, Miles et al. 2006; Peljto, Dasen et al. 
2010).  Most mouse ES-MNs however express the MMC marker LHX3(Wichterle, Lieberam et 
al. 2002; Soundararajan, Miles et al. 2006; Peljto, Dasen et al. 2010).   
Controlling subtype diversity of mouse ES-MNs  
Subsequent research identified a differentiation strategy which was able to generate motor 
neurons expressing more caudal HOX genes (HOXC6, HOXC8) which, following in vivo 
developmental rules, resulted in the emergence of more caudal columnar identities including 
FOXP1-expressing LMC motor neurons (Peljto, Dasen et al. 2010).  This differentiation strategy 




and subsequent brachial LMC fates were dependent on FGF and Wnt signaling endogenous to 
the cultured EBs, and operated through CDX-dependent mechanisms, as in vivo.  Further work is 
needed to generate more caudal motor neuron identities, to specify them by rational addition of 
salient patterning factors, and to increase the efficiency of differentiation.   
Elaboration of motor pool identities in ES-MNs in vitro 
Once these caudalizing conditions were defined it was possible to ask if the motor neurons with 
LMC phenotypes— expressing HOXC6 and FOXP1—were able to generate identified molecular 
phenotypes of motor pools characterized within the brachial LMC.  Caudalized ES-MNs 
expressed several LMC motor pool markers (SCIP, expressed by the FCU and PEA3, expressed 
by the CM) consistent with their HOX and LMC divisional profiles (Peljto, Dasen et al. 2010).  
Furthermore PEA3 expression was dependent on exogenous application of the growth factor 
GDNF, which is required for its expression in vivo.  These results suggest that if the appropriate 
HOX profile is established in ES-MNs, then coherent column identities will follow, and that if 
required growth factors are present, then motor pool identities will crystallize. 
 
Functional phenotypes of ES-MNs 
Electrophysiology 
Perhaps the most functional property of a mature neuron is its ability to integrate chemical 
synaptic activity into coherent and stereotyped electrophysiological responses.  It was therefore 
important to ask if ES-MNs were capable of developing mature electrophysiological 




developing motor neurons (Miles, Yohn et al. 2004):  they respond to salient neurotransmitters 
(GABA, glycine, glutamate), fire repetitive action potentials, and form synapses with myotubes 
in co-culture.  Impressively, when ES-MNs were transplanted into the mouse tibial nerve (distal 
to nerve sectioning) they were able to send projections to the gastrocnemius muscle, form 
synapses and drive muscle contractions, and ameliorate functional deficits (Yohn, Miles et al. 
2008).  Together these results demonstrate that ES-MNs have a significant capacity for 
functional maturation. 
Motor neuron subtype-specific phenotypes 
A series of xenotransplantation experiments supports the idea that ES-MNs can become 
functional, but that they exhibit phenotypes specific to their transcriptionally defined motor 
column subtype.  ES-MNs expressing the MMC marker LHX3 showed a strong preference for 
axial, MMC axonal trajectories upon transplantation to developing chick neural tube, thus 
confirming the functional nature of MMC identity for in vitro derived cells (Soundararajan, 
Miles et al. 2006; Peljto, Dasen et al. 2010).  When FOXP1
+
 ES-MNs were generated along with 
LHX3
+





 ES-MNs showed significant preferences for medial or lateral settling 
positions in accord with their endogenous MMC and LMC counterparts (Peljto, Dasen et al. 




 ES-MNs preferentially selected appropriate axonal 
trajectories through axial or limb innervating nerves respectively, as confirmed by retrograde 
labeling of axons of transplanted ES-MNs.  These findings demonstrated that ES-MNs with 
appropriate HOX and column marker profiles were competent to interpret endogenous cues for 
cell body positioning and axon guidance.  This suggests that if HOX and motor column markers 




Using ES-MNs to model ALS 
Several reports point toward the specific utility of ES-derived motor neurons for modeling ALS.  
Mouse ES-MNs were able to recapitulate the selective sensitivity to mutant SOD1  rodent 
primary astrocytes (Di Giorgio, Carrasco et al. 2007; Nagai, Re et al. 2007) shown by primary 
motor neurons. These data point to a significant role for non-cell-autonomous mechanisms in 
animal models of familial ALS. In one report there were indications of a potentially cell-
autonomous protein aggregation and survival phenotype for mutant-SOD1 ES-MNs (Di Giorgio, 
Carrasco et al. 2007), although these findings have not been confirmed by subsequent reports.  
 
Conclusions 
The promise of ES cell pluripotency was confirmed in the mouse system by the selective 
generation of motor neurons in vitro.  We have seen that in vivo developmental principles can 
guide successful differentiation strategies and that these need to be timed appropriately to 
parallel in vivo development.  The motor neuron subtypes generated showed specific 
combinatorial molecular profiles that matched in vivo categories.  Importantly when the HOX 
and column marker profiles were successively induced in ES-MNs then appropriate motor 
column and pool identities and functional phenotypes precipitated.  These results engendered the 
question of whether similar approaches and results could be taken in the human ES system, and 






Part IV. HUMAN EMBRYONIC STEM CELL-DERIVED MOTOR NEURONS 
Introduction 
The rapid adoption of mouse ES cell technology as a productive system for biological 
investigation made the establishment of human ES cell lines doubly exciting.  Human ES cells 
potentially made human specific aspects of neural development and disease available for study 
for the first time, as well as representing a potential allogeneic substrate for cell transplantation 
strategies.  Here we review the derivation of human ES cell lines and their utilization to generate 
spinal motor neurons. 
Human ES cells are pluripotent 
In 1989 human embryonic stem cells were first derived from surplus human blastocysts 
(Thomson, Itskovitz-Eldor et al. 1998).  These ES cell lines demonstrated the hallmark 
characteristics of self-renewal and pluripotency. While the gold standard pluripotency assays of 
morula aggregation or tetraploid embryo complementation are ethically impossible using human 
cells, human ES cells passed all the standard in vitro tests for mouse ES cells. They expressed 
similar markers to mouse ES cells, and were competent to generate 3 germ layers by spontaneous 
differentiation or teratoma formation.  Despite domestic and international political limitations 
many ES lines have subsequently been derived by similar methods, contributing to a moderate 
diversity of ES lines and an enriched understanding of the core transcriptional and functional 






Motor neurons can be differentiated from human ES cells using developmental mechanisms 
The demonstration that mouse ES cells could be efficiently directed to motor neuron fate then 
raised the question of whether the same approach could be used with human.   Several groups 
initially reported the differentiation of motor neurons from human ES cells (Li, Du et al. 2005; 
Shin, Dalton et al. 2005; Lee, Shamy et al. 2007).  While protocols varied slightly, especially 
regarding timing and means of neural induction, specification of the motor neurons in each 
system was based on the same developmental mechanisms used in mouse: caudalization of 
default anterior identity with RA and ventralization with SHH.  These cues were delayed and 
prolonged compared to mouse to adjust for the slower tempo of human development in vivo. 
Subsequent work has made advances in the efficiencies of motor neuron differentiation by 
several means.  First, the efficiency of neural induction could be increased by initiating small 
EBs by starting from single cell suspensions, utilizing an inhibitor of Rho kinase (ROCK) which 
permitted survival of isolated single ES cells (Watanabe, Ueno et al. 2007).  These conditions 
potentiated the effects of in-vivo inhibitors of non-neural differentiation like Noggin, and 
promoted homogenous differentiation by limiting EB size and thus the stochastic formation of 
uncontrolled signaling centers in large EBs.  More recently pharmacological means were found 
to increase the efficiency of neural induction to nearly 100% (Chambers, Fasano et al. 2009).  
When an inhibitor of TGF-beta superfamily Type I signaling (SB-431542, Activin Receptor Like 
Kinases (ALK)-4, -5, -7  inhibitor (Inman, Nicolas et al. 2002)) was used in combination with  
Noggin, nearly uniform neural induction was achieved at 7-10 days in advance of the average 
timing in previous protocols.  Finally, a pharmacological substitute for Noggin (LDN-193189, 
and inhibitor of ALK-2 and -3 (Yu, Deng et al. 2008) was shown to have equivalent if not more 




Analysis of generic ES-MN identity and differentiation efficiency 
Many other groups have now reported human ES-MN differentiation from ES cells and all have 
used either HB9 or ISL1 to identify motor neurons (Di Giorgio, Boulting et al. 2008; Li, Hu et al. 
2008; Marchetto, Muotri et al. 2008; Karumbayaram, Kelly et al. 2009; Wada, Honda et al. 
2009; Patani, Hollins et al. 2011).  HB9 is the more selective of these markers in rodent, because 
of the relative abundance of ISL
+
 interneurons in the spinal cord and dorsal root ganglia.  Finally, 
because other somatic cell types, particularly in the pancreas and esophagus (Ross, Ruiz-Perez et 
al. 1998; Hagan, Ross et al. 2000) also express HB9 or ISL, it is important to confirm the 




 cells in vitro as well.  The efficiencies of differentiation vary  
widely, from 8% (Di Giorgio, Boulting et al. 2008) 80% (Erceg, Lainez et al. 2008), however 
HB9 staining was as intense in cytoplasm of every cell shown as in nuclei.  Most groups show 
nuclear staining for HB9 and report efficiencies around 20-30%.   
Reported efficiencies are based on immunostaining nuclei using an HB9-specific antibody 
(Table 7.1, #1) and are completely dependent on the methods used seed cells, pick fields, and 
count  HB9
+
 cells.  For example only one group has reported strictly dissociated EBs which were 
subsequently quantitated for %HB9 out of all cells in the resulting re-seeded homogenous 
mixture, 8% (Di Giorgio, Boulting et al. 2008).  Most groups attach undissociated rosette clusters 
or EBs to polyamino acid/laminin substrata and immunostain heterogeneous and partly-three 
dimensional cultures.  This method is not amenable to accurate quantitation with respect to total 
differentiated cell numbers because heterogeneous fields must be hand-picked in the immediate 
environment of attached EBs.  Furthermore, many groups culture human ES-MN cultures for 3 




efficiency (30% and 17% respectively).  These authors do not report how fields are selected for 
analysis.   
In order to further confirm motor neuron identity only one group has tested coexpression of HB9 
and ISL1 ~80% of HB9
+
 cells expressed ISL1 (Li, Du et al. 2005), but as discussed above, field 
selection in these cultures means this value must be interpreted with caution.  Therefore this 
aspect of motor neuron transcription factor expression needs a rigorous quantitative treatment.  
Most groups have also shown ChAT expression by some HB9
+
 cells at mostly later (6-8 weeks) 
timepoints in culture, consistent with maturing motor neuron identity (Li, Du et al. 2005; Lee, 
Shamy et al. 2007; Di Giorgio, Boulting et al. 2008; Placantonakis, Tomishima et al. 2009; 
Wada, Honda et al. 2009; Boulting, Kiskinis et al. 2011). 
Maturation of ES-MNs in vitro 
Since human ES-MNs are born in vitro (above reports) about the same time as in vivo (30-50 
days of development (Hagan, Ross et al. 2000; Altman and Bayer 2001; Bayer and Altman 
2002)) they are presumably immature.  The utility of ES-MNs as a tool to study functional 
physiology or disease phenotypes may depend on their ability to attain significant maturation in 
vitro.  
Since the most fundamental functional property of motor neurons is their ability to integrate 
synaptic input and generate action potentials to trigger muscle contraction, their 
electrophysiological status and activity are a the key indicator of maturity.  Almost every group 
reporting ES-MN differentiation has shown a that some ES-MNs acquire electrical activity at 
later timepoints (day 30-90), including single or repeated action potentials, response to 




Singh Roy, Nakano et al. 2005; Lee, Shamy et al. 2007; Wada, Honda et al. 2009; Patani, Hollins 
et al. 2011).  In one instance depolarization of motor neuron (RA and SHH induced)  but not 
parallel control cultures released Acetylcholine, providing the only evidence thus far, beyond 
ChAT staining, for ES-MNs able to functionally secrete their characteristic neurotransmitter 
(Lee, Shamy et al. 2007).  However a detailed timecourse of the transition from recently-born 
ES-MNs to spike-train competent motor neurons or an analysis of the efficiency has not been 
reported.  Since no MN-selective electrophysiological properties have yet been investigated for 
hES-MNs, it would be useful to both describe the timecourse and character of ES-MN 
electrophysiological maturation, and to determine the extent to which this functional physiology 
mirrors in vivo MN-selective phenotypes. 
Another approach to assaying motor neuron-specific phenotypes is to study their behavior when 
transplanted in vivo.  In these conditions, hES-MNs were found to survive in the spinal cord, 
showed some evidence of ventral migration, projected axons to the periphery over long distances 
>3.5mm in pursuit of mostly axial and body wall targets (Lee, Shamy et al. 2007).  
Transplantation approaches to examine the phenotypic behavior of hES-MNs have shown basic 
proof of principle and may in the future be able test motor neuron subtype-selective phenotypes. 
ES-MN diversity 
One principal category of functional and molecular diversity among motor neurons in vivo is the 
division into one of 4 motor columns.  There is evidence that the MMC marker LHX3 is 
expressed by some post-mitotic ES-MNs.  When HB9-enhancer lentivirus labeled presumed ES-
MNs were FACS sorted for GFP, LHX3 mRNA was coenriched (Singh Roy, Nakano et al. 








 cells in 
cultures that also contained some HB9
+
 cells, but none of these cells was tested for either HB9 or 
ISL1 (Patani, Hollins et al. 2011).  In conclusion, although evidence from several reports 
suggests that some ES-MNs show a LHX3
+
 MMC-like columnar subtype identity no systematic 




 cells has yet been performed.  Since 
motor column subtypes have different developmental, survival, and disease related properties it 
is critical to systematically define the diversity of subtypes present in hES-MN differentiations. 
As we have seen from in vivo studies in mouse and chick, motor neuron columnar and pool 
subtypes are strongly dependent on rostrocaudal identity as encoded by HOX gene expression.  It 
is therefore of principal interest to characterize the rostrocaudal/HOX diversity of human ES-
MNs.  Several reports have addressed this aspect of subtype identity at the level of gene 
expression, by microarray or PCR, and also at the level of protein expression in single cells.  
HOXA5, HOXC6, HOXC8, HOXC9 and HOXC10 protein have been reported in hESMN-
containing cultures.  Only in the case of HOXC6 was this gated on a MN-selective marker 
(HB9), though HOXC8 was expressed by NKX6.1 cells, and HOXC6 and HOXC8 were 




 cells have 
been shown as examples from a group which routinely produces some of the most robust and 
most believable ES-MN cultures, however these HOXC8 cells have never been formally shown 







 staining in which, the HOXC8 stain was as cytoplasmic as the 
HB9 and accounted apparently for 80% of total cells (Erceg, Lainez et al. 2008).  Finally one 
group reported HOXC9 and HOXC10 expressing cells but these were not stained with HB9 or 




work on chick but not mouse, therefore these data must also be interpreted cautiously (Patani, 
Hollins et al. 2011).  Gene expression studies of ES-MN cultures or FACS purified HB9:GFP
+
 
cells have shown enrichment for anterior HOX1-6 genes indicative of hindbrain to brachial 
spinal positional HOX identities (Lee, Shamy et al. 2007; Placantonakis, Tomishima et al. 2009).  
In aggregate these data suggest that human RA-dependent ES-MNs may be biased towards 
rostral spinal fates, but there are some reliable examples of more brachial expression (HOXC6 
and HOXC8).  However, a quantitative profile of HOX protein-expression has yet to be 
established at the level of individual human ES-MNs.  Since columnar and motor pool identities 
emerge in the context of rostrocaudal identities, in order to begin studying these subtypes it is 
important to determine the rostrocaudal diversity and any biases present in ES-MNs.  
Furthermore if strategies to control motor neuron diversity are to be devised, it is critical to 
establish the rostrocaudal starting points. 
 
Conclusion 
Human ES cells have been used to generate cells with many of the molecular characteristics of 
motor neurons, importantly including the basic transcription factors HB9 and ISL and expression 
of appropriate neurotransmitter synthetic enzyme ChAT.  These ES-MNs appear to be rostrally 
biased and at least contain some LHX3-expressing cohort.  However a systematic 
characterization has not been undertaken and in most cases direct confirmation of pan-MN 
markers was lacking.  Human ES-MNs can acquire mature characteristics including active 
electrophysiology, and axonal pathfinding on transplant to chick embryo, which are consistent 




and extent of maturation at a quantitative and systematic level.  Assays which are more definitive 
for motor neuronal identity, rather than pan-neuronal, and functional assays that can discriminate 
between motor neuron subtypes are also needed.  Finally, most publications on hES-MNs do not 
employ methods of quantitation that can reliably represent the population of ES-MNs generated.  
It is therefore not possible to draw strong conclusions about overall differentiation efficiency or 
the relative contribution of motor neuron subtypes.  In order to measure the outcome of strategies 
aimed at controlling subtype diversity, it is important to be able to quantitatively account for the 
population representatively.  qPCR is one such approach, but it lacks the single cell resolution 
which can definitively assign, for example, HOXC8 expression to a cell also expressing a 
validated motor neuron marker, like HB9.  A homogeneous culture approach could allow for 
quantitative description of ES-MN diversity, and would additionally be well-suited for  high-
throughput assays for of phenotype or drug screening.  Therefore unbiased and homogeneous 
methods of culture and quantitation are needed to address developmental questions, characterize 
subtype diversity, and lay the groundwork for screening assays. 
 
Part V. INDUCED PLURIPOTENT STEM CELL-DERIVED MOTOR NEURONS 
Motivation 
Two of the major goals of translational stem cell biology are cell replacement strategies and 
modeling diseases using disease-specific stem cells.  Because of graft vs. host rejection of even 
immunomatched allogeneic transplants, a syngeneic alternative is obviously the ideal.  If 
replacement cells could be generated from the same individual this serious complication might 




then differentiate the transplant cells from these.  Another broad goal for the field is to use the 
disease genotype of patients suffering from genetic diseases to generate disease-allele bearing 
stem cells, and then produce the affected cell types from them for study in vitro.  Notably, this 
strategy provides a unique opportunity to generate disease models from patients where no known 
etiologic alleles have been identified.  For both of these aims it was thus important to generate 
patient-specific stem cell lines. 
 
Approaches to patient-specific and disease-model stem cell lines. 
Transgenesis, gene targeting, and somatic cell nuclear transplantation 
One approach to modeling ALS in human stem cell-derived motor neurons would be to 
differentiate these from stem cells bearing ALS causing alleles.  Since no extant ES cell lines 
harbor alleles linked to ALS, this goal required the insertion of pathological alleles as transgenes, 
via gene targeting, or the through the derivation of pluripotent cell lines natively harboring these 
disease-associated alleles.  While both transgenesis and gene targeting are routine tools in mouse 
genetics, they have been problematic to accomplish in human ES cells.  Human ES cells have a 
particularly vigilant and robust host defense mechanism which silences transgenic DNA.  In 
addition, if transgenic lines could be made they might be limited to alleles which show toxic gain 
of function phenotypes.  While a subset of ALS-causing alleles fits this description, notably the 
well studied SOD1 gene, other alleles (TDP43, FUS, PON) may not.  Furthermore, even if gene 
silencing can be overcome, the gene regulation and dosage achieved may vary greatly from the 
genetic setting of affected patients, and lead to an exaggerated model which may be less faithful 




function alleles in patient-specific lines.  To this end, a recent study identified the location of 
genomic ―safe harbors‖ showing limited silencing and unregulated expression which may offer 
an attractive alternative approach for therapeutic transgenes as well as disease modeling 
(Papapetrou, Lee et al. 2011). 
Gene targeting on the other hand, offers precise control of gene dosage and endogenous 
regulation of gene expression.  Unfortunately this strategy has proven even more difficult than 
transgenesis in human ES cells, having been successful only twice (Zwaka and Thomson 2003; 
Urbach, Schuldiner et al. 2004) and its success is potentially dependent on the targeted allele.  
Recently zinc finger nuclease-mediated gene-editing has been developed as a much higher 
efficiency method to induce or rescue pathogenic lesions (Lombardo, Genovese et al. 2007). 
Another strategy for developing patient-specific pluripotent cell lines is to convert somatic cells 
from affected patients into pluripotent cells.  In other species this has been achieved by 
enucleation of fertilized eggs and insertion of donor cell nucleus or DNA, a procedure known as 
somatic cell nuclear transplantation (SCNT), which was used to clone the much heralded sheep  
Dolly (Wilmut, Schnieke et al. 1997) thereby demonstrating the ultimate developmental 
competence of a reprogrammed somatic cell: the generation of an entire animal.  While this 
approach is very promising, it is for now blocked by tactical and technical obstacles in human 
cells.  First, procuring human oocytes is extremely difficult, hazardous to donors, and not 
scaleable.  More importantly, while this process has relatively high efficiency in mouse and 
many other species, even if it is extremely labor intensive, and it has recently been demonstrated 
in primates (Byrne, Pedersen et al. 2007), SCNT reprogramming has yet to be accomplished 





Somatic cell reprogramming with defined factors: induced pluripotent stem cells 
Mouse induced pluripotent stem cells (iPS) cells 
SCNT experiments in many species did however prove a critical principal: factors in the ooplasm 
are capable of reprogramming a terminally differentiated somatic cell to a state of pluripotency.  
This insight, combined with emerging consensus descriptions of ES cell and core pluripotency 
networks described above, became the foundation of a search to define these factors.  In a 
technical tour de force, a combinatorial approach was used to test highly expressed stem cell 
genes for their ability to reprogram somatic cells to pluripotency.  This study identified 4 genes 
that, when delivered by viral vectors, were sufficient to reprogram mouse somatic cells to a fully 
pluripotent state (Takahashi and Yamanaka 2006).  These cells, termed induced pluripotent stem 
(iPS) cells, derived from mouse, demonstrated equivalent pluripotency to mouse ES cells and 
were subsequently shown to contribute to germline in chimeras and then to pass the tetraploid 
embryo complementation assay of pluripotency (Wernig, Meissner et al. 2007). 
Human iPS cells 
Because of the understanding of the core pluripotency transcription factor network in human ES 
cells (Boyer, Lee et al. 2005), and its fundamental similarity to mouse, the rapid same viral 
reprogramming approach was subsequently used to reprogram human somatic cells (Yu, 
Vodyanik et al. 2007; Nakagawa, Koyanagi et al. 2008; Park, Zhao et al. 2008).  These 
reprogrammed cells were similar to ES cells and met all in vitro tests of ES cell pluripotency and 
the teratoma assay.  For ethical reasons, the formal proof of pluripotency, the ability to clone an 





Subsequent work has technically improved on the basic iPSC methodology.  Early 
reprogramming cocktails used the oncogene c-MYC, and this was later shown not to be 
necessary (Nakagawa, Koyanagi et al. 2008; Wernig, Meissner et al. 2008).  Other groups have 
found small molecules which could replace one or more reprogramming genes or increase 
efficiency.  Others have used removable cassettes (Soldner, Hockemeyer et al. 2009), or non 
integrating vectors, to avoid genetic lesions at integrations sites (Okita, Nakagawa et al. 2008).  
More recently attempt to use synthetic RNA reprogramming has been successful (Warren, 
Manos et al. 2010). 
 
Assessing the quality of human iPS cells 
General equivalence of iPS and ES cells and concerns 
Many concerns remain over the general comparability of first- or subsequent-generation iPS to 
ES cells as well as their utility in disease modeling or especially in cell transplantation 
approaches.  First there is widespread and legitimate concern that multiple genomic lesions viral 
integration sites creates the risk of seriously perturbing genetic function and cellular phenotype.  
However given the rapid advances in non-integrating reprogramming described above it is likely 
that these concerns will soon be historical. 
Persistent cellular memory of somatic cell identities in iPS cells may be a more difficult issue to 
resolve.  Failure to reset DNA methylation marks appears to result in misexpression of proteins 




Indeed it was recently shown that misexpressed proteins lead to immune rejection even in highly 
inbred syngeneic mice (Zhao, Zhang et al. 2011).  These are serious concerns for those 
contemplating cell replacement with iPS cells.  However, while these issues should serve as an 
important caveat to consider and variable to control in disease modeling studies they do not 
present a strong argument against the utility of iPS cells for these purposes.  
Indeed, even if first- or later-generation iPS cells are genetically damaged, or maintain epigenetic 
and or gene expression signatures of the somatic cells from which they were induced, it is 
possible that they could still be very useful tools for modeling disease.  As long as iPS cells can 
give rise to disease-relevant cell types whose function is relatively unperturbed by these defects, 
and if these cell types can manifest disease phenotypes in vitro, then they may still offer a unique 
and valuable resource for studying disease. 
 
Motor neuron lineage equivalence of iPS and ES cells 
Proof of principle 
Once iPS cells were derived from human somatic cells, the technical stage was set to ask if 
somatic cells from patients with genetic diseases, like ALS, could also be reprogrammed to 
pluripotency and if so whether this capacity would include the ability to generate cell types 
highly relevant to ALS: motor neurons and astrocytes.  To answer this question we participated 
in a collaboration with the Eggan Laboratory at Harvard University, clinicians at the Eleanor and 
Lou Gehrig ALS clinic at Columbia University Medical Center, and colleagues here in the basic 
sciences.  We were the first to demonstrate that iPS cells derived from ALS patient and control 




Mixed data on iPS MN-lineage differentiation efficiency 
While our data provided the proof of principle that ALS iPS cells could differentiate to disease 
relevant cell types, and others reported similar results for lines from a variety of diseases, a 
subsequent report showed consistently compromised neural differentiation efficiency, and most 
problematic, high variability in the motor neuron lineage differentiation when compared with 
one ES cell line controls (Hu, Weick et al. 2010).  Since the crucial step in using iPS cells to 
study disease will be to define disease phenotypes in vitro, the Hu study raised the worrisome 
possibility that large variability between iPS-MNs from different donors or reprogramming 
events, and in general between iPS and ES cells, might obscure disease phenotypes, making 
them technically ill-suited for disease modeling.  To address the utility of virally reprogrammed 
iPS cells for disease modeling, it was therefore necessary to test their ability to generate motor 
neurons, and compare the variability and efficiency in comparison to ES cells.  To this end we 
undertook a large comparative study of iPS and ES cell motor neuron differentiation described in 
Chapter 3. 
Ability of iPS cells to recapitulate disease phenotypes 
Several proof of principle demonstrations of the ability of iPS cells to model developmental or 
early onset diseases have been published, including Familial Dysautonomia (FDA) (Lee, 
Papapetrou et al. 2009),  Long Q-T syndrome (Moretti, Bellin et al. 2010), and SMA (Ebert, Yu 
et al. 2009).  The phenotype described for FDA-iPS cells was particularly interesting because it 
faithfully reproduced the sensory neuron-selective IKBAP splicing defects seen in vivo as well 
as functional neuronal phenotypes, and was amenable pharmacological rescue in vitro.  The 




marker—a reduced number of ISL+ cells—but it is not clear how this phenotype is related to the 
in vivo disease, and it was not rescued.  Importantly, while iPS cells have now been generated 
for a wide variety of late onset neurodegenerative diseases—ALS, Alzheimer‘s, and 
Parkinson‘s—no phenotypes have yet been reported and this remains the major challenge for the 
field.  
Another hope for the field of disease modeling is that human cells will be able to reproduce 
human-specific phenotypes not accurately reproduced in rodent models.  This potential remains 
to be tested.  Whether the disease phenotypes are specific to human cells or redundant to current 
mouse models, using human cell types as a screening platform may offer another significant 
advantage:  the potential to eliminate at the outset false positives from drug screens where 
activity is limited to model systems but fails in the human genetic context.  
Cell transplantation 
A startling proof of principle experiment has also demonstrated the potential utility of IPS cells 
for cell replacement gene therapy approaches.  iPS cells were derived from humanized sickle cell 
mice, the sickle allele was then corrected by gene targeting.  Gene corrected iPS clones were 
then differentiation into hematopoietic progenitors and transplanted back to the sickle cell 
donors, which generated a profound rescue of the sickle phenotype (Hanna, Wernig et al. 2007). 
 
Conclusions 
We have seen that iPS cells can be generated from mouse and human somatic cells and that these 




can generate the cell types affected in many diseases and have already been used to generate 
highly relevant new model systems for a variety of developmental disorders and diseases.  
Several challenges and question remain from a disease modeling perspective however.  Most 
generally, will iPS-derived neurons, with presumably an embryonic ―age‖ like ES-derived 
neurons be able to mature sufficiently to reproduce disease relevant phenotypes which take 
decades to develop in vitro.  It also remains to be shown that the genetic constellation driving or 
permitting ALS or other neurodegenerative diseases will be powerful enough to effect this 
pathological transition in vitro.  Finally, do human iPS cells regain the tabula rasa of embryonic 
cells which will allow them navigate in vitro the normal course of development to generate 
extremely specific differentiated derivatives?  Specifically, in the context of ALS and motor 
neurons, will iPS cells demonstrate responsivity to multiple patterning cues to enact programs of 
diversification into dozens of specific and coherent motor neuron subtypes? 
 
Summary of outstanding questions and results 
We have reviewed the categories of vertebrate motor neuron diversity and their ontogeny.  In 
order to address the open question of how relevant these molecular categories are to human 
motor neurons in vivo we present  in Chapter 2 an analysis of the molecular markers of human 
motor neurons in vivo.  This study shows that the human spinal cord is remarkably similar in 
molecular organization to the mouse at the level of HOX protein, pan motor neuron, column and 
divisional marker expression.  In addition several motor pools familiar from chick and mouse 




human cords.  Most important for our purposes these findings validate a set of markers which 
can be used to assess human motor neuron subtypes in vitro.  
 We have seen that mouse ES cells can be used to model motor neuron development and 
generate a spectrum of motor neuron subtypes which adhere to coherent in vivo categories and 
display appropriate functional phenotypes.  We have learned that human ES and iPS cells can 
also generate motor neurons with perhaps a larger variety that mouse ES cells.  However there is 
limited evidence regarding the subtypes of motor neurons generated from human stem cells.  
Furthermore the maturation of human ES-derived motor neurons has not been systematically 
addressed in vitro.  We therefore present in Chapter 3 a detailed description of the diversity of 
motor neuron subtypes generated from human ES cells at the level of rostrocaudal and columnar 
identity, and analyses of their morphological and electrophysiological maturation in vitro.  These 
studies show that human ES-MNs include cells matching the molecular profiles of all identified 
in vivo motor columns and divisions, but are restricted predominantly to rostral spinal levels.  I 
also present evidence of the temporal sequence of ES-MN maturation in vitro at the level of 
molecules, morphology, and electrophysiology. 
We  have reviewed the exciting advances in the field of iPS cell reprogramming, but the capacity 
of these cells to generate ALS relevant cell types has been called into question.  In Chapter 4 I 
therefore present the collaborative derivation of a test set of human iPS cell lines and analysis of 
these lines for their ability to generate functional motor neurons, in comparison to human ES cell 
lines.  The results of these studies demonstrated a fundamental equivalence of iPS and ES cells 
in their ability to generate motor neurons with coherent identities and functional 
electrophysiology.  We also identify potential demographic sources of variability which could 




Finally, we reviewed the developmental mechanisms which control the diversification of spinal 
motor neurons from generic progenitors into a diverse array of columnar, divisional, and pool 
identities.  However these mechanisms have not been rationally deployed to generate specific 
subsets of motor neurons.  I therefore present in Chapter 5 the design of a developmentally based 
strategy to generate rostral vs. caudal spinal motor neurons.  These studies show that both ES and 
iPS cells can be manipulated developmental cues presented in a defined in vitro developmental 
time window to generate rostral or more caudal motor neuron subtypes, together representing 
most of the molecular diversity of coherent spinal motor neurons subtypes down to the level of 
divisional identity.  
Together these studies lay the groundwork for asking if specific motor pool subtypes can be 
generated from human stem cells. They also establish the conditions to test whether specific 
motor neuron columnar or motor pool subtypes will show differential responses to ALS in vitro, 
with the hope that these future studies will illuminate the mechanism of degeneration and 


















Figure 1.1. Neuronal subtype diversity in the central nervous system.  

































Figure 1.2. Motor columns, divisions, and pools: anatomy, targets, and molecular markers 
Motor neurons are grouped into 4 columns in the spinal cord: media motor column (MMC), 
hypaxial motor column (HMC), preganglionic motor column (PGC), and lateral motor column 
(LMC). (A) the MMC is continuous, while LMC is restricted to limb-levels, and HMC and PGC 
are restricted to thoracic.  HOXC6, HOXC9, HOXC10 are expressed in brachial, thoracic, and 
lumbar spinal cord and determine column identities appropriate to level.  HOXA5, HOXC8, and 
HOXD9 expression spans limb and non-limb levels. HOXA5 and HOXC8 participate in motor 
pool diversification in the brachial LMC. (B) Cross section at  limb and non-limb levels showing 
columns present.  The LMC is partitioned into a medial and lateral division.  (C) Motor column 
muscle targets: LMC, limb muscles;  PGC, sympathetic ganglia; HMC; hypaxial muscles: 
intercostals and abdominals;  MMC, epaxial muscles.  (D) Combinatorial gene expression 
uniquely identifies motor columns and divisions;  black type, high expression; grey type, low 










Figure 1.3. HB9 is expressed by motor neurons in the human embryo  
Adapted from (Hagan, Ross et al. 2000) (A) Autoradiographic image of HB9 in situ on Carnegie 
stage (CS)15 (day 35-38) human embryo section at the cervical level shows motor neurons in the 
lateral ventral horn, subventricular HB9 expressing cells (presumptive progenitors), and stomach. 
(B) Motor neurons and presumptive progenitors at cervical level CS 17 (day 42-44). (C-D) CS 
19 (day 48-51) sections(Bayer and Altman 2002) at cervical (C) and sacral (D) levels show 



















Figure 1.4. Histological analysis of the developing human spinal cord. 
 (A) ―4 week embryo‖ showing newborn motor neurons extending axons through the ventral 
root, Ramon y Cajal 1909 (B) Gestational week (GW) 4-14 human embryo time series shows the 
period of motor neurogenesis and motor column segregation at the cervical level. From (Altman 


















Figure 1.5. Histological analysis of the period of motor neurogenesis in the human spinal 
cord 
(A) Gestational week (GW) 4.5 embryo section from cervical level shows the first motor neurons 
have migrated laterally. (B) GW 5.5 embryo at cervical level has large contingent of motor 
neurons in ventral horns and a thinned, potentially depleted ventral subventricular 








Figure 1.6. Sonic hedgehog protein patterns the ventral neural producing neuronal 
diversity 
 Sonic hedgehog (Shh) protein is secreted by the notochord and forms a ventral to dorsal 
concentration gradient in the ventral half of the neural tube.  Class I and Class II HD 
transcription factors are induced and inhibited at staggered Shh concentration thresholds.  Cross 
repressive interactions between Class I and Class II HD proteins resolve a series of 5 progenitor 
cell identities in specific dorsoventral domains.  Motor neuron progenitors (pMN)s express 
Nkx6, Olig2, and Pax6.  pMNs give rise to postmitotic motor neurons which express HB9, 












Figure 1.7. Wnt and FGF induce CDX gene expression which encodes caudal neural 
identity  
(A) Wnt is secreted from paraxial mesoderm and FGF from the primitive streak in Hamburger 
and Hamilton (HH) stage 3
+
/4 chick embryos leading to (B) expression of CDX genes by HH8 (4 
somite stage) in prospective caudal neural tissue (hindbrain and spinal cord).  Adapted from 
















Figure 1.8.  FGF and RA subdivide caudal neural pattern through HOXC genes  
(A) Between the 4- and 15-somite stages retinoic acid (RA) produced by rostral somites, and 
FGF secreted by the node generate (B) the pattern of spinal cord and motor neuron HOXC gene 
expression which controls motor column identity.  Node derived GDFs are required for 
















Figure 1.9. FOXP1 dose-dependently marks LMC and PGC motor neurons  
(A-D). FOXP1 is expressed at high levels by (A) brachial and (C) lumbar LMC motor neurons, 
and low levels by thoracic PGC motor neurons. (D) FOXP1 pixel intensity for dorsal spinal cord 
(dSC), HMC, MMC, brachial and lumbar LMC, and PGC shows ~5 fold lower level expression 
in PGC vs LMC motor neurons. (E-F) partial molecular profile of motor columns present at (E) 

























Figure 1.10.  Xenotransplanted mouse ES-MNs integrate into chick motor system 
Mouse HB9:GFP ES-MNs (green) were xenotransplanted to brachial spinal cord of HH 15/16 
chick neural tube and the host was allowed to develop for 2-3 days.  Mouse ES-MNs settled in 
ventral horns and projected along endogenous muscle nerves (neurofilament-red) towards 
hypaxial, epaxial, and limb muscles, but not towards sympathetic chain ganglia.  Mouse ES-MNs 








Chapter 2.  Molecular description of human motor neuron diversity: rostrocaudal regions, 
columns, divisions, and pools 
 
Introduction 
Since the experimental work in this thesis was to be focused on identification of human motor 
neuron subtypes, we first reviewed the published data on motor neurons in the fetal human spinal 
cord. Human spinal motor neurons are arranged in rostrocaudal columns in the ventral horns of 
the spinal cord (Altman and Bayer 2001; Bayer and Altman 2002).   These are anatomically 
divided into a medial group, innervating axial muscles and found throughout the cord, a lateral 
group, innervating limb muscles, found only at cervical and lumbar levels, and a dorsolateral 
group found predominantly at thoracic levels which innervates sympathetic ganglia (Altman and 
Bayer 2001; Bayer and Altman 2002).  In vertebrate model systems the molecular determinants 
and markers of the subtypes of motor neurons have been well defined at the ontological and 
molecular levels and were reviewed above.  Taken together these markers form a combinatorial 
code that links expression of a set of markers to in vivo subtype identities at the level of motor 
column and division (Table 2.1).  If similar correlations could be established for human motor 
neurons in vivo, this would provide important tools for developmental studies. 
While a wealth of histological information is available regarding the development of the human 
spinal cord (Altman and Bayer 2001; Bayer and Altman 2002), few molecular tools have been 
brought to bear on these samples.  Of the classical markers of motor neuron identity only HB9 
(Ross, Ruiz-Perez et al. 1998; Hagan, Ross et al. 2000) has been investigated at the level of 
mRNA.  However, this study did not address motor neuron columnar or rostrocaudal diversity.  




ER81 at GW 13, but did not find HMC-specific expression as expected (Clowry, Moss et al. 
2005).  These findings suggest that human motor neurons do express some of the markers 
characterized in other vertebrate models but leave the question of human motor neuron 
rostrocaudal and columnar diversity completely open.   
We have discussed the determinant role that HOX genes play motor neuron diversification.  We 
have also discussed the expression pattern and subsequent role that HOXA5 and HOXC8 play in 
diversifying the brachial lumbar LMC into a series of motor pools.  Other HOX proteins are also 
expressed throughout the rostrocaudal length of the spinal cord as well and serve as markers of 
rostrocaudal identity and appear to have significant functions in determining motor neuron 
diversity.  The expression profile of HOXD9 in mouse, for example, like HOXA5 and HOXC8, 
spans the border between thoracic and limb-innervating (lumbar) regions (Jung, Lacombe et al. 
2010), summarized in Table 2.1.  Furthermore, functional experiments show that HOXD9 over-
expression in thoracic spinal cord was able to ectopically drive LMC identity.  Additionally, 
because of surfeit of HOX paralogs and possible redundancies, their modular and shifting 
activities across evolution, and the action of multiple interacting co-factors, it will be important 
to test for the expression of proteins like HOXA5, HOXC8, and HOXD9, in addition to HOXC 
genes and other HOX proteins in human cords. 
Our overall goal was to determine which markers of motor neuron diversity at the level of 
rostrocaudal HOX protein expression and markers of motor column, division, and pools are 
conserved in the human system.  We hoped this effort would generate molecular markers and 
validated reagents that could be used to analyze the subtypes of motor neurons generated in vitro 
from human stem cells.  To this end we first defined the expression pattern of the classical motor 




sought to determine the presence and expression pattern of the molecular markers of motor 
column identity (FOXP1, LHX3, pSMAD, ISL2, and LHX1).  We then addressed whether the 
combinatorial expression of LIM homeodomain proteins and pan-MN markers could distinguish 
the medial and lateral divisions of the LMC.  We then searched for the molecular signature of 
specific motor pools in the brachial LMC, first by examining LIM homeodomain combinations 
in the context of column markers, and second by addressing expression of motor pool specific 
markers.  Finally, since HOX proteins are markers of rostrocaudal identity in vertebrate motor 
neurons, and some HOX proteins are determinant for columnar and many pool identities, we 
tested a series of HOX antibodies to determine the characteristic expression of HOX proteins 
along the rostrocaudal length of the spinal cord.   
 
Results 
Description of human embryonic spinal cord samples 
In order to compare the molecular profile of human motor neurons to the model established for 
chick and mouse, we collaborated with clinicians at CUMC to obtain first-trimester human 
embryos from voluntary terminations.  The developmental stage of samples was estimated by 
clinicians by patient oral history by subtracting 2 weeks from the date of the last menstrual 
period (LMP) to yield an estimated gestational week (GW) age of development.  In some cases 
this was supplemented by intrauterine ultrasound to measure crown-rump length.  Following 
informed consent and termination procedure, products of conception were evaluated for the 
presence of intact spinal tissues within 10 minutes.  Samples were photographed, dissected free 




dissected into ~5-mm segments for embedding, measured and photographed again (Fig. 2.1).  
Ten spinal cord samples from reported GW 6-10+ were collected, processed and embedded 
(Table 2.2).  The remaining sections (of three embryos, see below) and un-sectioned tissue 
blocks (seven embryos) will remain at the Project ALS lab as an open resource for the 
investigation of protein expression in early human spinal cords.  Three almost fully intact spinal 
cords were examined in this study in detail: one GW 8 and two GW 7 cords.  All samples 
initially showed a full complement of dorsal root ganglia, however many of these were removed 
during sub-dissection from the vertebral column.  Both GW7 cords showed thin ventral rootlets, 
while the GW8 sample showed thicker ventral roots. 
In GW7 sample 1 (Fig. 2.1A) the spinal cord was intact from the cauda equina, which was 
embedded in the pelvis, to the level of the clavicle whereas all more rostral neural structures had 
been lost.  The linear length of the cord was 17 mm ( all measurements post-fixation).  GW 7 
sample 2 (Fig. 2.1B) was largely intact from the pelvic cauda equina through most of the 
hindbrain, however several lesions were present including a large one at the juncture of the 
spinal cord and hindbrain.  The linear length of this cord, including hindbrain, was 25 mm.  The 
GW 8 sample (Fig. 2.1C) was intact from cauda equina to mid-lumbar level where a lesion had 
sectioned the cord, and then intact again up to the level of the clavicle.  The GW 8 spinal cord 
was thicker and whiter, suggesting more advanced neurogenesis and development of white 
matter tracts, and showed obvious enlargements in the lumbar and cervical areas.  Both GW 7 
week cords were dissected into three, and the GW8 cord into four, ~6-mm segments, embedded, 
and then sectioned through their entire length into 12 µm serial sections deposited serially on 59-
112 slides per cord with 6-7 sections per slide.  This allowed observation of 18-24 sections per 




human spinal cord samples are readily available following scheduled terminations, and that the 
vertebral column often protected this tissue from significant intra-operative physical damage 
even while most other neural and somatic tissues were lost or destroyed. 
Expression of pan-motor neuron and motor column markers 
We first sought to determine the rostral and caudal limits of the brachial and lumbar limb-
innervating LMCs using both histochemical and morphometric approaches.  Using antibodies 
that recognize the classical pan-motor neuron markers HB9 and ISL1, and another selective for 
the LMC (FOXP1) we identified groups of ventral horn cells positive for all combinations of 
these markers (Fig. 2.2A).  In order to align the two GW 7 cords we computed the rostrocaudal 









 (putative LMC MNs) by multiplying the number sections with LMC by the 
section thickness (12 µm).  The mean length of the rostral LMC-containing region was 3.3 mm 
(range=0.3 mm), and of the caudal LMC-containing region was 4.5 mm (range=0.4 mm), and 
these were designated as brachial and lumbar fore- and hind-limb innervating levels respectively.  
The length of spinal cord in between LMC-containing sections was designated as thoracic and 
measured 5.1 mm (range=0.3 mm) (Fig. 2.1D).  In these GW 7 cords the brachial and lumbar 
LMC were not visible as enlargements under the dissecting scope.  In the older, GW8 embryo 
however, both brachial and lumbar enlargements could be appreciated and corresponded to the 
rostrocaudal location of LMCs as identified later by immunohistochemistry (Fig. 2.1C).  In all 
subsequent experiments this allowed the coordinates of a given spinal section to be determined 




In order to determine whether human motor neurons shared the molecular markers of motor 
column identity as defined in chick and mouse, we analyzed the expression of the LMC and PGC 
marker FOXP1, and the MMC marker LHX3, among HB9 and ISL1-expressing cells in the 
ventral horns.  All observations were made on at least 4 sections per spinal level (limb/non-limb) 
and were consistent between both GW 7 and the GW 8 embryo, unless otherwise noted.  At all 





observed in a ventromedial position (Fig. 2.2A).  These cells could be clearly delineated into two 
columns on the basis of strong LHX3 expression in the more medial group and the absence of 
LHX3 in the more lateral group.  These molecular profiles are consistent with MMC and HMC 
identity in mouse and chick.   ISL1 expression was generally higher in the HMC than MMC, and 
HB9 expression generally higher in the MMC, although there was substantial variation in 
expression levels of each marker in both columns (Fig. 2.5).  We next sought to confirm the 
identity of the HMC using antibodies that detect the ETS protein ER81, which serves as a 
specific maker for the HMC  (Dasen, Liu et al. 2003) (Table 2.2).  However, none of the ER81 
antibodies showed specific reactivity with any cells in human samples.  Finally, a small 
population of  ISL1
+
 cells was observed in a dorsolateral position corresponding to the PGC 
(Bayer and Altman 2002) and these co-expressed low levels of FOXP1, corresponding to the  
molecular profile of PGC MNs in chick and mouse (Fig. 2.3; see below). 





) could be subdivided into a dorsomedial group with higher ISL1 and 
lower HB9 expression levels and a ventrolateral group with lower ISL1 and higher HB9 
expression.  These molecular profiles match those of the medial and lateral divisions, 




the medial or lateral divisions was more pronounced in the lumbar LMC (Fig 2.2 and see Fig 2.5 
for quantitation).    
In summary the motor columns of the human spinal cord show characteristic molecular profiles 
that correspond to those defined in mouse (summarized in cartoon, Fig. 2.2B, C).  At limb levels 
the MMC is marked by LHX3 and expresses HB9 and ISL1.  At non-limb levels LMCs are 
absent and the MMC is joined by the HMC and the PGC. For ease of reference data from 
subsequent figures has been incorporated into the summary diagrams of Fig. 2.2. 
PGC MNs express pSMAD and low levels of FOXP1 
In order to substantiate the identity of the putative PGC cells, we tested antibodies for other PGC 
markers (Fig 2.3).  First, cords were stained with an antibody specific for the phosphorylated 
forms of SMAD proteins 1,5 and 8, which act as a selective marker for chick and mouse PGC 
MNs (Dasen, De Camilli et al. 2008).  This antibody selectively distinguishes the dorsolateral 
population of putative PGC neurons found at thoracic levels, and was not co-expressed by MNs 
in other columns or spinal levels (Fig. 2.3B).  In addition we tested an antibody to neuronal nitric 
oxide synthase (nNOS) which is a specific marker for PGC cells in mouse. However this 
antibody showed no reactivity on human samples. 
Next, since PGC cells are known to express low levels of FOXP1 (Dasen, De Camilli et al. 2008) 
we analyzed the expression level of FOXP1 in LMC vs. PGC cells.  All images were captured at 
the same non-saturating exposure time in order to directly compare staining intensity.  In order to 
compare FOXP1 expression levels between these columns in one representative GW 7 embryo, 
we first restricted intensity analysis to the region including only the ISL1
+
 LMCm, at 2 








 cells at 4 representative levels of the thoracic cord.  We used Metamorph to measure 
the FOXP1 staining intensity for ISL1
+
 nuclei in each of these regions showed that FOXP1 
intensity was significantly different between PGC, brachial and lumbar LMCM  (Shapiro-Wilk 
normality test failed, p<0.05,  ANOVA, Kruskal Wallis ANOVA on RANKS , H=206.650, 
DF=2, P=<0.001).  PGC cells (n=235) showed significantly lower FOXP1 intensity compared 
brachial LMCM (n=269, Dunn‘s pairwise comparison, Diff. of ranks= 201.709, Q=10.801, 
p<0.05), or  lumbar LMCm (n=220, Dunn‘s pairwise comparison, Diff. of ranks=267.972, 
Q=13.658, p<0.05).  Interestingly the brachial LMCM expresses significantly higher levels of 
FOXP1 than the lumbar LMCm  (Dunn‘s pairwise comparison, Diff. of ranks=66.264, Q=3.485, 
p<0.05) (Fig. 2.3C).  Finally, when grouped together LMC cells showed significantly higher 
FOXP1 staining than  PGC motor neurons (Shapiro-Wilk normality test failed, p<0.05, Mann 
Whitney Rank Sum Test, T=48440.000  n(small)= 235  n(big)= 489  (P = <0.001)).  We 
concluded from these data that this population represented human PGC MNs since there is a 









 and a quantitatively low level FOXP1 expression.  
We therefore established that all mouse motor columns (MMC, HMC, LMC, and PGC)  are 
present in human at the same relative rostrocaudal levels as in mouse, and are unambiguously 
delineated by a combination of pan-MN (HB9 and ISL1) and motor column (FOXP1, LHX3, 
pSMAD) markers.  We next revisited the marked difference we had observed in HB9 and ISL1 
expression between lateral and medial LMC cells, in order to determine if the medial and lateral 
divisions of the LMC were molecularly distinct in the human.  To do this we used two 




can distinguish these divisions in mouse and chick, and second we performed a quantitative 
analysis on the expression levels of HB9 and ISL1 in these divisions and in control cells. 
Molecular characterization of the medial and lateral divisions of the human LMC 
To determine how closely human LMC medial and lateral divisions resemble mouse LMC 
divisions we profiled the expression of ISL2 and LHX1 in human LMC in the context of 
HB9/ISL1/FOXP1 expression (Fig. 2.4).  We found that LHX1 was excluded from the MMC 




  LMCL.  LHX1 was also 
expressed at moderate levels by many non-motor neurons in the spinal cord.  ISL1, as shown 
previously, is expressed in both MMC and LMCM, but only weakly in the LMCL.  ISL2 however 
was expressed in LMCL as well as the MMC and the LMCM.  This pattern of expression mirrors 
that in mouse and chick and is summarized in Figure 2.4.  We concluded that human LMC 
divisions express combinations of LIM homeodomain proteins and column markers conforming 
to the established vertebrate models of divisional identity. 
HB9 and ISL1 expression levels vary from cell to cell but are correlated with motor column 
identity 
Because we had observed an obvious qualitative difference in average expression level of HB9 
and ISL1 between different LMC divisions, and variation in relative expression levels in HMC 
and MMC columns, we sought to describe this phenotype quantitatively.  We hoped these 
analyses would clarify the utility and limits of these widely used ―pan‖-MN marker proteins by 
reference to in vivo expression patterns, and that this should have direct implications for the use 




We therefore quantified the qualitative expression pattern of HB9 and ISL1 that was consistent 
across all 3 embryos, by examining one representative GW 7 embryo in greater detail.  We first 
drew boundaries closely around the cell groups as defined by the foregoing combinatorial 
analysis of motor column and division markers (regions shown in thin lines labeled  by column  
Fig. 2.5A) and then used Metamorph Multiwavelength Cell Scoring module to identify all 
DAPI
+
 nuclei, as well as nuclei which expressed high levels of either HB9 or ISL1 (Fig. 2.5A).  
This analysis quantitated the number of motor neurons (as defined by high level expression of 
either HB9 or ISL1 and within the boundaries of motor columns defined here and consistent with  
previous histological studies (Altman and Bayer 2001; Bayer and Altman 2002)  in 2-3 
representative sections per spinal level (as defined by limb or non-limb innervating (Fig. 2.5B, 
D, E) as well as the expression level of each protein in each cell, as judged by 
immunofluorescence intensity, which allowed us to describe the mean intensity of expression for 
each marker in each column (Fig. 2.5C).  
To define the specificity of these markers in human spinal cord we first analyzed their expression 
in non-motor neuron populations.  A population of dorsal cells, presumptive interneurons, found 
at all spinal levels (DOR IN, Fig. 2.5A, C), showed ISL1 levels comparable to those in the MMC 
or HMC but expressed only background levels of HB9.  Dorsal root ganglia (DRG) sensory 
neurons expressed variable but very high levels of ISL1 but showed only background signal for 
HB9.    Finally we observed at all spinal levels that a population of columnar epithelial cells 
composing the ventral floorplate (FP) (Bayer and Altman 2002) showed only background level 
ISL1 staining, but stained for HB9 at levels comparable to those in the HMC.  We concluded 
from these analyses that coexpression of HB9 and ISL1 is restricted to MNs, but that HB9 and 




spinal cord at GW 7. With the exception of sub-floorplate expression, these expression patterns 
match those described in mouse literature. 
To determine if relative expression patterns of HB9 and ISL1 differed according to columnar 
identity, we next examined for each motor column the percentage of cells that scored positively 
for either marker, as well as the mean expression level per column (Fig. 2.5B-F).  All motor 













The extremes were constituted by the LMCL, where very few ISL1
+
 cells did not co-express HB9 
and the brachial and lumbar LMCM, where many MNs expressed ISL1 but not HB9 (Fig. 
2.5B,D).  At both brachial and lumbar levels, the mean intensity of HB9 expression was greater 
in the LMCL than the LMCM, and the mean intensity for ISL1 was the reverse.  The range of 
expression levels however was relatively large compared to the mean difference, especially at 
brachial levels (Fig. 2C).  We concluded from these analyses that ISL1>HB9 is characteristic for 
LMCM MNs and HB9>ISL1 is characteristic for LMCL MNs in vivo.  However due to the 
presence of many co-expressing cells in both divisions, the presence of robust numbers of 
individual divisional MNs which violate this rule, and a wide range of expression values, 
HB9/ISL1 co-expression levels are insufficient to predict the divisional identity of individual 
cells.  Importantly, the presence of many LMC MNs expressing low or background levels of one 
motor neuron marker indicates that either marker in isolation is insufficient to capture the 
breadth of motor neuron diversity.  Analyses based on HB9 alone will miss much of the LMCM 
and those based on ISL1 alone will exclude much of the LMCL, for example. 
Finally, to determine if there was a distinctive pattern of HB9 and ISL1 expression in MMC vs. 
HMC motor columns we performed the same analyses on these populations.  We observed that a 




some cells expressed only one or the other marker at high levels. (Fig. 2.5B, D).  We concluded 
that a more balanced level of HB9 and ISL1 co-expression is characteristic of both the MMC and 
HMC, when compared to the LMCs.  Again HB9 and ISL1 expression status alone could not 
alone distinguish columnar identity.  
In order to facilitate comparisons to ES-derived motor neurons in vivo, we also grouped these 
data together in several other ways.  Since ES-derived motor neurons may well include motor 
neurons from multiple columns at the same level, we asked what the overall distribution of HB9 
and ISL1 cells was if we grouped all columns together at a given level, grouped all levels of a 
given column together, or analyzed all motor neurons at once (Fig. 2.5E, F).  These could then be 
compared to similar profiles for ES- and iPS-derived motor neurons discussed in Chapter 3 and 
Chapter 5. 
In summary these analyses show that the ratio of HB9/ISL1 expression varied continuously from 
1:0 to 0:1.  This means that not all HB9
+
 MNs express ISL1 and vice versa.  Strong ISL1 
expression was characteristic of LMCM, strong HB9 expression characteristic of LMCL, and 
strong co-expression is characteristic for MMC and HMC.  However, wide variation between 
individual cells means that these markers alone are not sufficient to ascertain columnar or 
divisional identity and, outside the embryo, will need to be used in combination with other 
columnar or subtype markers.  
Molecular characterization of putative motor pools 
Having established that human motor neurons express the canonical markers delineating 
vertebrate motor neuron subtype identities at the level of motor neuron, column and division, we 




marker expression patterns to those of the mouse and chick.  We first looked at the rostral 
brachial LMC, a region in which in mouse and chicken motor pools have been mapped by 
retrograde tracing studies and correlated with a combinatorial code of LIM homeodomain protein 
expression (Ensini, Tsuchida et al. 1998) (Fig. 2.6).  First we established that MMC and LMC 
MNs at this level express HOXA5, thereby anchoring this region in the rostral brachial LMC 
(see below for HOX expression patterns).   
We first observed a more lateral-lying ventral population not found at other levels of the human 
cord which was positive for HB9, ISL1, ISL2, and LHX3 but not LHX1.  This distinctive 
molecular profile and lateral location are consistent with those of the chick rhomboideus (RB) 
motor pool, and we therefore concluded that this population is likely the human RB motor pool. 
We also observed a population of LMCL cells dorsal to the putative RB pool that expressed the 
combination of markers found in the chick deltoid (DL) motor pool: high ISL2, but not ISL1, 
and high LHX1, suggesting that this may be the human DL motor pool.  In the chick another 
LMCL pool is distinguishable at this level by its low level expression of ISL1 and LIM1, the 
extensor metacarpi radialis/ulnaris (EMR).  We did not see a clear indication of this molecular 
profile in our samples, however since it is based on a subtle reduction in staining intensity of 
ISL2 and LHX1 other markers may  be required. We did however observe another, more unusual 
combination of markers situated in a motor pool-size group of motor neurons situated within the 
boundary of the ISL1
+
 LMCM.  These cells expressed high levels of ISL1, ISL2, and FOXP1, but 
not LHX1, consistent with LMCM identity.  However, these cells also expressed high HB9, 
which as we have seen is not completely inconsistent with LMCM identity, especially at brachial 
levels. However such a concentrated group of strongly HB9
+
 cells in the LMCM was not seen at 




pattern was found in all three embryos examined.  There is no reported cognate for this 
expression pattern in mouse or chick, raising the possibility that this novel molecular profile 
corresponds to one or more motor pools that may be human- or primate-specific.  Although 
formal confirmation by retrograde labeling is clearly not feasible, this analysis therefore 
potentially confirms the presence in human of one motor pool, the RB, already identified in 
chick, provides evidence consistent with another, the DL, but fails to find clear evidence for the 
EMR motor pool. Interestingly we provide evidence for a novel species-specific motor pool with 
atypical molecular characteristics, which may be linked to evolutionarily new motor functions. 
Another approach to identifying human motor pools was to use motor pool-specific genes found 
in chick and mouse.  We tested several antisera used to identify chick and mouse motor pools 
including:  ER81, SCIP, PEA3, and RUNX1.  Of these only one, the anti-PEA3 antiserum, 
showed reactivity on human samples. A subset of motor neurons within the rostral end first 200 
µm of the HOXC8 domain (see below) of the rostral brachial LMCL (Fig. 2.7) stained for PEA3.  
Just caudal to these LMCL cells, a PEA3
+
 ,  LMCM population was also observed (not shown) to 
express PEA3 (Fig. 2.7).  The rostrocaudal position and divisional identity of the more rostral 
LMCL and more caudal LMCM putative motor pools match the anterior latissimus dorsi (ALD) 
motor pool in the chick/ the LD motor pool in the mouse and the cutaneous maximus (CM) 
motor pool in the mouse respectively (Dasen, Tice et al. 2005; Vrieseling and Arber 2006).  In 
the lumbar region we lack the precise rostrocaudal information conveyed by the 
HOXA5/HOXC8 boundary in the brachial LMC.  However since the PEA3
+
 cells were in the 
LMCL we can infer that they belong to the human cognate of one of three identified PEA3
+
 chick 
LCML motor pools: the iliotrochanterici (at chick LS1-3), the anterior iliotibialis (LS3-5), or the 




motor pools: rectus femoris (L1-L2) or the gluteus (L2-L5)  (Arber, Ladle et al. 2000). Because 
of the caudal location of this human PEA3
+
 LMCL putative pool (3.1 mm caudal to the rostral 
aspect of the 5.5 mm LMC region) it is more likely to correspond to the mouse gluteus, the 
chicken iliotibialis or caudilioflexorius muscles, the latter of which does not have a clear cognate 
in human.  More definitive assignment of any of these pools would require retrograde tracing 
studies or additional markers.   
We have therefore shown evidence by combinatorial expression of LIM-HD proteins as well as 
the specific ETS protein marker PEA3, that the some of the molecular categories down to the 
level of motor pool are conserved in human.  In the process we identified a novel species-
divergent motor pool potentially associated with evolved hand/wrist motor functions. 
HOX gene expression defines rostrocaudal motor neuron domains 
We next asked if HOX proteins were expressed in the stereotyped collinear array which controls 
chick and mouse motor neuron diversification (Dasen, Liu et al. 2003; Dasen, Tice et al. 2005). 
We first screened a panel of 15 commercial and academic anti-HOX antibodies for their 
reactivity with human antigens present in our spinal cord samples and found that antibodies 
against HOXA5, HOXC8 and HOXD9 (Table 7.1) exhibited strong and stereotypical staining of 
human spinal cords (Fig 2.8).  HOXA5 expression began in the cervical region and penetrated to 
the mid-brachial LMC; HOXC8 expression began in the mid brachial LMC and continued about 
halfway into the thoracic region; and HOXD9 expression was initiated caudal to thoracic 
HOXC8 expression, and continued caudally through the rostral third of the lumbar LMC.    This 
expression pattern is identical to that described in chick (Liu, Laufer et al. 2001; Dasen, Liu et al. 




concluded that human motor neurons conserved the same pattern of HOX protein expression for 
these family members. 
We also noted several other aspects of HOX expression which conform to expectations based on 
other vertebrate models.  First, the rostral onset of each HOX gene began in the dorsal, non-
motor neuron spinal cord, and gradually, within a few 100 µm caudal, penetrated ventrally to 
encompass all MNs at a given level.  Second, we noted that the HOX genes analyzed were 
almost never co-expressed by individual cells in any section examined.  This was especially 
important for the case of HOXA5 and HOXC8 whose expression zones in mouse and chick, and 
now in human, are immediately adjacent, and indeed slightly overlapped such that for several 
hundred µm  some LMC groups at the same level are HOXA5
+
 and some are HOXC8
+
.  Even at 
these levels however, individual cells coexpressing these HOX genes were exceptionally rare.  
We concluded from these data that these HOX genes were expressed mutually exclusively in 
human samples. 
Finally, as this thesis was being written, several HOX antibodies were reported to define the 
rostrocaudal subtype of human ES-derived motor neurons in vitro (Patani, Hollins et al. 2011)  
We therefore tested these in order to gain a more complete picture of HOX expression in the  
spinal cord.  One HOXC10 monoclonal antibody used in the Patani study showed no staining on 
any cells at any level in the spinal cord in our hands, and is reported to detect only chick and not 
mouse protein (Susan Morton and Jeremy Dasen personal communication, and DSHB data 
sheet).  Additionally, one HOXC9 antibody (#25 Table 7.1) stained every spinal cell at every 
location and dilution tested where any cells were stained.  These data suggest that the in vitro 






Together these studies provide a global map of human spinal motor neuron diversity that 
correlates the combinatorial expression of two classical motor neuron markers (HB9 and ISL1) 
with selective markers of motor column identity (FOXP1, LHX3), three accessory markers of 
columnar identity (ISL2, LHX1, pSMAD), and three HOX proteins (HOXA5, HOXC8, 
HOXD9) (Table 2.3).  We conclude that the molecular diversity of motor neurons at this early 
developmental stage is exquisitely conserved from mouse and chick to human, with the 
exception of one putative human-specific motor pool.  Importantly, these findings validate a set 
of antibodies that will be instrumental for characterization of in vitro derived human MNs. 
Human motor neurons show conserved molecular organization with vertebrate models 
We have provided evidence that human MNs in vivo are grouped into the same molecular 
categories as chick and mouse MNs.  This includes selective markers for the MMC (LHX3), 
LMC (FOXP1), and PGC (FOXP1
LOW
, pSMAD).  The medial and lateral divisions of the LMC 
(LMCM/L) also exhibited canonical distinguishing markers:  the LMCL showed dominant ISL1 
expression, and the LMCL showed dominant HB9 expression, and also the combination of ISL2 
and LHX1.  Human motor neurons also exhibited the conserved molecular signature of several 
individual motor pools.  At the brachial level, motor neuron groups matching the profile of the 
rhomboideus and deltoid motor pools were identified.  At both the brachial and lumbar levels 
restricted groups of LMCM/L motor neurons expressed PEA3, which matched the profile of 
anterior latissimus dorsi and cutaneous maximus pools at the brachial, and a likely match for the 




those HOX proteins which we were able to detect, precisely matches that in chick and mouse, 
where HOXA5 is expressed in cervical to mid-brachial, HOXC8 in mid brachial to mid thoracic, 
and HOXC9 in mid thoracic to mid-lumbar. 
Implications for developmental mechanisms 
The remarkable conservation of markers for these key aspects of motor neuron organization 
suggests that the a very durable and flexible logic for motor neuron diversification and 
integration with an evolving body plan was achieved early in vertebrate evolution and has not 
significantly changed since.  Importantly this conservation implies that many of the mechanisms 
orchestrate the developmental elaboration of this diversity may also be strongly conserved.  In 
support of this idea are the known functional roles for several of the marker proteins used.  
FOXP1 in particular plays a decisive role in directing the organization of limb-innervating motor 
neurons, as shown by the atavistic phenotype of knockouts (Dasen, De Camilli et al. 2008).  
HOXA5 and HOXC8 also play strong functional roles, although downstream of both HOXC6 
and FOXP1, in controlling the elaboration of brachial motor pool identities (Dasen, Tice et al. 
2005).  And HOXD9 can drive lumbar LMC identity when over-expressed in thoracic MNs, 
although at endogenous levels this function is kept at bay by the LMC-repressive activity of 
HOXC9 (Jung, Lacombe et al. 2010). 
None of the HOX proteins we were able to study exclusively determine motor column identity in 
chick or mouse.  This is clear since in model systems and now in human each of their expression 
domains crosses a boundary between limb and non-limb levels and they are expressed in both 
LMC cells at limb-levels and MMC and HMC cells at limb and non limb levels.  It will thus be 




expression of the HOXC genes (6, 9, 10) which have been shown to determine columnar 
identity.  This would add stronger evidence that the mechanisms underpinning motor column 
diversification are conserved in human, and also provide the most direct upstream markers by 
which to test ES-cell directed differentiation approaches aimed at controlling rostrocaudal and 
column specific identities.  Nevertheless the strong conservation of markers like FOXP1 and 
LHX3, known to be functional determinants of subtype identity, provides strong evidence 
supporting the idea that consensus vertebrate model mechanisms could be used as the basis for 
ES-cell directed differentiation approaches seeking to control the subtype output of motor 
neurons.   
Identification of a novel molecular profile and putative motor pool 
The one significant difference identified between human and other vertebrates was the 
identification of putative motor pool with novel characteristics in the rostral brachial LMCM.  
This pool expressed markers appropriate to the LMCM but also expressed LMCL markers, but 
more interestingly it expressed both LMCL and MMC marker proteins (FOXP1 and LHX3).  
There is no known cognate for this molecular profile in chicken or mouse.  In the most definitive 
study of human developmental spinal motor anatomy, which included inferences based on 
comparison to retrograde tracing studies in rat, cat, and other species, these authors speculate that 
motor neurons in this rostral cervical and most dorsal position were likely to innervate hand or 
wrist muscles (Altman and Bayer 2001).  It is tempting to speculate that this novel motor pool 
innervates a muscle with novel function in humans or primates, and one obvious choice would be 
thumb or hand muscles.  On the other hand, the presence of axial and limb muscle determinants 
may point toward an intermediate function, once involved perhaps in species or primate specific 




derived characteristic is shared with primates or if it is human specific.  In a general sense, we 
should expect more specific differences with mouse to emerge in future studies, particularly at 
the level of individual motor pools. 
Interpretation of negative results 
Most of the antibodies and antisera tested for HOX genes, column, and pool markers showed no 
reactivity on human samples.  We did not interpret these results as positive evidence that these 
factors were not expressed in human for the following reasons.  First, none of the reagents that 
failed to show staining in our hands have been validated by others to work on human tissues, 
with the exception of ER81, and we did not confirm the precise antiserum used in that study 
(Clowry, Moss et al. 2005).  Second, in most cases these reagents were designed based on chick 
or mouse protein sequences.  Protein sequence analysis where proteins or peptides were used for 
immunization, showed variable and incomplete similarity between human and mouse or chick 
sequences.  Even where differences concern only several amino acids, this could easily explain 
the inability to detect human proteins.  This points to the need to develop validated human-
reactive reagents for many marker proteins of interest, most importantly the HOXC proteins 6, 9, 
and 10 since these are determinant for columnar identities, and other motor pool markers.  In 
parallel, in situ hybridization approaches should be attempted to directly assess expression of 
human genes for which there are no antibodies. 
Interpretation of in vitro motor neuron phenotypes 
The map of marker expression detailed here can now be used as a strong basis from which to 
interpret in vitro molecular phenotypes (Table 2.2).  Based on this map, specific molecular 




identities.   Since some marker combinations were not observed in vivo—HOXA5+HOXC8+ 
cells for example—this map can also indicate where potential in vitro expression patterns do not 
match any in vivo cell type.  This map can therefore be used to evaluate the effect of 
differentiation strategies on subtype or rostrocaudal identities and to confirm that these subtypes 





Anne Davis, MD and her fellows were generous and enthusiastic collaborators who providing 
access to embryos which made this entire enterprise possible; Tom Jessell generously provided 
numerous monoclonal antibodies and antisera and Susan Morton provided antisera and 
monoclonal antibodies for HOX genes, pan-MN antibodies, and pool markers, and generously 
provided years of consultation on mouse expression patterns and antigen sequences, designed 
peptides and oversaw immunization projects and screened antisera to generate new 
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Table 2.1. Summary of motor neuron rostrocaudal, columnar, and divisional subtype 
marker expression in chick and mouse 
Compiled from chick and mouse primary references reviewed in Chapter 1, rostral/caudal 
subdivisions of brachial, thoracic, and lumbar are defined by expression of HOXA5, HOXC8 
(Liu et al. 2003) in chick and HOXD9 (Jung, Lacombe et al.) in mouse.  Black boxes indicate 
high level expression, grey boxes indicate low level or no expression, and white boxes indicate 
no expression. Question marks indicate lack of strong supporting evidence for marker expression 

























Figure 2.1. Documentation of human spinal cord samples and linear length of limb-
innervating and thoracic regions 
(A-C) embryonic human spinal cords from gestational week (GW) 7 and 8 used in this study. 
Scale bars 1 mm (D) Mean post-fixation linear length (µm) + range of regions in GW 7 samples 
(n=2) staining for FOXP1
+
 LMC in the brachial and lumbar regions, where thoracic was defined 
as the region between LMC
+





























Table 2.2. Human embryonic spinal cord resource 
Catalogue of human embryos collected for spinal cord staining.  Reported age in gestational 
weeks (GW) was determined by clinicians by patient reported last menstrual period and was 
sometimes informed by pre-operative crown-rump length ultrasound measurement.  Reported 
age was adjusted if embryonic development appeared to be out of phase with reported age.  All 
10 specimens were fixed, cryoprotected, dissected free from any attached tissue, photographed, 
subsectioned and embedded in OCT for cryosectioning.  Spinal cords in grey were fully 
sectioned (serially) and deposited on slides; unsectioned embryos were embedded in OCT and 
stored for future sectioned, along with unstained slides, at -80°C at the Project A.L.S. 
Laboratory.  Slides and tissue blocks are available as an open resource for studies of early human 
spinal cord development.  Sample #1 was overfixed but Tris-EDTA heat induced epitope 
retrieval unmasked antigen and revealed staining which matched other analyzed samples as 









Figure 2.2.  Human spinal motor neurons share column markers and organization with 
mouse 
(A)  Human spinal cords were found to contain populations of cells matching the molecular and 
anatomic characteristics of motor columns defined in chick and mouse.  MMC cells were located 
ventro-dorsally and expressed LHX3, HB9, and ISL1.  At non limb levels HMC motor neurons 
expressed neither LHX3 nor FOXP1.  At limb levels LMC cells expressed high level FOXP1. 
The LMC was subdivided into a lateral predominantly HB9high and ISL low/off  LMCL and a medial 
HB9 low/off  ISL1high LMCM.  Sections representative of all non-limb (cervical and thoracic) and 
limb (brachial and lumbar) spinal levels are shown. n=3 embryos. Scale bar 100 µm.  (B-C) 























Figure 2.3.  pSMAD and low level FOXP1 identify human PGC at thoracic levels  
Human PGC motor neurons were located dorso-laterally at thoracic (A) but not at (B) limb 
levels. PGC motor neurons were identified by staining for ISL1, FOXP1 and pSMAD.  Scale bar 
100 um. >3 sections/spinal level (thoracic vs. limb) were examined from n=2 GW 7 embryos.  
(C) PGC motor neuron FOXP1 expression is quantitatively lower than in either brachial or 
lumbar LMC;  mean+/-SEM  FOXP1 intensity/ISL1+ cell in the brachial LMCM, (n=270 cells 
from 2 representative hemi-sections), thoracic PGC (n= 236 cells from 4 representative 
hemisections), and lumbar LMCM (n=221 cells from 2 representative hemi-sections) from one 




























Figure 2.4.  Human MNs express markers of LMC divisional identities  
Human LMCM was identified by FOXP1 and high ISL1 expression with low or no HB9, as 
previously shown, and also expressed ISL2 and was negative for LHX1.  LMCL as described 
expresses FOXP1, high HB9 and low or no ISL1, however it also marker by LHX1 and ISL2.  
LHX1 therefore serves as a marker that distinguishes lateral vs. medial LMC divisions. Serial 
sections from lumbar cord shown are representative of  >4 limb level sections analyzed for n=3 























Figure 2.5.  HB9 and ISL1 expression levels in motor neuron columns, division, and control 
cells.  
(A) motor neuron columns and divisions, as defined in serial sections by column and division 
markers described above, and control cell populations, were isolated as regions of interest 
(shown in dotted lines on sections: HMC, MMC, LMCM, LMCL, all motor columns at a given 
level considered together, HB9low sub floorplate cells (SUB FP), ISL1+ dorsal interneurons 
(DOR IN), non-motor neurons (NON MN), and ISL1+ dorsal root ganglia(DRG)) on 
representative sections from non-limb and limb levels and quantified for HB9 and ISL1 
expression. (B)  Cells in LMC, HMC, MMC anatomical regions were scored for high level of 
either HB9 or ISL1 were defined as motor neurons and pie charts show the percent of all motor 
neurons/column expressing either HB9 or ISL1: HB9+ (green), HB9+ISL1+ (yellow), or ISL1+ 
(red); n=1 cervical and mean of n=3 brachial or n=2 thoracic and n=2 lumbar sections, from one 
representative GW 7 embryo (#4).  Individual motor neurons were not counted in more than one 
category.  The area of the pie chart is proportional to the total number to motor neurons in the 
column, shown in (D).  (C) Average intensity/cell in each motor column at each level and in 
control cell populations (mean+/-SD, n=1 section analyzed/level).  For all regions with HB9+ or 
ISL1+ cells, intensity was analyzed among motor neurons only, except for the NON-MN region 
where intensity is for all cells in the region. (D-E) Total number of motor neurons per motor 
column (mean of n=2 sections/level except cervical n=1, and brachial n=3), and percentage of 
those cells in cell scoring categories as graphed in (B). (E) Total number of motor neurons in 
each cell scoring category, in all motor columns at each level (mean+/-SD, n=2 sections/level 




for all motor neurons, mean+/-SD, All MMC n=8 sections, All HMC n=3 sections, All LMCM 




























Figure 2.6. Some rostral brachial LMC pools identified by combinatorial expression of 
LIM-HD and column marker proteins. (A) Staining of serial sections of rostral (HOXA5
+) 
brachial spinal cord reveals LMC cells (FOXP1+) can be subdivided into putative motor pools 
matching those in chick by expression profile of LHX1, LHX3, HB9, ISL1 and ISL2.  Diagram 
at left indicates putative pool expression profiles matched for the MMC, rhomboideus (RB), 
deltoid (DL), and novel human specific putative motor pool which expresses LHX3 and FOXP1 









Figure 2.7. PEA3 marks brachial and lumbar LMC pools 
At the HOXA5 level of the brachial spinal cord, and in the lumbar spinal cord, PEA3 selectively 
marks pool-size groups of LMCL  motor neurons. Representative sections of  n=2 GW 7 and n=1 
GW 8 embryos.  Scale bar 100 um. Diagonal (left) and horizontal (right) bars indicate position of 


















Figure 2.8.  Human motor neurons in vivo express HOX proteins in rostrocaudal collinear 
sequence  
(A) HOXA5 was expression at cervical levels (rostral to the LMC) and persisted through the 
rostral half of the brachial LMC.  The most rostral HOXC8 expression was detected in dorsal 
spinal cord cells rostral to the caudal limit of HOXA5 expression. Within 200 um HOXC8 
displaced HOXA5 expression in motor neurons; in this intermediate brachial region some groups 
of motor neuron, likely LMC pools, expressed HOXA5 and some expressed HOXC8, but <20 
individual cells, of thousands of motor neurons examined, expressed both HOX proteins.  
HOXC8 expression persisted caudally into thoracic levels until just short of halfway between 
brachial and lumbar LMC levels.  HOXD9 expression was initiated in dorsal cells just after the 
caudal limit of HOXC8 expression and there was no overlap of expression at the same levels of 
the cord.  HOXD9 expression in the cord and in motor neurons persisted caudally through the 
first half of the lumbar LMC.  We did observe some low level HOXD9 staining at brachial 
levels, mostly in dorsal non-motor neurons.  n=3 embryos showed the same expression pattern; 
representative sections from GW 7 embryo #4 shown.  Length of spinal cord positive for: 
HOXA5= 3.7 +/-0.8 mm; HOXC8= 5.7 +/-0.7 mm; and HOXD9= 4.1 +/-0.3mm, (mean +/-SD 
of two GW 7 embryos).  Scale bar 100 um. (B) Diagram summarizes HOX expression patterns 
with respect to motor neuron column marker staining pattern. Diagram drawn to scale along 
rostrocaudal axis (scale bar 5 mm) but mediolateral dimension is dilated for clarity of labeling; 











Table 2.3. Summary of motor neuron rostrocaudal, columnar and divisional subtype 
marker expression in human  
The same expression profile was detected for HB9 and ISL1, and all column and divisional 





 pool detected at HOXA5
+
 levels of the brachial LMC.  Black boxes, high level 
expression; grey boxes, low or low to no expression; white boxes, no expression; yellow boxes, 







Chapter 3. Motor neuron differentiation from human embryonic stem cells: optimization, 
characterization of subtype diversity, and analysis of maturation 
 
Introduction 
The larger goal of these studies was to establish the conditions for modeling ALS using human 
ES cell-derived motor neuron subtypes.  Our first goal in this chapter was therefore to 
systematically describe the subtypes of motor neurons differentiated from human stem cells.  To 
do this we needed first to define a robust and reproducible method of differentiation which 
would be amenable to quantitative analysis.  Next, in order to establish confidence in the 
relevance of ES-MN biology in vitro to motor neurons in vivo, we needed to demonstrate that 
key in vivo phenotypes would be manifested in vitro.  Finally, since several hypotheses about the 
mechanisms of motor neuron degeneration in ALS hinge on mature characteristics of affected 
MNs, we needed to demonstrate maturation of ES-MNs in vitro and in vivo. 
MNs have now been differentiated from human stem cells by many different groups.  There is 
great variety among the protocols, methods of analysis, and efficiencies of differentiation in 
these reports.  Our first goal was therefore to develop a reproducible and highly robust protocol 
for motor neuron differentiation which was compatible with quantitative analysis of the entire 
population of differentiated MNs.  While some markers of motor neuron positional and columnar 
subtype identity have been tested in ES-MN cultures, in no case have these been systematically 
and representatively assessed in MNs as defined by HB9 and ISL1 expression. We therefore 




markers and expression criteria defined in vivo in Chapter 2.  This description would also 
provide a necessary starting point for designing strategies to control subtype identities in future 
studies (Chapter 5) 
A general challenge for the utility of any stem cell-derived cell type is to demonstrate its in vivo 
bona fides.  To address this we picked several characteristic features of motor neurons in vivo 
and asked if in vitro generated cells would meet these expectations.  Expression of multiple 
subtype markers is in itself the first bar, but also allows us to ask if ES-MNs meet more subtle in 
vivo expression patterns, for example, mutual exclusion of specific HOX gene pairs and mutual 
exclusion of motor column markers.  MN-selective electrophysiological features and the 
interpretation of in vivo axon guidance cues have also not been addressed in previous studies, but 
would support the functional equivalence of ES-MNs to their in vivo counterparts and thus argue 
for their utility in modeling motor neuron biology and disease. 
Finally, several proposed mechanisms of MN-selective degeneration in ALS concern features 
typical of more mature motor neurons.  The large total size of MNs, specifically axo-dendritic 
outgrowth, may place unusual demands on energy metabolism and mitochondrial function, and 
axonal transport, suggesting that ES-MNs should achieve significant total outgrowth in order to 
better study disease relevant pathologies.  Finally, motor neuron degeneration may be linked to 
glutamate excitotoxicity.  In order to adequately address this hypothesis it is necessary to 
demonstrate electrophysiological activity in vitro, which several groups have done.  However an 
unmet need, with respect to designing in vitro assays of disease mechanisms is to systematically 







Defining a Standard Protocol for efficient and robust motor neuron differentiation 
Our first goal was to define a simple and robust protocol for motor neuron differentiation from 
human ES cells, which was devoid of complicated manipulations and in which differentiated 
cells could be analyzed as a homogenized mixture.  In order to support homogeneity, enhance 
neural induction, and reduce manual intervention we made several adaptations to a previously 
published embryoid body (EB)-based differentiation protocol from the Zhang lab (Li, Du et al. 
2005).  The Zhang protocol requires positive and negative manual selection to isolate rosette 
neuroepithelia and remove non-neural colonies during a period of transient attachment.  We 
maintained EBs in suspension during the entire protocol to avoid potential bias of these manual 
interventions.  In order to increase the efficiency of neural induction without manual 
intervention, we made two further modifications to the Zhang protocol.  To both limit the size of 
EBs and ensure that their sizes were as regular and reproducible as possible we used a Rho 
kinase inhibitor (Y-27632) to maintain survival of individual ES cells at the pluripotent state 
(day 0 of differentiation) as they gradually nucleated EBs (Watanabe, Ueno et al. 2007).  This 
produced an initial population of very small (5-20 cell) EBs which was extremely regular in its 
size distribution (Fig. 3.1B, day 4).  Recombinant Noggin was also used during this time period 
to suppress induction of non-neural fates by BMP signaling (Munoz-Sanjuan and Brivanlou 
2002; Watanabe, Ueno et al. 2007; Elkabetz, Panagiotakos et al. 2008).  Beginning at day 10 RA 
and recombinant mouse SHH were used to impose the caudal (spinal) and ventral identity 




EBs were composed of tightly packed neural rosettes (Fig. 3.1B) (Elkabetz, Panagiotakos et al. 
2008).  We also observed that nearly all cells in all EBs expressed the neuronal marker NCAM 
and/or the neuronal progenitor marker Nestin (Fig. 3.1C).  We concluded that this protocol 
generated a highly regular population of EBs which was composed dominantly of neural 
derivates as judged by neural rosette morphology and neural lineage marker expression.   
We next asked whether motor neuron progenitor (pMN) marker OLIG2 and the post-mitotic 
motor neuron marker genes ISL1 and HB9 were expressed by qPCR (Fig. 3.1D).  As has been 
previously reported (Bock, Kiskinis et al. 2011) we detected low level expression of both ISL1 
and HB9 in undifferentiated ES cells, but this was extinguished by day 6.  HB9 expression 
increased at a relatively linear rate from day 6 to day 31, when it reached maximum measured 
levels.  ISL1 expression increased at a lower linear rate from day 6-17 and then rapidly reached 
maximum levels between day 17 and day 31.  OLIG2 expression, which we expected to precede 
the post-mitotic motor neuron markers, was only slightly increased at day 17 (<1%), but reached 
maximum expression by day 31.  We then confirmed these gene expression data at the protein 
level by immunostaining cryosectioned EBs (Fig. 3.1F).  These data showed that OLIG2 could 
be readily detected at day 17, but was considerably more prevalent at day 26 and 30.  ISL1 
protein was not detected until day 17, and then at low abundance, but was increased by 26 and at 
maximum by day 31.  HB9 protein on the other hand was not detected until day 26, and 
increased substantially by day 31.  To confirm the emergence of post-mitotic motor neurons we 
then tested this protocol on the motor neuron reported line HBG1, which expresses eGFP under 
control of the mouse HB9 promoter (Di Giorgio, Boulting et al. 2008).  GFP was first expressed 
in scattered cells at day 24 (not shown) but was robustly expressed by day 31 (Fig. 3.1D).  




neurogenesis (Chapter 1, Part II) if 5 days are added to the developmental time of ES cell 
differentiation (since they are derived from day 5 blastocysts).  We concluded from these data 
that under this protocol the motor neuron lineage was efficiently induced, that post-mitotic motor 
neurons were generated starting around day 25, and that they reached abundant levels by day 31.   
We next sought to assess the efficiency of motor neuron generation by measuring the most 
selective motor neuron marker available, HB9 as well as the other selective marker, ISL1.  We 
observed large differences within and between individual EBs in terms of the density of HB9 and 
ISL1 cells.  In order to assess the entire population, EBs were therefore dissociated to single cells 
using trypsin and mechanical trituration, seeded on poly-amino acid and laminin coated 
substrate, and fixed two days later.  Cells were then stained and scored for high level expression 
of HB9, ISL, and TuJ1 using the Multiwavelength Cell Scoring module in Metamorph (Fig. 
3.2A).  We observed a smooth continuum of expression levels for HB9 (and all other pan-MN 
and MN-subtype nuclear markers, not shown) (Fig. 3.2C).  A threshold of staining intensity was 
set for each immunostain and then empirically optimized to score the maximum number of 
intensely stained HB9 cells as positive, and keep to an absolute minimum the number of cells 
with very low or no appreciable HB9 staining scored positive (Fig. 3.2D).   The accuracy of 
utomated cell-scoring was therefore manually checked for each experiment and condition.  The 
result of this conservative approach to automated cell scoring was that cells scored positive for 
HB9 were restricted to those with high intensity staining, although this population included a 
large range of staining intensity, as illustrated for individual scored cells (Fig. 3.2D) and by the 
standard deviation of the mean of HB9 or ISL1 cells (Fig. 3.2E).  In addition some ―HB9-― cells 
showed some real level of HB9 staining (Fig. 3.2 D, #1).  We therefore undercounted the total 




strongly positive.  This same approach to cell scoring was also taken with ISL1 and all 
subsequently discussed subtype markers. 















only 4.4 ±1.1% (mean ±SEM, n=5 independent experiments, Fig. 3.2B). The ratio of HB9 to 
ISL1 expression was continuous from 1:0 to 0:1  (Fig 3.2A) and included a broad range of values 
for both HB9 and ISL1 (Fig. 3.2E).  This percentage breakdown, and deviation closely matched 
the profile to what we had observed for MNs in vivo (Chapter 2, Fig. 2.5).  The percentage of in 
vitro cells expressing high level HB9, ISL1, or both was most similar to that produced when 
multiple in vivo columns were grouped together for analysis, and interestingly was closest of all 
to profile of the group of all MNs present at brachial levels (Fig. 2.5E).  We concluded from 
these data that the distribution of pan-MN makers in ES-MNs reproduced the spectrum of values 
we defined for MNs in vivo. 
Because HB9 and ISL1 are expressed in the pancreas and in other non-neural cells we co-stained 





 cells were indeed neurons (Fig. 3.2F).  We found that 65 ±9% of all cells 
expressed TuJ1, and that 96 ±1% of HB9
+
 cells were positive for TuJ1 (mean ±SEM, n=5 
independent experiments).  We concluded that this protocol efficiently generated a highly 
neuronal population, and when the large number of Nestin
+
 presumable neural precursors (Fig. 
3.1D) are included, a dominantly neural population.  Importantly the TuJ1/HB9 stain 
demonstrated that HB9
+
 cells were indeed neurons and not non-neural lineage HB9
+
 cells.  
Importantly the dissociated-reseeded endpoint is almost unique among motor neuron protocols 




differentiation culture by unbiased sampling and cell scoring of thousands of cells in a 
homogenized population.  This approach would also facilitate unbiased and representative 
analysis of motor neuron subtype frequencies (see below). 
 
Testing optimizations for the Standard Protocol for motor neuron differentiation 
In order to evaluate the effect of the optimizations we added to the Standard Protocol we tested 
them against the Zhang protocol.  To determine whether Noggin played a strong role in 
preventing non-neural fates and supporting default (Munoz-Sanjuan and Brivanlou 2002) or 
spontaneous neural induction we performed Standard Protocol single cell start EB 
differentiations described above and in one pilot experiment omitted Noggin.  We used %HB9 as 
the endpoint most relevant to our interest and also as a proxy for the efficiency of neural 
induction.  We found that Noggin strongly increased the % HB9 (Fig. 3.2A).  Since seeding 
density had been an important factor in optimizing mouse ES-MN differentiation protocols 
(Wichterle, Lieberam et al. 2002), we tested 3 different initial seeding densities, and found that 
without Noggin, only the highest was efficient for generating ES-MNs, and with Noggin all were 
efficient but the highest density was superior (Fig. 3.2A).  When we compared our Standard 
Protocol with the EB protocol from which it was derived, and also tested the efficiency of 
positive and negative manual selection for neural rosettes we found only a slight increase in HB9 
efficiency with manual selection, but both non-single cell EB protocols were less efficient than 
the Standard Protocol condition with Noggin.  We concluded that Noggin supported more 
efficient ES-MN differentiation, likely by supporting more efficient neural induction, and we 




concluded that in our hands the protocol (referred to subsequently as Standard Protocol) was not 
only simpler but as or more efficient at ES-MN differentiation than published alternatives. 
Since motor neuron differentiation requires a caudal spinal identity and Wnt signaling has been 
linked to the induction of caudal neural identity (Nordstrom, Jessell et al. 2002; Nordstrom, 
Maier et al. 2006) we decided to provide a Wnt signal on days 10-17 of differentiation (see 
Chapter 4 for logic and timing of this decision).  To assess the impact of this decision we then 
asked if Wnt3a conditioned medium (Wnt3a-CM) (Willert, Brown et al. 2003) affected either the 
efficiency of neural induction, as measured by percent of cells staining for neuronal beta-III 
tubulin (TuJ1), or motor neuron induction efficiency, as measured by percent of cells positive for 
HB9 or ISL1.  We found that there was no significant difference in the percent of differentiated 
neurons (62% vs. 63%, n=4 independent experiments, t-test, p= 0.66) with or without Wnt3a-
CM.  To exclude the possibility that Wnt-CM affected the HB9
+
 cells differentially we measured 
the %TuJ1
+
 of HB9 cells and found no significant difference (92% vs. 94%, n=4 independent 
experiments, t-test, p= 0.79).  We also found that the efficiency of motor neuron differentiation, 
as measured by %HB9- and %ISL1-expressing cells, was not affected by Wnt-CM (n=4 
independent experiments, 11% vs. 12% HB9, t-test, p=0.93; 10% vs. 11%ISL1, t-test, p=0.37).  
We concluded from these data that exogenous Wnt-CM was not required for motor neuron 
generation, but also that it did not negatively affect differentiations.  Furthermore, in anticipation 
that Wnt might work in cooperation with other caudal patterning cues (see Chapter 5) we elected 





Subsequent to the completion of most studies in this report which used the Standard Protocol 
described above, new publications showed that pharmacological inhibition of TGF-β signaling 
increased the efficiency of neural induction to nearly 100%, and accelerated its timecourse by 7-
10 days (Chambers, Fasano et al. 2009).  We therefore asked if we could adapt our protocol with 
these inhibitors to increase the efficiency and speed of motor neuron differentiation (Fig. 3.4A).  
We substituted another inhibitor of TGF- β signal transduction for Noggin, which we report in a 
subsequent chapter and a previous publication (Boulting, Kiskinis et al. 2011).  Because of the 
shorter overall timecourse of this protocol we reasoned that we could start with slightly larger 
EBs, and thus avoid the single-cell suspension process we used to initiate the Standard Protocol.  
We found that this protocol was indeed able to generate a uniform population of very small EBs 
which grew consistently throughout the differentiation (Fig. 3.4B, C).  Initial experiments with 
the HBG1 MN-reporter line showed GFP expression at day 15 (data not shown): 10 days in 
advance of the Standard Protocol.  EBs were therefore dissociated to single cells at day 21, 
seeded, and fixed at day 23 for analysis. 
To ask if the Accelerated Protocol generated increased motor neuron percentages in this shorter 
timeframe we stained dissociated cultures with HB9 and ISL1, and NF (for wild type ES-MN) or 
GFP (for motor neuron reporter ES-MN) we observed a two-fold increase in the efficiency of 
motor neuron generation (22-31% HB9 depending on cell line, and 37% GFP) vs. Standard 
Protocol (Fig. 3.3D-G vs. Fig. 3.2).  Accelerated Protocol ES-MNs expressed HB9 and ISL1 in 
the same partially overlapping pattern as described above for the Standard Protocol.  When we 
analyzed the fidelity of the GFP reporter for ES-MNs we found that 70% of GFP cells expressed 
high levels of HB9 or ISL, and when considered together this figure was nearly 80% (Fig. 3.3H).   




from ES cells.  We could therefore use it to validate reagents and more rapidly test hypotheses 
about mechanisms of differentiation.  For example, when a new lot of SHH protein was acquired, 
we titrated its activity using the accelerated protocol (Fig. 3.4F).  Since the %HB9 was less than 
1% in control or low SHH (200ng/ml) doses, this result also demonstrated the SHH dose-
dependence of ES-MN differentiation.  Accelerated protocol experiments were performed after 
the majority of work reported in these studies, therefore we used the Accelerated protocol for 
only a subset of studies and will indicate clearly where that is the case, while the Standard 
Protocol will be the default unless otherwise indicated. 
In summary we developed two robust protocols that do not require manual intervention and that 
reproducibly generated motor neurons at consistent efficiencies.  Both of these were established 
with dissociated re-seeded cells as the endpoint, and are therefore amenable to both bulk 
cryopreservation (see below) and homogenized phenotypic analysis.  We next asked if and how 
the ES-MNs generated in our hands would be capable of maturation in vitro. 
Maturational phenotypes of ES-MNs 
Since many significant aspects of motor neuron biology—e.g., trophic factor dependent survival 
and axon pathfinding— require maturation beyond initial specification, and because modeling 
ALS in vitro may require the elaboration of specific mature characteristics, we next sought to 
characterize the state of maturation of ES-MNs over 2 weeks in vitro using electrophysiological, 
morphological and immunocytochemical approaches.   
ES-MNs show progressive electrophysiological maturation during extended culture 
In order to address the maturation of ES-MNs we turned first to the principal functional feature 




our cultures, we used a motor neuron report line (HBG47) which expressed GFP under control of 
the mouse HB9 locus on transgenic bacterial artificial chromosome (Placantonakis, Tomishima 
et al. 2009) to prospectively identify ES-MNs for recordings.   
Progressive changes in active membrane properties 
To investigate the electrophysiological properties of ES-MNs over time we prepared low density 
cultures and our collaborator Tomonori Takazawa (Amy B. MacDermott‘s lab) tested passive 
and active membrane properties using patch clamp recordings between 2 and 13 days following 
seeding mat day 31 of dissociation. Recorded cells were backfilled with dye, fixed and then 
stained with motor neuron markers HB9 and ISL when cells were recoverable.  We confirmed 
that all intact recorded cells (n=7) expressed both GFP and the motor neuron marker HB9 or 
ISL1 (Fig. 3.5A).  When we asked if ES-MNs were competent to fire action potentials we found 
that 27 of 28 cells recorded were able to fire action potentials (APs) with depolarizing current 
injections, while the one AP-incompetent cell was at the youngest timepoint tested (day 2).  
Representative examples of voltage changes in response to depolarizing currents, and 
accompanying backfills are shown for 3 different cells at 3 different time-points (Fig. 3.5B-G).  
These data show an increase in repetitive firing accompanied by a decrease in input resistance 
over time in culture.  We conclude from these experiments that ES-MNs showed rapid and 
progressive functional maturation over time in culture.  We next sought to quantitatively describe 
these progressive changes in electrical properties. 
Progressive changes in membrane properties 
When input resistance was graphed as a function of time in culture, we found that it decreased 




This decrease is consistent with an increase in the total number of ion channels contributing to 
leak conductance at resting potential.  Resting potential did not change significantly over the 
timecourse studied, however the mean decreased from -50 mV to -60 mV by the latest timepoint 
(Fig. 3.6B).  The rheobase—current step magnitude required to elicit AP—was also unchanged 
over this timecourse (Fig. 3.6C).  We conclude from these data that ES-MNs show evidence of 
maturation, decreased input resistance, and may have been entering a phase of further maturation 
as indicated by the lowering of resting potential at the end of the timecourse.  We next sought to 
examine more specific and quantitative changes in the APs generated by ES-MNS. 
Progressive changes in AP characteristics 
To understand in greater depth the maturational changes suggested by the increased frequency 
and number of APs fired by ES-MNs we next examined these spike trains quantitatively.  The 
duration of APs (as measured by half-width) showed a significant decrease from the earliest 
timepoint to all older time-points ((Fig. 3.6D) n=25 cells, One Way ANOVA, p < 0.01).  This 
result suggested a more mature profile of acute AP discharge which implied a more mature 




 channels.  Because both AP-half-width measures and 
rheobase showed a range of values even at the oldest time-points, we plotted rheobase vs. half-
width for individual cells at day 43 (Fig. 3.6E).  This analysis suggested that two distinct 
populations were present in older cultures: one with low rheobase and broad action potentials, 
and another with tight action potentials and higher rheobase.  This result could be interpreted as 
evidence of two different ES-MN subtypes, or as evidence for a less and a more mature 




To distinguish between the two possibilities we examined maturation state of ES-MNs more 
directly. As motor neurons mature they develop the ability to fire repetitive trains of action 
potentials (Gao and Ziskind-Conhaim 1998).  We next investigated whether a similar change had 
occurred with time in vitro. At the earliest timepoint studied, no ES-MN recorded was able to 
fire more than one action potential even during extended (1s) current injections.  Many ES-MNs 
however showed repeated AP-trains on subsequent days in vitro (Fig. 3.5B-G).  Indeed the 
maximum frequency of AP firing showed a progressive and significant increase over time ((Fig. 
3.6F) n=28 cells, One-Way ANOVA, p<0.05,).  Interestingly, even at the latest age measure, 
some ES-MNs were capable of firing only a single action potential, even during injections of 
large depolarizing current (>140 pA), showing that even after 13 days of maturation, ES-MNs 
are a mixture of cells with less and more mature properties.  We concluded from these 
experiments that in aggregate ES-MNs underwent progressive functional maturation, as shown 
by their membrane properties and increasing ability to fire repeated high frequency AP-trains 
and that late time point cultures consist of a mixture of more and less mature ES-MNs. 
Progressive development of motor neuron selective electrophysiological signatures 
We next asked if we could detect more subtle aspects of maturation consistent with motor neuron 
firing properties in vivo.  First, we noticed that the timing of APs within repeated spike trains 
gradually increase, a phenomenon identified in vertebrate motor neurons in vivo and termed 
spike frequency adaptation (SFA) (Fig. 3.7A).  When we graphed the ratio of last to first spike 
interval over time, we found a progressive increase with time in culture (Fig. 3.7B, n=8 cells, 
R=0.73, p= 0.05, Pearson‘s linear regression).  We concluded from this analysis that ES-MNs 
progressively acquired more mature physiological profile with time, and that this profile was 




We also noted that some ES-MNs showed depolarizations in response to hyperpolarizing current 
injections.  In some cases these post-inhibitory rebound depolarizations triggered APs, a 
phenomenon described in vertebrate MNs and termed rebound action potentials (RAPs) (Fig. 
3.7C).  No ES-MNs displayed RAPs at day 33; however at this timepoint one neuron did exhibit 
post-inhibitory rebound depolarization.  At every other subsequent time however nearly half of 
ES-MNs displayed RAPs (Fig. 3.7D).  We concluded from this analysis that many ES-MNs 
exhibit mature firing properties characteristic of MNs in vivo. 
 
 
ES-MNs show progressive morphological maturation with time in culture 
We have seen that ES-MNs showed a maturation of electrophysiological properties over time in 
culture.  But we also observed a second population of cells with immature characteristics at later 
time-points in culture.  The less mature cells might either correspond to a subset of ES-MNs 
refractory to maturation or to a population of newly born MNs generated during the maturation 
period.  We favor the latter, as parallel studies in the lab following HB9:GFP expression have 
seen dramatic increases in GFP
+
 cells after a week in culture (Nuno Lamas, Bethany Kerner, 
unpublished data).  Furthermore BrdU labeling of mitotic cells demonstrated ongoing birth of 
new motor neurons during this time period (Nuno Lamas, Bethany Kerner, unpublished data).  
This interpretation also fits both with the high level of OLIG2 expression we observed at day 31, 
and with the evidence for an extended timecourse of human motor neurogenesis in vivo: day 25-
56 (Hagan, Ross et al. 2000; Altman and Bayer 2001; Bayer and Altman 2002).  To address the 




analog used to label dividing cells which is more compatible with immunostaining.  When we 
stained cultures with or without EdU we first observed that the number of total cells in EdU 
treated cultures was greatly decreased (not shown).  This suggested that EdU was acting as a 
mitotic poison at the dose used (0.5 µM).  When GFP cells were co-stained with EdU we found 
that at each timepoint fewer than 10% of cells were labeled with Edu and we observed a gradual 
decrease in GFP cell numbers rather than the dramatic increase reported by colleagues above 
(Fig. 3.8).  We concluded from these experiments that maturation with EdU treatment was able 
to almost completely eliminate newborn ES-MNs from our cultures.  We could therefore 
examine the non-mitotic ES-MN population for progressive features of maturation in EdU 
treated cultures.  
Morphological maturation of ES-MNs 
In order to determine if surviving ES-MNs showed progressive maturation at the morphological 
level, we quantitated neurite outgrowth of all GFP
+
 cells during a 14 day timecourse subsequent 
to plating on day 31 of differentiation.  We optimized analysis parameters for each timepoint and 
condition separately to ensure the most accurate tracing possible, and then applied these to all 
cells for each of two coverslips per condition per timepoint.  First we noticed a clear increase in 
the extent of neurite projections with time (Fig. 3.9A), and determined that automated tracing 
could accurately quantify this morphological phenotype.  This outgrowth phenotype is 
represented at the qualitative level by camera lucida overlays of an unbiased sample (the first ten 
fields imaged) (Fig. 3.9B).  This analysis indicated that at a qualitative level cell outgrowth was 
progressive and substantial.  Quantitative analysis of morphometric parameters showed 
progressive increases in all measures of neurite outgrowth, complexity, and cell body size (Fig. 




non-normally (Shapiro-Wilk tests failed, P <0.050) therefore a Mann-Whitney Rank Sum Test 
was performed which showed a significant difference between the population of day 33 and day 
45 cells in both cell soma area (median 88 vs. 158 µm
2
, U=9723.000, T=29757.000 
n(small)=105 n(big)=323 P= <0.001) and total outgrowth (median 110 vs. 406 µm, U=5535.000, 
T=34374.000 n(small)=106 n(big)=323 P= <0.001) (Fig 3.9D, E).  Population histograms 
showed the contribution of increasing numbers of very large and complex cells to the mean 
outgrowth and cell body size (Fig. 3.9F, G).    Finally, in order to estimate the morphological 
characteristics of cells which were recorded in the previous experiment, all recorded, backfilled 
cells which were recoverable for staining were imaged and their morphometry was quantified as 
for the morphological time series and plotted on histograms (Fig. 3.9F, G). 
We conclude from this series of morphometry experiments that while ES-MNs are undergoing 
electrophysiological maturation they are also undertaking morphological elaboration.   This 
maturation consisted of progressive somatic growth and elaboration of neurites which were 
increasingly long and complex.  By eliminating proliferative cells that disrupt the growth of 
more differentiated cells and are capable of giving rise to new, smaller, ES-MNs, this 
morphological maturation could be quantified directly.  We next asked if there were any 
molecular changes which paralleled this morphological and functional maturation. 
ES-MN maturation marked by a switch to NF-H expression 
We next asked if we could detect any changes in the molecular profile of surviving matured ES-
MN under the anti-mitotic conditions defined above.  We have previously shown that short term 
(2 days after dissociation at Standard (day 31) or Accelerated (day 21)) cultures were composed 




NF-H.  We therefore seeded differentiated cells from two different ESC lines (RUES1 and 
HB9:GFP) in parallel: a replicate well was fixed at day 2, and another allowed to mature with 
mitotic inhibition for 8 days and then fixed.  Both sets were then stained for motor neuron 
markers HB9:GFP or HB9/ISL1( for RUES1 cells) and NF-H.  First, we noted a dramatic 





) expressed NF-H, however by day 8 every single HB9/ISL1 or 
GFP cell (n >50 cells per cell line in one experiment each) expressed high level NF-H (Fig. 
3.10).  We also observed a strong qualitative increase in the intensity of NF-H staining in each 
cell suggesting a maturational switch to a higher expression level of NF-H.  Qualitatively, ES-
MNs showed long primary axons and dendrites in the older cultures compared to the bipolar or 
spindle shaped ES-MNs at day 2.  Surprisingly, EdU-mediated suppression of motor 
neurogenesis in culture was accompanied by a dramatic increase in the percent purity of motor 
neurons.  We observed at a qualitative level nearly every cell (n>50 cells for each cell line in one 
experiment each) positive for NF-H was also positive for HB9 or ISL1 or for HB9:GFP.  These 
striking differences are representative of 3 additional independent experiments, but should be 
more precisely quantified in future studies.  In combination with the previous data on functional 
and morphological maturation, we concluded that mitotic inhibition allowed us to observe a 
maturational switch from TuJ1 expressing MNs with immature morphology, to morphologically 
elaborate NF-H
+
 phenotypes.  And surprisingly, simply by eliminating dividing cells the fraction 
of motor neurons in culture rose nearly to purity. 
In conclusion our morphological, electrophysiological and molecular data demonstrate that ES-




population of mature and immature cells in aged cultures.  Interestingly this can be suppressed 
by EdU treatment and the maturational fraction can be observed independently. 
 
Characterization of ES-MN diversity in vitro 
ES-MNs express all motor column markers found in vivo 
We next asked if ES-MNs co-expressed the markers of motor column identity we had validated 
in vivo by staining cultures for the MMC marker LHX3 and the LMC/PGC marker FOXP1.  We 




 cells expressed neither columnar marker, 57% and 54% 
respectively; 27% and 25
 
% expressed only LHX3 respectively; 9% and 10% respectively 
expressed only FOXP1; and 7% and 8% respectively expressed both LHX3 and FOXP1 (Fig. 
3.11A-C, n=4 independent experiments).  Cells expressing HB9 or ISL1 and neither columnar 
marker match the expression profile for the human HMC in vivo and those expressing LHX3-
only match the expression profile of the MMC.  Cells expressing FOXP1-only could match the 
profile of the LMC or PGC, however, since high level FOXP1 expression was required to score a 
cell as positive for FOXP1, these cells are a better match for the LMC.  Cells with lower level 
FOXP1 (not included in the scored total fro FOXP1+) would then match the PGC (and would 
come out of the current putative HMC subset).  Cells expressing both LHX3 and FOXP1 do not 
match any defined motor columns, however they did match a group of MNs that we identified in 
the dorsal HOXA5
+
 brachial LMCM observed in vivo (Fig. 3.11D and Chapter 2).  Alternatively 
these cells may have confused or transitional identity. We concluded from these analyses that 








 population.  We next 
turned to the issue of rostrocaudal identity. 
HOX protein expression in ES-MN 
To determine the rostrocaudal identity of ES-MNs we next tested the HOX protein antibodies 
which had shown specific rostrocaudal domains of expression in vivo (Chapter 2).  We found 
that many cells expressed HOXA5 whereas a much smaller number of cells expressed HOXC8 
or HOXD9 (Fig. 3.12A, B).  This suggested that most cells with a positively identifiable 
rostrocaudal identity were cervical.  When HOX gene expression gated on MNs (cells with high 
HB9 or ISL1) we found that about half of  ES-MNs expressed HOXA5 (45% of HB9
+
 and 50% 
of ISL1
+
 cells, n=4 independent experiments) with significantly smaller percentages which were 
HOXC8
+
 (3% of HB9
+
 and 13% of ISL1
+ 
respectively, n= 4 independent experiments, unequal 
variance rank sum test p=0.029 and t-test p=.008 respectively ) or HOXD9
+
 (3% of HB9
+ 
cells 
n= 3 independent experiments  and 3% of ISL1
+
 cells n=4 independent experiments, unequal 
variance rank sum test p=0.029 each) (Fig. 3.12C, D).  Interestingly the percent of MNs positive 
for each HOX gene was much higher than the percent of all cells, suggesting that HOX gene 
expression was somewhat selective to MNs as in vivo.  We also noted that ISL1
+
 cells had a 
larger fraction of HOXC8
+
 cells.  We concluded that under RA based differentiation conditions, 
ES-MNs adopted a predominantly HOXA5
+
 HOX phenotype, and based on our in vivo data this 
suggests a cervical or rostral brachial positional identity.  Interestingly, the group of motor 
neurons co-expressing FOXP1 and LHX3 was detected in cervical spinal cord expressing 




 ES-MNs might correspond to 




or HOXD9 expression, suggesting that small number of ES-MNs adopted caudal brachial or 
thoracic identity.   
Because MNs in vivo expressed only one of these three HOX genes depending on their 
rostrocaudal location, and mutually exclusive expression is a key outcome of repressive inter-
HOX interactions in mouse and chick, we asked if ES-MNs would conform to in vivo standards 
and express HOX proteins in a mutually exclusive manner.  When we triple stained cultures for a 
motor neuron marker (HB9 or ISL) and HOXA5 and HOXC8, or HOXA5 and HOXD9 we 
found that the majority (>96%) of ES-MNs expressing either HOX gene did so exclusively (Fig. 
3.12E, F).  We concluded from these results that ES-MNs adopt a range of coherent rostrocaudal 
phenotypes, strongly centered on the cervical spinal region. 
Cryopreserved ES-MN can be thawed for subsequent analyses 
Finally, because of the length of differentiation protocols, and the anticipated needs to revisit 
experiments, use differentiated motor neurons for either bulk screening purposes or 
transplantation experiments—either of which would be difficult to precisely time with respect to 
the end of differentiations—we next asked if it would be possible to cryopreserve motor neurons 
for subsequent live culture and analysis.  At the day of dissociation MNs were seeded as 
described and analyzed, while some were cryopreserved.  When these were later thawed, seeded 
as described for fresh MNs, and stained for motor neuron markers, we found that the matched 
cultures still contained robust populations of neurons and motor neurons (Fig. 3.13A).  The 
percentage of neurons was not significantly affected (n=3 independent experiments, t-test 




 MNs of all cells were still robust but were significantly 




freshly dissociated cultures (Fig. 3.13B, C).  When we examined the expression of HOX proteins 
we also found a reduction in percentage, though this was not significant (HOXA5 fresh n=5 and 
frozen n=3 experiments, t-test p=0.131; HOXC8 fresh/frozen n=4 experiments, t-test p=0.846; 
and HOXD9 fresh n=3, frozen n=4, t-test p=0.296), and the same relative HOX distribution was 
preserved (Fig. 3.13D).  When we analyzed the motor column marker expression we found no 
change in %LHX3 of all cells (fresh n=2 and frozen n=3 experiments, t-test p=0.544) and a small 
but significant increase in %FOXP1 of all cells (n=5 experiments, t-test p=0.022) (Fig. 3.13E).  
We concluded from these experiments that while ES-MNs were sensitive to cryopreservation 
compared to all cells, they could in general be cryopreserved with limited reduction in survival 
or purity and limited effect on the distribution of rostrocaudal or columnar subtypes. 
Matured cells increase LMC marker FOXP1 expression in percent and quantity 
Having established the columnar identities among freshly dissociated ES-MNs we next asked if 
these identities changed during the maturation period described above using EdU treatment.    
Surprisingly, when EdU-treated matured cells were stained with FOXP1 and LHX3, we found 
that the vast majority (85%) of cells at 8 days after dissociation expressed extremely high levels 
of FOPX1 protein (Fig. 3.14).  This is in striking contrast to the 12% of ES-MNs which 
expressed FOXP1 at 2 days after dissociation.  Additionally the staining intensity for FOXP1 
was much brighter by eye at this later timepoint suggesting a large increase in expression level.  
One interpretation of this result is that only FOXP1
+
, putative LMC cells were able to survive 
under these conditions.  This interpretation does not explain the dramatic up-regulation in 
FOXP1 expression level for individual cells however. These data therefore better support the 
idea of maturational conversion to a nearly uniform FOXP1
+
 LMC phenotype, but they also do 




compared to any other columnar subtype.  To determine if this column phenotype conversion or 
survival was a direct effect of anti-mitotic treatment, or the result of selective survival under 
these conditions, we next asked if we could devise non-EdU conditions under which to observe 
exclusively post-mitotic cells. 
 
 
FOXP1 cells show a distinctive morphological phenotype  
To ask if non-mitotically poisoned cells would show an increased percent and expression level of 
FOXP1, we used FACS to purify cells which expressed high levels of GFP immediately after 
dissociation.  These were then seeded at very low density on monolayers of commercially 
available human fetal spinal cord astrocytes and allowed to mature for 12 days.  When these 
cultures were fixed and stained 12 days later we again observed a percent of FOXP1 cells (72%),  
far higher than at day 31 and a complete lack of LHX3 staining (Fig. 3.15A, B). These cells 
again displayed extremely high intensity FOXP1 staining typical of matured ES-MN.  We 
concluded from these results that the increase in FOXP1 percentage and intensity was not a 
byproduct of selective resistance to mitotic poison. Because of the generally low survival 
following FACS these experiments did not however address whether the resulting increase in 
percentage of surviving FOXP1
+
/LMC  ES-MNs was a result of selective survival or a 
conversion of columnar phenotype. 
We next wanted to ask if FOXP1 cells would show a functional phenotype correlated with their 
expression profile.  Since these cultures were seeded at very low density we were able to perform 




where cells were in direct contact, the field was excluded from quantitation.  We found that 
FOXP1
+
 (n=39) cells had trend increases in most aspects of neurite length and complexity, and 
the mean and median process length compared to FOXP1
-
 (n=20) cells were significantly larger 
(t-test, p<0.05, Fig. 3.15C).  This morphological phenotype was specific to neurite outgrowth 




 cells showed large increases in cell soma area; there was 
no significant difference between the two populations. Since the total outgrowth of cells is 
traditionally a robust metric reflecting their morphological maturation, and FOXP1
+
 cells trended 
higher but not significantly so, we next examined the population distribution by cumulative 
percentage (Fig. 3.15D).  This analysis revealed both populations contained the same percent of 
smaller cells: 50% of cells had total outgrowth <0.91mm).  However The FOXP1
+
 cells 





 cells was mostly accounted for by a larger number of 
large (>0.1 mm: 43% vs. 20%) and very large (>1.8 mm: 20% vs. 5%) cells.  First we concluded 
that FOXP1
+
 putative LMC cells may exhibit a motor column-specific functional morphological 
phenotype in vitro consisting of more extensive neurite outgrowth in vitro.  Second we 
concluded from these pilot data that low density non-mitotic culture conditions are another 
promising assay in which to search for motor neuron subtype-specific phenotypes. 
ES-MNs show behavior on transplant consistent with functional subtype identities 
Finally we asked if human ES-MN would be competent to interpret in vivo cues directing motor 
axons projection patterns.  To do this we conducted a series of pilot experiments in which GFP
+
 
ES-MNs were transplanted to the chick neural tube at HH stage 15-16 and allowed to develop for 
2-3 days (Wichterle, Peljto et al. 2009; Peljto, Dasen et al. 2010).  We found that many ES-MNs 




MNs and maintained expression of motor column markers FOXP1 or LHX3, and extended 
projections towards ventral roots (Fig. 3.16A, B).  We also found that transplanted ES-MNs were 
able to project axons very long distances (> 1.8 linear mm) out of the spinal cord, towards 
epaxial, hypaxial and limb muscles (Fig. 3.16C, D).  We also noted that the proportion of 
FOXP1
+
 ES-MNs in this context was again disproportionately high compared to pre-transplant 
cultures.  We conclude from these preliminary results that hES-MNs were able to respond to 
chick axon guidance cues in vivo and projected axons along in vivo paths muscle targets which 
were consistent with the columnar diversity of transplanted cells.  However, without backfilling 
projections and labeling for motor column markers, we have no evidence that individual ES-
MNs exhibited column-specific axonal pathfinding. 
 
Discussion 
Summary of findings 
We have defined 2 robust protocols for differentiating MNs from human ES-cells.  Both 
protocols are simple, robust, do not require manual intervention and utilize a homogenized 
dissociated cell endpoint.  This allowed us to perform the first systematic description of the 
diversity of ES-MNs.  ES-MNs are defined, like their in vivo counterparts, by expression of the 
motor neuron markers HB9 and or ISL and we found that the spectrum of expression matched 
that observed in vivo: a continuous range from 1:0 to 0:1.  We then showed that ES-MNs 
expressed motor column marker combinations consistent with all motor columns (MMC, HMC, 
LMC, and PGC) and describe their relative abundance.  The rostrocaudal diversity of ES-MNs 










) cells were 
generated as well.  We also show that ES-MNs displayed several phenotypes characteristic for 
motor neurons in vivo.  HOX genes were expressed in a mutually exclusive fashion, and column 
markers were expressed in a mostly exclusive fashion.  ES-MNs displayed electrophysiological 
features (spike frequency adaptation and rebound depolarizations) consistent with in vivo 
physiology and they could pursue a variety of axonal trajectories in the periphery consistent with 
their transcriptional diversity.  Finally, we show that ES-MNs undergo progressive and rapid 
maturation in vitro characterized by a conversion to mature neurofilament expression, extensive 
neurite outgrowth, and maturation of passive and active electrophysiological properties 
culminating in action potential spike trains.  Unexpectedly, during maturation in three different 
paradigms—EdU mitotic inhibition,  low density culture of FACS purified cells on astrocyte 
monolayer, and in chick transplant—the percentage of FOXP1+ (LMC) MNs was increased 
dramatically and LHX3 expression was lost. 
 
Simple, robust and quantitative protocols for ES-MN differentiation and phenotypic analysis 
Optimized protocols for ES-MN differentiation 
The Standard Protocol we describe relied upon facilitated spontaneous neural induction and 
proceeded at an in vivo-like developmental timecourse.  This direct comparison with in vivo 
timing should facilitate modeling developmental events with aim of controlling ES-MN subtype 
identities (Chapter 5).  The second, Accelerated Protocol increased the efficiency of neural 
induction using TGF-β signaling inhibitors and attained ~2 fold higher ES-MN differentiation 




Efficiency of motor neuron induction 
In comparison to previously published results the pan-MN efficiency of our protocols (12% HB9 
for the Standard Protocol, and 25% HB9 for the Accelerated Protocol) are lower than most 
reports.   However, reported ES-MN differentiation efficiency is determined by different 
approaches.  The group of Su Chun Zhang was among the first three papers to describe human 
ES-MN differentiation, and this group consistently reports higher HB9% than our data, and 
generate what appear to be very high quality and bona fide motor neurons.  However their 
analysis of pan-MN differentiation efficiency (%HB9) is conducted when EBs are attached 
whole to substrate and some cells migrate out from clusters.  They report that HB9 rarely occurs 
outside of these clusters and HB9 was quantified by taking several fields surrounding, or perhaps 
within, several 3-dimensional masses of cells.  When we dissociated cells we are therefore 
killing some HB9
+
 motor neurons, and we are certainly looking at substantially different 
endpoint.   Based on their own statements, we can only assume that if their differentiations were 
quantified from dissociated re-seeded cell suspensions, their HB9 efficiency would be much 
lower. 
Additionally, as we have shown, HB9 is detected in a nearly smooth continuum from extremely 
bright, >10,000 grey levels above background, to 1 grey level above background.   When we 
assessed methods for quantifying HB9 we decided to restrict ourselves to scoring only the 
brightest and most unambiguously positive HB9-expressing cells in order to be certain that co-
expression analyses were restricted exclusively to MNs.  In the zero sum game of cell scoring, 
this decision minimized false positives, and as we have shown, necessarily increased the rate of 
false negatives, thereby depressing our %HB9 relative to less conservative approaches to cell 




examination of published immunocytochemical results suggests that we have placed ourselves, 
as intended, at the most conservative end of the most conservative group.   Under our 
Accelerated Protocol however, our conservative estimate of motor neuron efficiency (25%) 
compares favorably with top echelon of reliable reports in the literature.  Most importantly we 
achieved our goal to develop robust differentiation protocol with high efficiency of motor neuron 
differentiation which would be amenable to rigorous quantitative analyses.   
Homogenized cultures 
Our decision to treat differentiations as a homogenous whole had direct implications for both the 
differentiation protocol we chose to develop and the endpoint, and was motivated by several 
factors.  First we elected not to perform any manual selection during the differentiation.  This 
undoubtedly retained some non-neural derivatives in Standard Protocol cultures.  Although in 
agreement with previous reports (Chambers, Fasano et al. 2009), these were minimized to 
apparently zero under the Accelerated Protocol. The ―hands-off‖ design of both of our protocols 
simplifies them and minimizes variability between experiments and operators.  Most importantly 
this decision was taken so that different populations of motor neurons were not inadvertently 
selected for or against at any stage.  This decision will become especially important when we 
turn to the topic of manipulating subtype identity by changing differentiation conditions in 
Chapter 5. 
Since few robust methods have been reported for purification of motor neurons, or efficiency of 
differentiation approaching 100%, all current ES-MN cultures are a mixed population of ES-
MNs and other cells.  The second implication of our commitment to homogeneity was therefore 




that dissociating all EBs and re-seeding cells in a homogeneous mixture would provide the most 
rigorous approach to unbiased sampling of the population to quantitatively assess its constitution.  
One drawback of this approach is that we could not directly measure heterogeneity between EBs.  
Second this method engendered a non-zero level of cell death, of MNs and non-MN alike, due to 
trypsinization and physical trituration, which likely lowered our total efficiency of motor neuron 
induction.  An alternative approach such as acute fixation and intracellular staining of dissociated 
cells could provide an interesting window into the changes introduced by EB dissociation and 
reseeding in the future.  The motivation for this decision was four-fold.  First, when we later 
attempt to manipulate rostrocaudal identity by adding posterior patterning factors (Chapter 5) we 
did not want to bias results by excluding any EBs or cell types affected by these treatments.  
Second, we anticipated that defining and studying more mature phenotypes of motor neurons and 
motor neuron subtypes, especially disease related or survival phenotypes, would be greatly 
simplified by assaying a homogenous population which started from the same state of individual 
single cells, rather than cells emerging from distinct and variable 3-dimensional EB matrices. 
Third, in order to study motor neuron subtype phenotypes, we sought render any intercellular 
effects homogenously distributed throughout the culture.  Fourth, we wanted to be able to 
cryopreserve motor neurons for future phenotypic or screening studies.  Our short term and 
mature cultures were completely homogeneous across culture surfaces and the variability 
between fields in a sample was therefore extremely low.  We conclude that our protocols meet 
the above requirements and using very strict and conservative quantification show respectable 
and highly reproducible motor neuron yields. 
 




Precise characterization of pan-MN markers 
We have provided here the first detailed and quantitative treatment of co-expression of the pan-
MN transcription factor markers HB9 and ISL, which ranged continuously from an expression 
ration of 1:0 to 0:1.  Our data confirms the widespread co-expression of these markers in many 
cells, which has been reported previously (Li, Du et al. 2005; Di Giorgio, Carrasco et al. 2007; 
Li, Hu et al. 2008).  We substantiate these reports as well as contribute previously undocumented 
detail of the wide spectrum of expression levels which constitute this overlap.  The extent of 
apparent co-expression varies inversely with the strictness of thresholding used to score cells as 
positive for either marker.  Therefore our reported % of co-expressing cells does not include 
many cells which express low levels of the other marker.  However our analysis points to the real 
existence of many ES-MNs which are completely devoid of one or the other pan-MN marker.  
This finding matches the in vivo staining we show for human ES-MN in vivo in Chapter 2.  The 
in vivo suggested interpretations for the identity of HB9 and ISL1 expressed cells as well.  The 
in vivo cognate of any cell expressing appreciable levels both HB9 and ISL1 cannot be other 
than a spinal motor neuron.  Cells which express HB9 predominantly could match a minority of 
MNs in the MMC or many MNs in the LMCL, especially at lumbar levels.  While we observed 
few HB9
+
 interneurons in vivo, these are known to exist in other species at other timepoints, so it 




 cells correspond to these.  Given 




 cells could 
match a small subset of low/no-HB9 MMC, a slightly larger subset of HMC, many LMCM, 


















at all levels of the spinal cord, as well as dorsal root ganglion cells.  Given the high level of SHH 




 cells are unlikely to be dorsal 





 cells are ventral motor neurons, however additional markers would be needed to 
address this proposition.   Choline Acetyltransferase (ChAT) would be a good marker to support 
motor neuron identity for HB9- or ISL1-only cells, however congruent with previous reports that 
ChAT is not expressed by ES-MNs until 6-8 weeks in vitro (Li, Du et al. 2005) , we observed no 
robust staining for this enzyme, although qPCR did indicate transcript was expressed (data not 
shown).  
When we examined the expression of GFP driven by the HB9 promoter in transgenic ES-MNs 
we found that most GFP
+
 cells expressed either HB9 or ISL1 (70%) and the vast majority (80%) 
expressed high levels of one or the other.  We also observed that many of the remaining 20% of 
cells expressed low levels of one or both motor neuron markers, but due to our conservative 
approach to thresholding were not included in this figure.  Our data supports previous 
publications using this reporter line, showing that its GFP expression is MN-specific, but shows 
that some cells express very little of one or both pan-MN markers. Given the distribution of HB9 
and ISL1 both in vivo and in wild type cells, the expression pattern of this reporter appears more 
faithful to pan-MN identity, than it is to strictly HB9 protein expression per se.  Furthermore the 
high level of LHX3 expression in our cultures supports the likelihood of this idea since LHX3 
and ISL1 are known to act directly on the HB9 promoter (in concert with NGN2, which we did 
not measure).  
In summary we have provided the most specific and systematic description, informed by in vivo 




HB9 is the much more selective marker in vivo therefore the most conservative approach would 
denominate almost any HB9
+
 neuron as a motor neuron with high confidence.  Of these most 
should express high or intermediate levels of ISL1, while some should have low or no ISL1 
expression, especially if LMC cell types have been induced.  ISL1
+
 cells are also likely MNs 
under strong ventralizing protocols; again most but not all of these should co-express some level 
of HB9.  Finally, especially if LMC subtypes have been induced, some ES-MNs should express 
high ISL1 and low or no HB9.  Therefore from our data we suggest that some or all of these 
ISL1-only cells should be considered ―MNs‖ but without additional markers it is not possible to 
positively determine what percent. 
 
Quantitation of motor neuron column markers 
We also provide a quantitative description of the motor column diversity present in hES-MNs 
using the LMC/PGC and MMC specific markers FOXP1 and LHX3.  This is the first 
quantitative description which is strictly gated by validated markers of pan-MN identity, HB9 or 
ISL1.  Most ES-MNs expressed neither marker suggesting an HMC phenotype, while many 
expressed LHX3 suggesting an MMC phenotype, and fewer still expressed FOXP1 at the high 
level required for scoring, suggesting an LMC phenotype.  The prevalence of LHX3 expressing 
cells matches with other anecdotal reports showing LHX3 expression in ES-MN cultures as well 
as with the evidence of overwhelming LHX3 expression in mouse RA-based ES-MN 
differentiation (Wichterle, Lieberam et al. 2002; Soundararajan, Miles et al. 2006; Peljto, Dasen 
et al. 2010).  Only one previous  reports has shown FOXP1 expression in human neurons 




2011), however neither of these markers were gated by either motor neuron transcription factor 
marker, but rather by non-phosphorylated neurofilament (SMI-32).  Furthermore these authors 
do not undertake to demonstrate the MN-specificity of SMI-32 in vitro.  On the other hand we 
have observed (data not shown and corroborated by Bethany Kerner, unpublished observations) 
has found that SMI-32 reactivity in ES-MN containing cultures is not selective for cells 
expressing HB9 or ISL1.  
Since we stained for LHX3 and FOXP1 in separate channels, as opposed to same species same 
fluorescent channel (Patani, Hollins et al. 2011), we could document 2 additional features not 
previously appreciated in any report on human cells.  First, these markers were expressed in most 
cells exclusively.  This suggests that the columnar phenotypes within individual cells are 
molecularly coherent.  Second we identified a subset of cells expressing both column markers in 
vitro.  This molecular phenotype has no cognate in mouse in vivo.  We considered two 
possibilities which could account for this hybrid identity.  First we did identify a hybrid 
population expressing this combination of markers in human in vivo.  This population was 
located in the HOXA5
+
 rostral brachial spinal cord, which is also the identity of most hES-MNs 




 are a likely match the molecular profile of this 
newly identified population in terms of both HOX protein and column marker expression.  
However we did not directly co-stain LHX3, FOXP1, HB9 or ISL, and HOXA5 simultaneously, 
which could directly test the idea of an equivalence between our LHX3/FOXP1 coexpressing 
cells and those found in vivo.  Another possible interpretation of this molecular profile is that 
these hybrid cells have a confused or transient molecular identity.  Since LHX3 is a known 
determinant of pan-MN identity, it is possible that in vitro its down-regulation in non-MMC cells 




(personal communication Hynek Wichterle).  And when more caudal conditions generated 
FOXP1
+
 cells from mouse ES-MN, most FOXP1
+
 cells were LHX3
-
, however a subset of cells 
was positive for both markers ((Peljto, Dasen et al. 2010) and M.W. Amoroso personal 
communication of unpublished observations). 
The broad diversity of MN-subtypes we describe has important implications for future studies on 
hES-MNs.  Because ES-MNs are a mixed population studies directed at defining motor neuron 
phenotypes, normal or diseased, will need to carefully address the possibility that different motor 
neuron subtypes may show different responses based on columnar and or rostrocaudal identity.  
Because of the consistencies between our results and protocols and other reports, the map of 
potential identities we provide is likely to be relevant for most hES-MN differentiations using 
RA for caudalization.  Whether or not the precise percentages are similar in our study or others, 
the markers we describe can be used to identify many subpopulations, and will therefore enable 
investigation of their specific properties.  Indeed when we began to look for such behaviors we 
found that LMC-phenotype MNs showed enhanced outgrowth characteristics.  Future studies 
directed at defining disease related phenotypes may benefit from this approach as well.  For 
example, will LMC subtype ES-MNs show enhanced or accelerated sensitivity to ALS 
genotypes or pathogenic triggers?  The ability to define LMC vs. non-LMC ES-MNs in vitro 
using molecular markers lays the technical foundation for asking this question. 
Precise characterization of rostrocaudal HOX profile 
Finally we have provided the first quantitative description of the rostrocaudal identity of hES-
MNs which is gated directly by motor neuron markers.  Previous work has not quantified the 




expression in the context of an independent marker of pan-MN identity.  Our data show a strong 
cervical bias (~50%HOXA5
+
) but also trace populations of HOXC8 and HOXD9 expressing ES-
MNs.  The predominance of HOXA5 expression squares with evidence from developmental 
models systems showing direct action of RA on anterior HOX gene promoters.  Other reports 
have documented some HOXA5 expressing hES-MNs (Elkabetz, Panagiotakos et al. 2008).   
The presence of small but identifiable populations of HOXC8 and HOXD9 positive hES-MNs is 
at odds with the largely cervical nature of mouse ES-MN expressing HOXC4 and HOXA5 but 
lacking HOXC8 or HOXD9 positive MNs (Wichterle, Lieberam et al. 2002; Soundararajan, 
Miles et al. 2006; Peljto, Dasen et al. 2010).  This suggests that human ES-MN differentiations 
may develop some endogenous caudalizing activities during differentiation, or that human 
mechanisms of development are more open to caudal identity.  Our data fits with reports of more 
caudal HOX gene expression, HOXC6, HOXC8, HOXC9, HOXC10 in hES-MN containing 
cultures (Li, Du et al. 2005; Lee, Shamy et al. 2007; Patani, Hollins et al. 2011).  Although 
HOXC8 expression was not gated by a pan-MN marker in any report, the impressively high and 
believable % of HB9 expression in at least one publication (Li, Du et al. 2005) suggests that this 
HOXC8 expression may indeed have been in motor neurons.  Another report indicated even 
more caudal HOX genes HOXC9 and HOXC10, but this was without RA and in the presence of 
FGF and will be discussed in Chapter 5 (Patani, Hollins et al. 2011).  Gene expression studies on 
hES-MN-enriched vs. control cultures have also show induction of preferentially rostral HOX 
genes HOX1-6, which fits very well with the rostrally biased profile we show here (Lee, Shamy 
et al. 2007). 
While we have presented the first systematic account of rostrocaudal identity in ES-MNs, over 




based on the rostral HOX activity of RA that many of these cells express HOX genes found in 
the vertebrate hindbrain, HOX1-4.  Our studies of gene expression also indicated the presence of 
HOXC6 (see Chapter 5) which fits with the identification of FOXP1 cells since evidence from 
chick and mouse shows HOXC6 is  required for brachial LMC identity.  A more comprehensive 
description of the rostrocaudal profile at the level of individual motor neurons will require the 
generation of new reagents to specifically detect human HOX proteins and mRNA by in situ in 
vivo and in hES-MNs in vitro. 
 
Maturational phenotypes 
Timecourse of physiological maturation and emergence of motor neuron selective characteristics 
We described for the first time the rapid timecourse under which ES-MNs acquire 
electrophysiological activity.  The characteristic of repeated action potential firing matches many 
previous studies done on ES-MNs but most of these were performed several weeks or months 
later than in this report.  Therefore our findings show that physiological maturity is attained by 
ES-MN earlier than has been previously appreciated and show the rapid and progressive nature 
of this maturation.  We also demonstrate two features which are characteristic for motor neuron 
firing properties in vivo.  Rebound action potentials are associated with rhythmic locomotor 
activity and spike frequency adaptation in AP trains is an optimal electrical strategy for inducing 
muscle contraction.  This report is therefore the first description of physiological properties 
beyond pan-neuronal characteristics, and therefore provides strong evidence of functional 




The identification of MN-selective electrophysiological phenotypes and the description of 
mature physiological characteristics have important implications for studying ALS pathology in 
vitro.  First, since glutamate excitotoxicity has been identified as a potential mechanism of 
degeneration, it is important to rapidly achieve physiologically active motor neurons in vitro.  
Second, circuit and firing properties—loss of inhibition and relative vulnerability of fast vs. slow 
twitch motor neurons—selective to motor neurons have been implicated in ALS as well.  ES-
MNs have now been shown to adopt several in vivo motor neuron functional firing properties 
which increase the likelihood of modeling disease which is associated with connectivity and 
electrical activity. 
Molecular changes in matured ES-MNs 
Coincident with electrophysiological maturation we report progressive maturation in 
morphology and expression of the NF-H subunits.  These characteristics have not been 
investigated in previous studies, and add to our electrophysiological results in suggesting that 
ES-MNs rapidly acquire more mature features.  Surprisingly in both FACS and mitotic inhibition 
experiments we saw a dramatic increase in the relative proportion of FOXP1
+
 ES-MNs at later 





 cells or a conversion of columnar identity in favor of LMC in older cells.  
Our data does not strongly support either possibility preferentially.  It is also possible that at later 
timepoints FOXP1 becomes a less specific marker for LMC identity, although there is no 
evidence for this in mouse or human to date.  The only other report showing FOXP1 staining in 
hES-MN containing cultures examined cells after 9 weeks of differentiation (Patani, Hollins et 




overall percent of FOXP1 expression, especially in the context of low HB9 efficiency, was 
extremely low.  Future studies are needed to address this point in detail. 
We also observed that LHX3 expression was extinguished in mature cultures.  Whether this is 
explained by late down-regulation of pan-MN-progenitor LHX3 expression, the loss of 
LHX3
+
/MMC cells, or both is not addressed by the scope of our studies.  HB9 and HB9-driven 
GFP expression were also down-regulated in our hands at this timepoint.  The down-regulation 
of HB9 supports a previous report in older ES-MN cultures (Lee, Shamy et al. 2007), however, 
the timecourse of HB9 and ISL1 down-regulation has not been carefully defined in vivo in 
mouse and not addressed in human.  These findings suggest that early pan-MN markers may not 
retain their relevance as motor neurons mature and this in turn has implications for studying ES-
MNs for extended periods in vitro 
One important unresolved question which follows from these studies is what underpins the 
dramatic increase in the number of FOXP1
+
 cells?  As discussed we do not have experimental 
grounds to speculate on the relative contributions of FOXP1
+
/LMC-specific survival vs. a 




 phenotypes.  Future studies should directly 
address this issue since it has important implications for the utility of this system and may in 
itself constitute an interesting LMC vs. MMC/HMC phenotype. 
Morphological maturation of ES-MNs 
The progressive elaboration of large and complex neurites we describe for ES-MNs has 
implications for modeling ALS in vitro.  The extraordinary size of MNs, specifically their 
extremely long axons has been suggested as one characteristic leading to their selective 




a pathology which may also begin in the axon or neuromuscular junction.  Deficiencies in axonal 
transport and accumulations of proteins and varicosities are also hallmarks of disease and were 
speculated to trigger the degeneration.  Finally the energy demands of large cells and 
mitochondrial dysfunction have been identified as potentially relevant players (Boillee, Vande 
Velde et al. 2006).  We present methods to culture ES-MNs for extended time period, to very 
large sizes with increasingly complex and mature morphologies, which provides a novel and 
appropriate cellular substrate for testing these hypotheses. 
 
Future Directions 
Searching for functional and subtype specific phenotypes 
Data from mouse ES-MN studies argues that molecular motor column phenotypes are strong 
predictors of functional motor column phenotypes.  When mouse ES-MNs were 
xenotransplanted to the chick neural tube they showed significant preference for column-
appropriate settling position dependent on whether they had a MMC (LHX3
+
) or LMC 
(FOXP1
+
) transcriptional identity (Peljto, Dasen et al. 2010).  MMC or LMC transcriptional 
identities also resulted  in column-appropriate axial vs. limb muscle axonal trajectories 
(Soundararajan, Miles et al. 2006; Peljto, Dasen et al. 2010).   
Will human ES-MN‘s with LMC vs. MMC molecular marker expression shown functional 
motor column-specific phenotypes?  To begin to answer this question we conducted several pilot 
experiments to look for functional motor column-specific phenotypes.  First, in a preliminary 
study we found that FOXP1
+
 cells showed a larger total outgrowth than non-FOXP1
+
 cells after 




of a human motor neuron phenotype which is potentially specific to motor neuron subtype.  
Second, we observed a dramatic increase in the relative abundance of FOXP1 cells in this assay, 
as well as when mitotic cells were killed by EdU.  Third, when ES-MNs were transplanted to the 
chick, the incidence of FOXP1
+
 cells was again higher than in the starting population. The 
relative abundance of FOXP1 vs. non-FOXP1 cells which we observed in these three different 
paradigms may constitute a column-specific phenotype.  However we cannot say if this was the 
result of selective survival of FOXP1
+
 cells, or initially-FOXP1
-
 cells turning on FOXP1 
expression.  It will be of great interest to determine the mechanism underlying these results. 
Our transplantation also showed many limb-projecting ES-MN axons.  In the future it will be 
crucial to use backfills to establish whether FOXP1
+
 putative LMC ES-MNs preferentially 
interpret chick axon guidance cues to seek limb muscle targets. 
Motor pools 
Many interesting aspect of motor neuron biology emerge at the level of the motor pool: the group 
of motor neurons dedicated to synapse on a particular muscle.  These include later stage axon 
pathfinding and arborization, gene expression changes in MNs, competence to selectively engage 
circuit afferents (Dalla Torre di Sanguinetto, Dasen et al. 2008), as well as disease associated 
survival differences.  For any study directed at motor pool identity or phenotype one must ask 
first if motor pool identities will emerge in human ES-MNs in vitro.  This final level of motor 
neuron specificity was not addressed in these studies.  However experience from mouse ES-MN 
differentiation predicts by analogy that they will.  When mouse ES-MNs were specified to 
express HOXC8 and the LMC marker FOXP1, and provided with GDNF, it appeared that a 








marker) and not LHX1 (LMCL marker) (Peljto, Dasen et al. 2010).  Moreover, this 
transcriptional profile appear to be functional since PEA3 expression was dependent on 
exogenously added GDNF as it is in vivo.  Motor pool identity emerges within the context of 
established columnar identity, which in turn depends upon rostrocaudal identity.  Therefore our 
efforts to precisely identify the rostrocaudal profile of ES-MNs were a necessary prerequisite to 
an informed search for motor pool identities and phenotypes in vitro.  For example, phrenic 
motor neurons which innervate the diaphragm are generated in the HOXA5
+
 region of mouse the 
spinal cord.  This population does not show a differential response to ALS; however its function 
is crucial to patient survival.  Since we have established that the rostrocaudal identity of hES-
MNs is dominantly focused on this HOX region, it is therefore reasonable to begin looking for 
phrenic motor pool motor neurons in these cultures, or in matured cultures derived from them.  If 
phrenic motor neurons could be defined from these cultures in vitro, their specific survival 
requirements, naïve or in the context of ALS genotypes, could be tested in vitro.  In turn this 
could lead to the development of new cell replacement strategies for reinnervation of diaphragm 
in ALS patients or for discovery of new drug candidates. 
Two motor pools show a unique resilience to ALS degeneration: the oculomotor neurons of 
cranial motor nucleus III, and the MNs of Onuf's nucleus in the sacral spinal cord which 
innervate sphincters subserving urinary continence and male sexual functions.  Because of the 
rostral bias to defined rostrocaudal subtypes in our system it is unlikely that progenitors of 
Onuf‘s nucleus MNs are present in our cultures.  However since our cultures are rostrally biased, 
and 50% HOX-, it is not impossible that oculomotor motor neurons were generated, but we find 




would be of great interest to pursue strategies designed to generate these disease refractory motor 
neurons.  
Because of the scalability and reproducibility of the ES-MN differentiation protocols we have 
described, and the precisely defined mixture of subtypes generated, these populations may be a 




















Figure 3.1. Establishing a Standard Protocol for ES-MN differentiation  
(A) Schematic of motor neuron differentiation protocol showing drugs, morphogens, and growth 
factor treatments. (B) Phase timecourse of ESC and EB morphology: day 0 typical ES colony 
morphology; day 6 EBs are small, uniform spheres; day 9 smoothness typical of neural spheres; 
day 24 large EBs showing high purity closely packed neural rosettes, scale bars 436 µm. (C) Day 
26 fixed, whole-mount stained EB, 10x Apotome optical section shows some differentiated 
neurons (NCAM) and abundant neural precursors (Nestin), scale bar  100 µm. (D) qPCR for 
motor neuron lineage genes OLIG2, ISL1, and HB9, % of maximum value/gene normalized to 
GAPDH (mean ±SEM), n=4 independent experiments.  (E) Day 30 fixed , whole-mount EB, 
with abundant HB9:GFP+ ES-MNs 10x Apotome optical section, scale same as (D). (F) 
Representative staining of fixed EB cryosections shows ordered progression of MN-lineage 























Figure 3.2. ES-MNs are defined by expression of HB9 and/or ISL1 at varying ratios  
(A) Day 33 cultures stained for HB9, ISL1 (B) % of all DAPI nuclei with high intensity staining 
for HB9, HB9 and ISL1, or ISL1 (mean ±SEM, n=5 independent experiments), ES-MNs exhibit 
a balanced, partially overlapping profile. (C-D) The wide range of mean HB9 fluorescence 
intensity grey levels (gl) per nucleus generates a smooth curve when (C) ranked and (D) includes 
high and low expressing cells (top, grey levels at left); typical Metamorph scoring result in 
subfield from (A) using a typical conservative 1600 gl above background threshold shows some 
cells scored HB9+ have high intensity, some less so, and some low expressers are scored DAPI-
only (grey), though most DAPI-only have no obvious HB9 signal.  (E) Mean HB9 and ISL1 
intensity (±SD) for the ~950 of 3500 cells ranked in (C) which were HB9+ and/or ISL1+ shows 
an equally broad range of intensities for both markers within ―ES-MN‖ population which is 
similar to the profile for MNs in vivo (Fig. 2.5).  Colored lines indicate background intensity 
ISL1 (red) and HB9 (green). (F) HB9+ and ISL1+ cells are neurons by morphology and TuJ1 
staining. (G) 65% of all cells in culture were neurons and 95% of HB9+ cells were neurons, 
























Figure 3.3. Optimization of a Standard Protocol for ES-MN differentiation  
(A) Single cell seeding and Noggin enhance motor neuron differentiation efficiency.  % HB9+ of 
total cells, (mean of 8 fields/condition ±SEM, n=1 experiment) shows Standard Protocol (single 
cell start) protocol is the most efficient tested when supported by Noggin.  Higher density is 
more efficient and much more efficient than traditional EB protocol even with manual selection 
(day 17-28) for rosettes; single-cell start densities tested: 0.1, 0.2, 0.4M cells/ml. (B) Wnt3a-
conditioned medium(CM) had no significant effect on neuronal differentiation, % TuJ1 of total 
cells (red), or the neuronal identity of HB9+ cells, %TuJ1 of HB9+ cells (yellow) (mean ±SEM 
n=4 independent experiments, t-tests, p=0.66 and 0.79 respectively.  (C) Wnt3a-CM also had no 
effect of on the efficiency of motor neuron differentiation % HB9 (green) or %ISL1 (blue) of 























Figure 3.4. Defining an Accelerated Protocol for high efficiency ES-MN differentiation 
(A) Schematic of Accelerated protocol for the differentiation of ES-MNs showing drugs, 
morphogens, growth factors, and time. (B-C)  EBs were homogeneous and smooth when small 
(day 4) and after expansion (day15) for both (B) RUES1 and (C) HBG1 (HB9:GFP) ES lines, 4x 
phase-2 (D-E) Accelerated protocol generates ES-MNs at high purity by day 23 from both 
RUES1, 27% HB9+ or ISL1+ of total cells (mean ±SEM, n=3 independent experiments), and 
HBG1, 40% (n=1 experiment), with normal partial overlap of these markers. (F) Accelerated 
Protocol can be used to optimize reagents and test differentiation conditions: dose response curve 
for recombinant SHH protein shows activity plateau at 800ng/ml, no MNs with negative control 
or 200ng/ml, n= 1 experiment, mean of 8 fields/condition. (G-H) HBG1 HB9:GFP reporter 
retains high fidelity to endogenous HB9 expression under this protocol (70% of GFP+ cells 




















Figure 3.5.  ES-MNs progressively acquire action potential firing capacity 
(A) Representative image of day 36 HBG47 BAC-HB9:GFP human ESMNs showing mature 
neuronal morphology and coexpression of GFP with motor neuron marker HB9 and ISL1, scale 
bar  50 µm (B,D,F) Current-clamp voltage recordings of representative cells show GFP+ ES-MN 
action potential spiking increases consistently over 13 days,  bottom traces show injected 
currents.  (C,E,G) all recorded cells were injected with biocytin and example cells and GFP+ 






























Figure 3.6. Progressive maturation in passive and active ES-MN membrane properties 
(A) Input resistance decreased over time in vitro (n = 28, P < 0.01, one-way ANOVA).  P < 
0.01, Tukey‘s post hoc test.  (B) Resting membrane potential and (C) rheobase did not change (n 
= 27 and 29, respectively).  Rheobase was defined as the current step magnitude required to 
activate the minimum number of action potentials.  Positive current steps were in 5 pA 
increments to distinguish small difference in rheobase among individual neurons.  (D) Half-
width of action potentials (APs), measured at 50% of peak amplitude at rheobase, changed over 
time in vitro (n = 26, P < 0.001, one-way ANOVA).  P < 0.01,  P < 0.001, Tukey‘s post 
hoc test.  (E) hESMNs at 43 days (n= 8) appeared to be divided into two distinct populations: 
neurons having small rheobase with narrow APs, and neurons having large rheobase with wide 
APs.  (F) Maximum frequency of APs after current injection increased over time in vitro (n = 28, 
P < 0.05, one-way ANOVA).  P < 0.05, Tukey‘s post hoc test.  Dots shows frequency values 
for individual neurons.  The numbers in parenthesis indicate the number of neurons used for 


























Figure 3.7. ES-MNs display two characteristic features of in vivo motor neuron firing 
ES-MNs displayed spike frequency adaptation (SFA), and rebound action potentials (RAPs).  
(A) Inter spike intervals (ISIs) after positive current injection increased gradually during 1 sec 
steps. ISIs were normalized to the first ISI.  Inset shows APs (upper) and injected currents 
(bottom). APs between which 'a' and 'b' ISI values were measure are indicated in the inset as a 
and b, respectively.  (B) SFA ratio, calculated as the maximum value of normalized ISIs after 
any amplitude of positive current injection, increased developmentally (n = 8, R = 0.73, P < 0.05, 
Pearson‘s linear regression).  (C) RAPs were observed in a subset of hESMNs .  Upper trace 
shows voltage change after negative current injection.  Bottom trace shows injected negative 
current steps.  RAP follows the return of current to baseline after the hyperpolarizing step.  (D) 
Incidence of RAPs in hESMNs at 4 different ages (n = 29).  Negative current steps with 5 pA 












Figure 3.8  
 
Figure 3.8.  EdU inhibits motor neurogenesis 
Fewer than 10% of ES-MNs (%Edu of GFP, red) costained for EdU; scattered flat non-neuronal 
cells with very large (>60 µm diameter) nuclei were internal positive control for EdU labeling.  
Total GFP+ ES-MN numbers declined steadily (323, 312, 135, and 105 cells at day 33, 36, 40, 
and 45 respectively), % of day 33 (blue), in stark contrast to the much high numbers in parallel 
cultures without EdU (362, 405, 300, 265 cells at days 33, 36, 40, and 45 respectively).  This 
accords with unpublished data Nuno Lamas and Bethany Kerner, Project ALS lab, however they 











Figure 3.9.  Progressive morphological maturation of ES-MNs  
(A) Representative images of HBG47 BAC-HB9: GFP+ ES-MNs cultured with EdU and stained 
for GFP (green) and HB9 (red) show progressive elaboration of increasingly complex projections 
between day 33 and 45. (B) Metamorph automated neurite tracing was performed on all GFP+ 
neurons on two coverslips (n=323-105 cells/timepoint, n=1 experiment).  Camera lucida traces 
from the first 10 fields encountered show qualitative increases in outgrowth and complexity. (C) 
Mean cell body size, neurite outgrowth length and complexity increased over the timecourse 
(mean % of maximum value/metric +/-SEM, n=323, 312, 135, and 105 cells at days 33, 36, 40, 
and 45, respectively, in one experiment).  We confirmed zero values for the >100 cells counted 
by hemacytometer after dissociation at day 31 for number of neurites, branches, and total 
outgrowth, therefore these metrics include a day31 nominal 0 value (D-E) Total mm of neurite 
outgrowth (D) and um2 soma area (E) increased significantly between day 33 and 45 (mean/cell) 
Mann-Whitney Rank Sum Test P < 0.001, black line is median, grey boxes 25th-75th 
percentiles, whisker bars  10th-90th percentiles, and outliers individual hashes. (F-G) Total 
neurite outgrowth per cell (F) and cell soma area (G) Population histograms, normalized to 100 
cells, for day 33 and day 45, revealed many cells with only modest increases,  but a population of 
cells with much  larger outgrowth and soma area.  Backfilled cells from physiology experiments 
(Fig. 3.5) which were successfully recovered for staining (n=6), were subjected to morphometry 
and plotted on population histogram in the appropriate bins showing that physiology studies 
were performed on cells with broad range of soma areas but not in the larger component for 







Figure 3.10.  ES-MNs rapidly acquire mature NF-H expression profile 
Accelerated Protocol ES-MNs  HBG1(HB9:GFP) (top) or RUES1 (bottom, HB9/ISL) seeded at 
day 21 at high density (0.5M/12mm coverslip) and fixed two days later (day 2)  showed 
moderate intensity NF-H staining in only a little over half of cells, however ES-MNs seeded at 
low density (0.05M/12mm coverslip) , incubated with EdU for  8 days with a 2/3 media change 
at day 4 and then fixed, all showed high intensity NF-H staining in all observed cells.  With 
mitotic inhibition ES-MN purity was greatly increased: almost all (>80%) of NF-H+ cells were 
GFP+ or HB9+/ISL1+. This clear qualitative result was consistent across 3 independent 






Figure 3.11.  ES-MNs express marker combinations matching all in vivo motor columns  
(A) Standard Protocol RUES1 ES-MN differentiations were stained for ISL1 (or HB9, not 
shown), FOXP1, and LHX3 to determine the presence and frequency of putative motor column 
subtypes. (B-C) ISL1+ (B) or HB9+ (C) cells  which showed quantitatively high intensity 
staining for FOXP1 only, LHX3 only, neither, or both, correspond to the expression profiles of 
human LMC, MMC, HMC, and the novel HOXA5+ brachial pool shown in Fig. 2.6 and again 












Figure 3.12.  ES-MNS express predominantly HOXA5 and exclude HOX-protein 
coexpression 
(A) Day 32 Standard Protocol RUES1 ES-MNs were stained for HB9 (A, red) or ISL1 (B, red) 
and HOXA5 (green), HOXC8 (green), or HOXD9 (green) to profile their rostrocaudal identities, 
scale bar 50 µm.  Both HB9 (C) and ISL1 (D) MNs were predominantly HOXA5+ (45% and 
50% respectively), and only small percentages coexpressed HOXC8 (3% and 13% respectively) 
or HOXD9 (3% and 3% respectively), indicating a dominantly cervical identity. (mean ±SEM, 
n=4 except n=3 for HB9 HOXA5 HOXD9 stain.  Significant differences were found between the 
% of HB9+ or ISL+ cells stained for HOXA5 vs. either HOXC8 or HOXD9; and also the % of 
ISL+ cells which stained for HOXC8 vs. HOXD9. (E-F)  When cultures were costained for HB9 
or ISL1(not shown) and both HOXA5(green) and HOXC8 (red) or HOXA5 and HOXD9 (red) 
we observed that  fewer than 5% of HB9+ or ISL1+ cells positive for either HOX gene 
coexpressed the other (yellow bar for HOXA5+HOXC8+, aqua bar for HOXA5+HOXD9+).  
(mean ±SEM, n=4 independent experiments). Statistical Analyses:  *p<0.05 for unequal variance 
Rank Sum test for all comparisons except HB9+HOXA5+ vs. HB9+HOXD9+, and ISL1+HOXC8+ 



















Figure 3.13.  ES-MNs can be cryopreserved with limited effects on subtype identity  
(A) Day 31 RUES1 Standard Protocol ES-MNs from the same experiment were either seeded for 
fixation and analysis at day33, or cryopreserved, thawed and seed for analysis at +2 days; both 
cultures showed abundant live ES-MNs neurons by Tuj1+ morphology and HB9, ISL1 staining.  
(B) The mean %Tuj1+ of total cells was decreased but not significantly t-test p>0.05, (mean 
±SEM , n=3 experiments). (C) The percentage of HB9+ or ISL1+ of total cells were significantly 
reduced (t-tests, p<0.05), but many ES-MNs survived (mean ±SEM, n=5 experiments).   (D) 
surviving cells showed reduced percentage of HOXA5 and HOXD9 cells, but no changes were 
significant (mean ±SEM;  HOXA5, n=5 fresh, n=3 frozen; HOXC8, n=4; and HOXD9, n=3 
fresh, n=4 frozen, t-tests, p>0.05). (E) Surviving cells showed an increased %FOXP1 and LHX3 
of total cells (mean ±SEM ; FOXP1, n=5; LHX3, n=2 fresh, n=3 frozen) which was significant 












Figure 3.14.  ES-MN in matured cultures are predominantly FOXP1
+   
Accelerated Protocol HBG1(HB9:GFP) (top) or RUES1 (bottom) ES-MNs  seeded at high 
density (0.5M/12mm coverslip) and fixed at day 2 show the normal 5-10% range of %FOXP1 of 
ES-MNs we have described above.  However when seeded at low density and matured for 8 days 
in the presence of EdU, almost every ES-MN examined (n>100 cells for each of 2 ESC lines in 1 
experiment/line) stained intensely for FOXP1.  In addition these cultures were stained for LHX3 
(not shown) which identified abundant ES-MNs at day 2, but almost no MNs at day 8.  This clear 


















 ES-MNs show a subtype-specific morphological phenotype  
(A) HBG1 (HB9:GFP) Standard Protocol ES-MNs were FACS sorted for GFP and seeded at 
ultra low density (0.01 M/12 mm coverslip) onto confluent layers of commercially available 
human fetal spinal cord astrocytes in one pilot experiment.  After 12 days 72% of surviving ES-
MNs showed intense FOXP1 staining, while LHX3 could not be detected (not shown), field 
width 900 µm. We also observed that astrocyte nuclei showed very weak but above background  
FOXP1 staining.  (B) FOXP1
+
 cells (n=39) showed significantly (t-tests p<0.05) longer mean 
and median process lengths and trend increases in all other aspects of neurite outgrowth, but no 
change in cell soma area compared to FOXP1
-
 cells (n=20); Metamorph neurite outgrowth 
morphometry was paired with a custom interactive journal to score celsl for FOXP1 and analyze 
neurite outgrowth.  Any GFP cells in direct contact with other GFP cells were manually excluded 
from analysis (C) Cumulative percentage population histogram showed that FOXP1
+
 cells had 























Figure 3.16. Human ES-MNs respond to in vivo cues in xenotransplant to chick spinal 
cord.  
(A-D) Standard Protocol HBG1 (HB9:GFP) ES-MNs  were transplanted to the prospective 
brachial level of HH stage 15-16 embryos and allowed to develop for 2-3 days.  When chicks 
were sacrificed and cryosectioned we observed GFP
+
 human cells in many embryos (n=8 of 16 
surviving embryos).  Many GFP
+
 also expresssed FOXP1, and some but fewer which expressed 
LHX3.  Human ES-MNs extended projections (>1.8 linear mm in C and D) through ventral roots 
(A, C, D) or ectopic dorsal exit point in the case of one dorsal transplant (C) and in most cases 















Chapter 4. Motor neuron differentiation from human induced pluripotent stem cells: 




The discovery that somatic cells could be reprogrammed to a pluripotent state opened the door to 
the study of previously unavailable cell types with relevance to human disease (Takahashi and 
Yamanaka 2006).  The precise genotype of patients with disease could now be captured in a 
pluripotent cell with the potential to generate unlimited quantities of affected cell types in vitro 
(Park, Arora et al. 2008; Lee, Papapetrou et al. 2009; Soldner, Hockemeyer et al. 2009).  ALS-
iPSC lines were among the first human lines generated from patients because the human motor 
neurons affected in ALS were not otherwise available and their differentiation from human ES 
cells had been established.   Subsequent studies, however, have reported differences between 
iPSC and ESC lines.  In order for ALS-iPS-MNs to become a productive tool to model ALS it 
will be necessary to determine the reproducibility with which they can generate motor neurons.  
In addition it will be necessary to show that motor neurons derived from iPSC are bona fide 
motor neurons and capable of functional maturation.  Our first goal was therefore to generate a 
large test set of iPSC lines and compare these to ESC lines for their ability to generate motor 
neurons.  Second, we wanted to establish that motor neurons generated from iPSCs were 
functional and met specific criteria established by in vivo studies and for ESC-derived motor 




would routinely be encountered when building disease models, affect the performance of iPSC 
lines.  
Are iPSC lines comparable to ESC lines in making motor neurons? 
Several concerns have been raised about the general comparability of iPS to ES cells.  Some 
groups have reported epigenetic and gene expression differences between iPS and ES cells, 
potentially the result of incomplete reprogramming or epigenetic memory of their somatic cells 
of origin (Chin, Mason et al. 2009; Doi, Park et al. 2009; Taura, Noguchi et al. 2009; Armstrong, 
Tilgner et al. 2010; Ghosh, Wilson et al. 2010; Grigoriadis, Kennedy et al. 2010; Stadtfeld, 
Apostolou et al. 2010; Tokumoto, Ogawa et al. 2010; Xi, Khalil et al. 2010).  From the 
perspective of modeling ALS in vitro, the most relevant and troubling report concluded that 
iPSC lines have categorically and substantially lower rates of neural induction and more variable 
differentiation to motor neurons compared to ESC lines (Hu, Weick et al. 2010).  This study, 
however, used a relatively small number of iPSC lines, which limits the strength of conclusions 
about the general and motor neuron-specific comparability of iPS to ES cells.  Therefore a larger 
study which methodically addressed these issues was required.  
Does individual genetic background influence iPSC performance? 
The small sample sizes of previous comparative studies have also limited the investigation of 
potential sources of variability between iPSC lines.  This issue is no less acute in the case of ESC 
lines, where many studies have described large variability between lines.  The sources of this 
variability are poorly understood.  Methods of derivation, culture, and differentiation vary 
widely.  However because of the extremely limited availability of fertilized embryos from which 




variables, it has not been feasible to study the contributions of these variables to ESC 
performance.  iPSC lines on the other hand are easily derived from any individual and it is 
therefore now possible to begin to ask what impact demographic factors and individual genetic 
background have on stem cell properties.  Understanding these effects will have major 
implications for the use of iPS-derived cell types to study cellular physiology and disease 
models.  Studies of a large number of iPS lines distributed across several demographic variables 
which will be commonly encountered as researchers undertake disease modeling are required. 
We have seen that some variability among ES lines may be related to the method of derivation.   
However a direct test of this idea is not possible since it is possible to derive a line only once 
from a unique embryo.  Multiple iPSC lines however can be derived from the same donor.  
Studying multiple lines from the same donor in comparative studies should contribute two 
related insights.  First, this could help define the extent of variability associated with the one-
time event of reprogramming since all lines will start from the same individual genotype.  At the 
same time, if conserved properties are found between lines from the same donor vs. other donors, 
this would provide the first demonstration of the effect of human genetic background on 
pluripotent cell properties and differentiation potential.  Studies aimed at assessing sources of 
variability should therefore also include multiple iPSC lines derived from the same donor. 
Are iPS-MNs functionally comparable to ES-MNs? 
The last question raised by studies of gene expression and epigenetic differences between iPSC 
and ESCs is whether terminally differentiated cells will be functionally compromised in 
important ways.  For example we have seen that ES-MNs acquire a specific set of dominantly 




ES-MNs as they are by motor neurons in vitro.  Since HOX-protein mutual exclusion is a 
principal mechanism by which limb-innervating motor pool identity is acquired, it is important 
that iPS-MNs not only respond similarly at the first level to patterning cues (by expressing 
HOXA5 in response to RA for example) but that the subtleties of gene expression are also 
preserved (mutual HOX-exclusion).  We have also defined the short timecourse during which 
ES-MNs acquire electrophysiological activity in vitro, which mirrors important aspects of motor 
neuron physiology in vivo.  If iPS-MNs are to be used to model disease in which 
electrophysiological activity may play a role, it is important that iPS-MNs are able to attain 
functional electrical properties matching or relevant to motor neurons in vivo as well.  While 
many groups have now reported the expression of pan-motor neuron transcription factors in iPS-
MNs, the rostrocaudal HOX subtype and HOX exclusion have not been tested.  And while others 
(Hu and Zhang 2009; Karumbayaram, Novitch et al. 2009; Hu, Weick et al. 2010) have shown 
that iPS-MNs can acquire functional physiological properties, this has not been done 
systematically on a large set of iPS lines.  It was therefore important to ascertain if iPS-MNs 
would display in vivo-like transcriptional identities, and to test their functional maturation. 
 
Statement of Contributions 
This chapter contains work which was highly collaborative; performed exclusively by 
collaborators; or led and performed almost entirely by myself at the experimental level, in that 
order.  Figures 4.1, 4.2, 4.3 (with the exception of  Figure 4.3D which was performed by myself 
contemporaneously), and 4.4A were adapted from a publication by the Eggan Laboratory, and 




as described in the published manuscript (Dimos, Rodolfa et al. 2008) with the following 
exceptions:  for this publication I optimized skin biopsy and fibroblast culture methods and 
initiated and maintained cultures with technical help from Mary Lee;  I also adapted and 
optimized motor neuron differentiation and staining protocols which did not appear in, but 
contributed to the technical basis for this publication. The remaining figures are adapted from 
(Boulting, Kiskinis et al. 2011) and Figure 4.18 from (Bock, Kiskinis et al. 2011) with the 
exception of my unpublished data (Fig. 4.4B-D, and Fig. 4.8).  GFC performed biopsies and 
fibroblast cultures with technical help from Mary Lee, and some help from Annie Hon, MWA, 
and DHO.  CTR and JTD reprogrammed all iPS lines.  GLB and EK initially expanded all iPS 
lines and GFC, Annie Hon, MWA, and DHO expanded early passage lines at the PALS lab.  
FACS experiments of day 0 and day 29 cells were optimized and overseen by GFC with 
technical advice from KTR and some technical help from MWA, and analyses were performed 
by DJK with help from GFC, MWA, and DHO.  Standard motor neuron differentiations in the 
PALS lab were performed by MWA and GFC with some help from DHO.  Optimal motor 
neuron differentiations were performed by MWA and GFC.  HOX analyses were performed by 
GFC and MWA.  ABM, DJW, and DHO designed and carried out Ca2
+
 imaging experiments.  
BJW, GLB, and CJW performed physiological recordings.  MY assisted with teratomas.  LD 
assisted with quantitative cell scoring of imaging data in the Eggan Lab.  MWA and GFC 
performed quantitative cell scoring of imaging data in the PALS lab.  Southern Blots were 
performed by GFC and MWA with technical advice from Andrew Sproul (NYSCF) and the 
Eggan lab.  Statistical analysis was performed by GFC, with the following exceptions: FACS 
statistics performed by DHO, and sex difference ANOVA by MWA, 2 correlations performed by 




Scorecard analyses of iPS lines was conducted entirely in the Meissner/Eggan laboratories as 
described in their publication (Bock, Kiskinis et al. 2011). 
 
Results 
iPS-MNs and iPS-astrocytes: proof of principle experiments 
iPS cells from older ALS patient donors are pluripotent 
Since ALS is an adult-onset disease it was important to determine whether iPSC lines could be 
derived from ALS patients of advanced age, and to show that these lines could generate cell 
types of disease relevance.  We therefore obtained informed consent and cultured ALS patient 
skin biopsies to derive primary fibroblast cultures (Fig. 4.1A) (Dimos, Rodolfa et al. 2008).  
Cultures were transduced with 4 reprogramming factors and after several weeks colonies with 
ES-like morphology were observed (Fig. 4.1B).  These colonies stained with conventional 
markers of human ES and iPS cells (Fig. 4.11C, and (Dimos, Rodolfa et al. 2008))  These lines 
showed the same genetic mutation in the SOD1 gene (L144F) as the patient donor (data not 
shown, (Dimos, Rodolfa et al. 2008)) confirming that they were generated from patient 
fibroblasts.  Under a non-directed spontaneous differentiation protocol (Fig. 4.2A) these iPSC 
lines demonstrated pluripotency by generating cells expressing proteins indicative of 
differentiation to all three primary germ layers (Fig. 4.2B).  We concluded from these data that 
age and disease status were not obstacles to generating iPSC lines from ALS patients.  We next 
asked if these lines could generate the cell types of primary interest for modeling ALS in vitro, 




ALS patient-derived iPS cells are competent to generate motor neurons 
To test the ability of patient-derived iPS cells to generate spinal motor neurons we applied a 
standard protocol from the Zhang lab used to induce motor neurons from human ES cells (Li, Du 
et al. 2005) described in Chapter 3, with minor modifications.  Retinoic acid was used to induce 
caudal, and SHH to induce ventral positional identity, and we maintained EBs in suspension until 
dissociation or seeding, rather than manually select rosettes (Fig. 4.3A).  When these cultures 
were stained for the markers of pan-MN identity, HB9 and ISL1, we observed that 20% of cells 
expressed HB9, and 90% of these co-expressed ISL1 (Fig. 4.3B).  The neuronal identity of these 
cells was confirmed by strong reactivity for the neuronal marker βIII-tubulin (TuJ1) and 
neuronal morphology (Fig. 4.3C, D) and over half of HB9
+
 cells stained for the MN-
neurotransmitter synthetic enzyme ChAT (not shown).  We concluded from these data that 
patient-derived iPS cells were capable of generating motor neurons.  We next asked if astrocytes, 
which manifest a strong toxicity for motor neurons in mouse models of ALS in vivo (Boillee, 
Vande Velde et al. 2006) and mouse and human in vitro models of ALS (Di Giorgio, Carrasco et 
al. 2007; Nagai, Re et al. 2007; Di Giorgio, Boulting et al. 2008), could also be generated from 
ALS-iPS cells. 
iPS cells are competent to generate astrocyte-like cells 
To determine the ability of patient-derived iPS cells to generate astrocytes we assessed the 
expression of the astrocytic marker glial fibrillary acidic protein (GFAP).  At the same timepoint 
that the above iPS-MN phenotype was observed (~40days of differentiation) many cells  that 
stained strongly for GFAP had small somata and few and very long processes suggestive of a 




for the radial glia antigen RC-2 (not shown) at this timepoint, supporting this idea. Since 
gliogenesis begins around 3-4 months in human in vivo (Bayer and Altman 2002), we 
maintained cultures for this time in vitro with infrequent passaging.  After 120 days we observed 
that nearly all cells in the culture displayed flattened multipolar astrocytic morphology, most 
expressed GFAP in all possible permutations with the early astrocyte marker CD44 and the glial 
progenitor marker Vimentin (Fig. 4.4B-D).  While astrocyte generation was not the focus of our 
studies, and this novel qualitative result was not quantified, and further gene expression and 
functional analysis would be required to substantiate an astrocytic identity, we concluded from 
these experiments that ALS-iPS cells were capable of giving rise not only to motor neurons, but 
to cells with key molecular and morphological features of astrocytes as well. 
Establishing a test set of iPSC lines 
In order to address general concerns about the comparability of iPS and ES cells, specific 
concerns about reduced motor neuron differentiation efficiency, and test potential sources of 
variability, we set out to construct a large ―test set‖ of iPSC lines.  We generated 14 new iPSC 
lines, which, combined with the 2 lines reported above were derived from seven different donors, 
healthy or diagnosed with ALS, male and female, and whose ages ranged from 29 to 82 years 
(Table 4.1).  All 14 new lines were generated by 3-factor reprogramming, i.e., without c-MYC, 
to allow us to test for the impact of this oncogene by comparison to the two previously described 
iPSC lines.  To determine if individual genetic background had a strong impact on phenotype we 
included several independent lines derived from the several individual donors.  To compare iPSC 





All test set iPSC lines are pluripotent 
To determine whether these iPS cell lines met the established criterion for human ES cells we 
first assayed them using standard assays for marker expression and functional pluripotency.  All 
iPSC colonies showed classical ESC-like cellular and colony morphology, stained for cell-
surface, cytoplasmic, and nuclear markers of pluripotency, and showed active cell-cycle 
parameters similar to ESC controls (Fig. 4.5A, B, C).  All iPSC lines generated cells from all 3 
embryonic germ layers in undirected differentiation (Fig. 4.5D) and all tested lines formed 
typical teratomas including tissues from all 3 germ layers when injected into immune-
compromised mice (Fig. 4.5E).  These data demonstrated that all iPSC lines in our test set passed 
all conventional assays of pluripotency for human ES cells.  We then asked how these lines 
would perform in motor neuron directed differentiation. 
Most iPS cell lines generate functional motor neurons with in vivo-like molecular identities 
To compare the ability of iPSC and ESC lines to properly specify motor neurons, all lines were 
differentiated under standard protocols previously shown to generate motor neurons from ES 
cells (Fig. 4.6A).  To determine the robustness of these lines, differentiations were conducted in 
parallel in the Eggan laboratory and in the Project ALS laboratory.  We found that 81% (13/16) 
of iPSC lines, and all ESC lines generated robust populations of ISL1
+
 cells which also stained 
for TuJ1 and showed typical neuronal morphologies (Fig. 4.6B).  Of the lines tested in parallel in 
both labs there was a striking consistency in the quantitative %ISL1 for individual lines (Fig 
4.6C).  A Pearson correlation, however, did not show a strong correlation between lines tested in 
both labs however (n=10 lines, r=0.5038).  However, in both labs the same 3 of 16 iPSC lines 
failed to generate almost any ISL
+




The striking consistency of line malperformance between labs could not be included in the 
Pearson correlation because these are non-numerical values (Fig. 4.6C).  If lab was considered as 
an independent variable, on the other hand, then there was no significant difference between the 
aggregate efficiency observed between labs (ANOVA, p>0.05, Table 4.2).  We therefore pooled 
the data between labs for subsequent analyses of all 13 lines which had generated ISL1
+
 neurons.  
Importantly, as a group, the 13 iPSC lines that generated ISL1
+
 cells did not show a significantly 
different efficiency compared to ESC lines (Table 4.2).  There were, however, significant 
differences in %ISL1 efficiency  between lines, and post-hoc tests showed that lines 11a and 11c 
in particular were significantly different from 18c (Fig. 4.6D, Table 4.3).    We concluded from 
these data that iPSC lines show robust and characteristic behavior in multiple settings, suggesting 
that motor neuron differentiation efficiency was a stable and intrinsic property of individual 
iPSC lines.  These data also showed that iPSC lines did not have more variable or lower 
efficiency motor neuron differentiation than ESC lines. 
To further validate the motor neuron phenotype defined by ISL1 expression, we tested several 
other endpoints required for more definitive assignment of motor neuron identity.  First, we 
found that all 13 lines tested generated HB9
+
 cells which stained for TuJ1 and showed neuronal 
morphologies (Fig. 4.7A).  We again observed characteristic differences between lines which 
paralleled the differences observed for %ISL1 (Fig. 4.7B).  Many ISL1
+
 cells from iPS and ES 
lines alike expressed the characteristic motor neuron neurotransmitter synthetic enzyme ChAT 
(Fig. 4.7C).  To ask if stem cell derived motor neurons were post-mitotic we stained cultures for 
the cycling cell marker Ki67, and found that ISL1
+
 cells were not positive, while PAX6
+
 
progenitor cells served as an internal positive control (Fig. 4.7D).  Finally we used qPCR to 




neuronal marker TuJ1 were strongly upregulated in these cultures compared to undifferentiated 
ESC or IPSC, or fibroblasts (Fig 4.7E).  We concluded from these data that iPSC-derived 
neurons met all established in vitro criteria to be considered bona fide motor neurons.  We next 
wanted to ask if these iPS-MNs met the criteria of coherent positional identity as defined by 
patterns of HOX protein expression as we have shown that ES-MNs did in Chapter 3. 
To determine if iPSC lines would respond to the patterning cue RA in a similar fashion to ESC 
we tested the expression of HOXA5 and HOXC8 (Fig. 4.8A).  iPS-MNs adopted a strikingly 
similar positional profile to that of ES-MNs (Fig 4.8B).  The largest fraction of iPS- and ES-MNs 
expressed HOXA5 (42% vs. 41% respectively), indicative of a cervical positional identity, 
whereas about ~4 fold fewer motor neurons from both cell types expressed HOXC8 (14% vs. 
12% respectively), indicative of a brachial to thoracic identity.  Impressively, the fraction of 
motor neurons abnormally expressing both HOXA5 and HOXC8 was extremely small and was 
consistent between iPS- and ES-MNs (4% and 2% respectively).  We concluded from these data, 
that iPSCs appear to interpret the positional cue RA with the same results as ESCs.  Furthermore, 
iPS-MNs are no less faithful to the in vivo phenomenon of HOXA5-HOXC8 mutual exclusion 
than are ES-MNs.  This phenomenon is particularly important since it controls the diversification 
of several brachial motor pools from generic LMC precursors.   
To test whether iPS-MNs were functional we compared the electrophysiological activity of 
neurons from four iPSC and two ESC lines using the Ca
2+
 sensitive dyes Fura Red AM (Fig. 
4.9A, B) and Fluo-4 AM (Fig. 4.9C).  Spontaneous Ca
2+
 transients were observed in many cells 
from all iPSC and ESC lines tested (Fig. 4.9C, H, J).  When cells were exposed to the ionotropic 
glutamate receptor agonist kainate (KA) 78% of cells with neuronal morphology (n=132 cells) 
responded with rapid increases in intracellular Ca
2+




to depolarize cells by shifting the electrochemical equilibrium of the perfusion medium, many 
KA responsive cells again showed Ca
2+
 fluxes (Fig. 4.9G, I, K).  Post-imaging stains of these 
cultures confirmed that many active cells were ISL1
+
 motor neurons.  These data showed that 
iPS-MNs, like ES-MNs, had spontaneous and evocable electrical activity consistent with 
functional neuronal identity.  To further examine the basis for this activity and to ascertain if 
iPS-MNs could fire action potentials, we performed whole cell patch clamp recordings on cells 
with neuronal morphology from an ESC control (HuES3 HB9:GFP, n=9) and iPSC lines (18a, 
n=10; 27b, n=10).  All cells showed fast voltage-activated inward currents followed by slow 
outward currents, consistent with voltage-activated sodium and potassium channels (Fig. 4.10A, 
B).  Inward currents were blocked by TTX, a specific inhibitor of voltage-gated sodium channels 
(Fig. 4.10C).  Finally, current clamp recordings revealed that action potentials could be elicited 
by current injection in both ESC- (n=2) and iPSC-derived neurons (n=2), as well as repetitive 
firing from one neuron derived from iPS line 18a (Fig. 4.10 D).  We concluded from these 
studies that iPSC lines generated electrically active functional neurons similar to ESC lines. 
 Potential sources of iPSC variability and rescue of atypical lines 
Our data demonstrated that iPSC lines were able to generate functional motor neurons with 
coherent (HOX-mutually exclusive) positional identities with equivalent efficiency to ESC lines.  
The variability between iPSC lines was no greater than between ESC lines however our data did 
show significant line-dependent differences in motor neuron differentiation efficiency.  We also 
noted that 3 lines showed a defective phenotype of near complete failure to generate ISL1
+
 motor 
neurons.  We therefore investigated several potential sources of inter-line variability and for this 
defective phenotype: persistent transgene expression, karyotypic instability, the effect of any of 






Persistent transgene expression 
We and others have reported some persistent or reactivated expression of viral reprogramming 
transgenes in iPSC lines.  To gauge the extent of this phenomenon in our test set and to see if this 
correlated with variable motor neuron differentiation efficiency we monitored expression of 
endogenous and viral reprogramming genes in undifferentiated and differentiated iPSC cultures 
(Fig. 4.11).  For most cell lines viral transcription was very low, and for SOX2 it was 
undetectable (Fig. 4.11A-C).  Many iPSC lines however expressed varying levels of KLF4 (11b, 
11c, 15b, 18b, 18c, 27b, 27e, and 29e) in both undifferentiated and differentiated cultures (Fig. 
4.11B).  Several lines also expressed viral OCT4 (15b, 18c, and 27b) in both undifferentiated and 
differentiated cultures (Fig. 4.11C).  Notably, transgene expression was stable: present in 
undifferentiated and differentiated cultures from that line, not reactivated on differentiation.  To 
determine if OCT4 protein was expressed in differentiated neurons we double-stained cultures 
for ISL1 and OCT4 and found, surprisingly, that many individual ISL1
+
 neurons in viral OCT4-
expressing lines co-expressed nuclear OCT4.  Despite this inappropriate gene expression, there 
was no correlation between total transgene expression and motor neuron differentiation 




=0.1687).  Furthermore many of the lines showing 
transgene expression were those that had previously been shown to generate electrically active 
motor neurons with normal HOX profiles.  We concluded from these data that although some 
iPS lines maintained transgene expression, it had no detectable effect on the differentiation 





Karyotypic instability is a well described phenomenon in both mouse and human stem cell 
cultures.  We therefore asked if irregular karyotypes might have affected iPSC performance.  The 
majority of iPSC lines tested (9/15) retained normal karyotype at both early and late passage 
whereas 6 lines (29d, 27b, 29e, 11a, 11b, and 15b) showed abnormal karyotypes of varying 
severity (Table 4.4).  Only two (29e, 11b) of the three defective lines showed abnormal 
karyotypes therefore this alone could not explain the defects.  Furthermore line 27e had a normal 
karyotype and showed the same specific defective phenotype as 29e (see below).  Finally, 
excluding defective lines (11b, 27e, 29e) there was no significant difference in ISL1
+
 motor 
neuron differentiation efficiency between lines with normal vs. abnormal karyotype (Table 4.2).  
We concluded that abnormal karyotype could not explain variability or defective lines.  We next 
sought to establish quantitative phenotypes for the 3 failed lines and to investigate the nature of 
their defects.  
Identification and rescue of defective iPSC lines 
Two of three defective lines (27e and 29e) showed a dramatic cystic disaggregated EB 
phenotype at day just after day 10, which first distinguished them from all other stem cell lines 
studied (Fig. 4.12A).  When EBs were dissociated and seeded at the same density we found a 
significant difference in the total number of attached cells at day 32 for both of these lines (Fig. 
4.12B, Table 4.5).  Since these lines were easily identifiable by the qualitative EB and 
quantitative dissociated-cell phenotypes, and since the remaining cells were not positive for TuJ1 
or ISL1, we excluded these lines as outliers from subsequent analyses.  The third defective iPS 




total cells at day 32.  However, when cultures were stained for the neuronal marker TuJ1 we 
observed a significant decrease in the percent of neurons (Fig. 4.13A, B and Table 4.6).  Because 
the first defective phenotype (for 27e and 29e) occurred during the period of consolidation of 
neural identity and the second phenotype (11b) was a reduced percent of neurons, we 
hypothesized that both phenotypes might be underpinned by a defect in neural induction. 
To test whether these abnormal phenotypes were related to failed or low efficiency neural 
induction, we attempted to rescue them using essentially the Accelerated Protocol (described in 
Chapter 3, Fig. 3.3) which forces rapid neural induction using two ALK inhibitors.  We found 
that both defective lines and two ES control lines displayed normal, smooth and round EB 





(Fig. 4.14A).  All iPSC and ESC lines showed very high neuronal differentiation efficiency (70-
90% TuJ1
+
) (Fig. 4.14B) and comparable percentages of both ISL1
+
 (10-20%) and HB9
+
 (3-6%) 
(Fig. 4.14C, D).  Since strong inducers of neural identity were able to completely rescue both 
defective phenotypes, we concluded that the defects were somewhere in the pathway of neural 
induction.   
Sources of variation 
To understand the line-specific variability observed for %ISL1 efficiency in the 13 of 16 normal 
iPSC lines, we next investigated whether any of the demographic or technical variables which 
we built into the test set had an effect on the outcome.  There was no difference between ALS 
and control or between 3- and 4-factor lines (Fig. 4.15 A, B; Table 4.2).  Similarly there was no 
correlation between donor age and %ISL1 (R
2
=0.0084).  However iPSC lines derived from 
female donors did show a significantly higher percentage of ISL1
+




When ESC lines were included in this comparison the mean difference between male and female 
lines was smaller but still significant (Fig. 4.15D, Table 4.7).  Since our test set was included 
multiple lines from 3 donors, we could assess whether individual genetic background affected 
differentiation efficiency.  Indeed we observed very low variability between lines from the same 
donor and large variability between the means of all lines from one donor compared to another.  
ANOVA revealed that donor genetic background significantly affected differentiation efficiency 
(Fig 4.15E, Table 4.7).  Post hoc pairwise comparisons comparing all individual donors did not 
however identify significant differences between any individual donors.  However, the n for lines 
from the same donor (1-3; Table 4.7) was too low to reasonably expect any pairwise 
comparisons to be statistically significant, and the lack of significant pairwise comparisons 
should not detract from the significant finding in the more powerful ANOVA.    Finally, because 
donor sex is part of donor genetic background we cannot be certain that the sex-specific 
difference does not alone account for the difference between donor genetic backgrounds.  We 
concluded from these data that donor genetic background, including or in addition to sex had 
significant effects on the motor neuron differentiation efficiency of individual lines.   
We next considered an alternative explanation for the low variability in ISL1
+
 performance for 
lines from the same donor.  Since most lines from individual donors were derived from the same 
reprogramming cultures, it was formally possible that cells from an initial clonal transduction 
event had physically moved in culture and were subsequently isolated and mistakenly considered 
to be independent lines.  To directly address this possibility we conducted Southern blots using 
probes for 2 different viral transgenes, SOX2 and OCT4 (Fig. 4.16).  The SOX2 probe showed a 
differential pattern of molecular weight species for all of the lines from donor 29, 18, and 11.  




are not the same line.  We concluded from these data that the low intra-donor variability was not 
the result of the same line being erroneously considered as multiple lines, and therefore that these 
effects on performance were likely the result of donor genetic background and or sex. 
Scorecard predictions match line-specific empirical behaviors 
During the course of our experiments, which showed significant differences between individual 
lines in motor neuron differentiation efficiency, another group was using a subset of this test set 
of iPSC lines to develop comprehensive reference maps of variation among ES and iPS lines 
(Bock, Kiskinis et al. 2011).  Additionally these authors developed a targeted microarray 
approach to predict the differentiation propensities of individual lines based on short-term 
spontaneous EB differentiation: a ―scorecard‖ for pluripotent cell differentiation potential.  For 
each cell line we plotted the neural and ectodermal lineage indices generated by this scorecard 
analysis against the percentage of ISL1
+
 neurons we had measured empirically for that line, and 
we found a strong correlation for both lineages (Fig. 4.17A, B).  As a control for specificity we 
showed that there was not a strong correlation between endoderm and mesoderm lineages and 
ISL1
+
 efficiency (Fig. 4.17C,D).  We concluded that the same result was obtained by both 
methods, thereby cross validating both our empirical and their scorecard approach to estimating 
the intrinsic lineage competence and proclivity for individual lines. 
 
Discussion 




We have shown that patient derived iPSC lines can generate motor neurons and astrocytes: two 
key cell types affected in ALS.  Next we constructed a large set of iPS lines encompassing 
several demographic variables likely to be encountered when attempting to model disease using 
iPS-derived cells.  We demonstrated that 1 in 5 iPSC lines had a serious defect in neural 
differentiation, but these were easily detectable.  The remaining iPSC lines generated motor 
neurons with positional identities and functional electrophysiological behavior equivalent to 
ESC-derived motor neurons.  Finally, we excluded several of the demographic variables—age, 
disease status, number of reprogramming genes—as sources of variation among iPS-MNs, but 
identified donor genetic background (including and potentially limited to sex) as a significant 
factor.  These studies provide a resource of disease and control cell lines for studying ALS and 
also provide practical guidelines for the derivation and analysis of iPSC lines.  Most importantly 
they provide confidence that iPSC lines can generate differentiated motor neurons with 
comparable functional characteristics to those derived from ESC lines, and set the stage for 
making models of genetic disease. 
iPS-MNs are functional and show in vivo like transcriptional phenotypes comparable to ES-MNs 
iPS-MNs showed spontaneous and evoked electrophysiological activity no different than ES-
MNs.  Since adult-onset diseases like ALS affect cells that are developmentally mature in vivo, 
studying more mature motor neurons in vitro may increase the chances of defining disease 
relevant phenotypes.  Indeed, several hypotheses about the mechanisms of motor neuron 
degeneration in ALS hinge on characteristics that appear only with maturity.  For example 
glutamate excitoxicity has been implicated in ALS, and to adequately address this hypothesis it 
would be useful to test ALS-MNs which have functional glutamate receptors and maturing firing 




glutamate receptors—in Ca2+ imaging experiments—as well as electrophysiological maturity 
capable of sustaining repeated action potential spike trains.  These functional 
electrophysiological characteristics suggest that iPS-MNs may be able to model activity-
dependent aspects of ALS.  In the future it will be important to demonstrate that iPS-MNs can 
achieve the type of mature and motor neuron-typical physiological activity which we have 
described for ES-MNs in Chapter 3.  Other hypothetical ALS mechanisms have pointed to 
relatively unique morphological features of motor neurons to explain their selective 
vulnerability: the giant cell size (mostly axonal) may be linked to the pathology observed in 
axonal dieback and varicosities, ubiquisome overload, protein folding dysfunction and 
aggregation, axonal dieback, axonal transport defects, and energy metabolism and mitochondrial 
dysfunction.  In order to adequately address these hypotheses it will be important to demonstrate 
that iPS-MNs can undergo morphological maturation as we described for ES-MNs in Chapter 3.   
Another aspect of in vivo motor neuron biology that may be leveraged to study ALS in vitro is 
the differential susceptibility shown by specific motor column and motor pool subtypes.  We 
know from studies in mouse and chick that these subtype identities emerge downstream of 
rostrocaudal patterning as articulated by HOX genes.   Because iPS cells can differentiate to 
motor neurons, in our hands and in others‘, shows that they can respond to developmental cues 
(RA and SHH) and assume differentiated identities.  In order to generate specific motor column 
or motor pool subtypes the fidelity of this developmental response must be high enough to 
generate the coherent HOX identities that drive those subtypes.  We show that all iPS lines 
tested, just like ES lines,  generated motor neurons with HOX profiles congruent with natural in 
vivo cervical positional identities (Chapter 2 and 3): they expressed mostly HOXA5 (cervical) 




the diversification of motor pool (HOXA5-C8 and others) and column (HOXC-6, -9, -10) 
subtype identities.  Since our data suggest the functional activity of these HOX mechanisms, it 
predicts that they may be used to generate specific motor neuron subtypes with enhanced utility 
for modeling ALS.  The equivalent ability of iPSC and ESC to follow developmental cues and 
mechanisms in order to make highly-specific neuronal subtype cell-fate choices supports the idea 
that iPSC will be able to follow developmental trajectories to specific cell types relevant to other 
diseases. 
Reproducibility and net equivalence with ES  
By using a large set of iPSC lines and ES lines and a standardized differentiation protocol we 
showed that iPSC lines are no worse and no more variable than ESC lines in generating motor 
neurons.  This result is at odds with the most in-depth previous study of this question (Hu, Weick 
et al. 2010).  One explanation for this discrepancy is that the manual selection protocol used 
previously for motor neuron differentiation (see Chapter 3 for discussion) unintentionally biased 
the results against iPSC lines.  Another explanation might be that the cell bank fibroblasts used 
to make those iPS lines had accumulated cytogenetic problems or mutations during 
indeterminate periods of culture, passage, or cryostorage.  Additionally, the number and variety 
of iPSC and ESC lines which we used was much larger than in the previous study (16 iPSC and 
5 ESC vs. 4 iPSC and 1 ESC), allowing us to test variability within iPSC and ESC categories 
independently and also compare the two statistically.  Additionally, the ESC lines used for motor 
neuron comparison in the previous report (H9) is well known to show better than average 
efficiency for basal neural conversion.  On the other hand the authors show a very clear 




which none the above explanations can fully account, except cell bank degradation.  More 
studies will be needed to resolve these issues in the future. 
The performance of individual iPSC lines was remarkably similar between the two different labs 
involved in our study.  This shows that lines retain intrinsic properties across passages, and their 
performance in well defined differentiation protocols (with at least 4 different operators) was 
highly robust.  This finding gives confidence that iPSC are reproducible tools: an important 
criterion required for cellular substrates of disease modeling and drug screening. 
While the majority of iPSC lines (81%) were equivalent to ESC lines, we did identify 3 defective 
lines.  These defective lines were easily detectable and at a rate of just under 1 in 5 lines, we 
conclude that this error rate is an acceptable cost of making iPSC lines.  Although motor neuron 
differentiation in these lines could be rescued with a forced neuralization protocol, for all 
practical purposes we recommend that simple steps be taken to remove lines like these from 
experimental sets.  Since we excluded transgene expression and karyotypic instability as 
sufficient causes for these defects, we hypothesize that random viral integration events are 
responsible for these defects, and therefore newer reprogramming techniques such as synthetic 
RNA, non integrating vectors, or chemicals should avoid this complication altogether.  Indeed, 
whether viral genomic lesions are responsible for causing these particular defects, non-
integrating approaches are clearly a more conservative approach to generating iPSC lines. 
Sources of variation 
Our results showed that donor sex/genetic background significantly affected motor neuron 
differentiation efficiency.  This result could explain some of the variation which others have 




well show marked differences in differentiation efficiencies for the motor neuron (Di Giorgio, 
Boulting et al. 2008) and other lineages (Osafune, Caron et al. 2008). This finding was made 
possible by the categorically greater capacity of iPS vs. ES cells to sample and study individual 
genetic variation.   This capacity is a double edged sword however: because of the tremendously 
greater natural variation in human populations than in any model system for genetics we predict 
the issue of unexpected variation in differentiation phenotypes will arise repeatedly in years to 
come as more terminal cell types become the subject of directed differentiation studies using iPS 
cells.  This will need to be carefully controlled for in future studies as it could complicate or 
confound disease phenotypes.  On the other hand the abundance of human genetic variant alleles 
may provide a unique opportunity to study gene function in the mechanisms of differentiation in 
vitro (see Chapter 6). 
Because donor sex is part of donor genetic background it is possible that the sex-specific 
difference alone accounts for the difference between donor genetic backgrounds.  Because we 
did not have a balanced number of lines from each donor and across sexes, we could not perform 
a 2-factor ANOVA to directly test this possibility.  However, consistent with this possibility the 
lowest performing lines, from donor 11, were male, while the highest performing lines, from 
donors 18 and 29, were both female.  Based on the large variability between lines from different 
donors, and very small variability between lines from the same donor in our study, a new study 
with 3-4 lines/donor from a 5 male and female donors each could address this question.   
The variable phenotype (%ISL1
+
) which we describe was unlikely to be related to ALS.  
However, ALS is less common in females, therefore it is tempting to speculate that some sex-
linked genetic determinant may link depressed basal rate of in vitro motor neuron differentiation 
to ALS susceptibility.  More intriguingly our measurement of %ISL1
+




represent a motor neuron survival difference in response to some in vitro stressor (EB 
dissociation for example).  On the other hand the %ISL1
+
 phenotype may be completely 
unrelated to ALS, and the mechanisms and potential linkage of these phenomena were not within 
the scope of our study.   
There is also one technical caveat for the donor-genetic background result, which applies less 
strongly to the sex-difference result.  Because independent lines from the same donor were 
derived from the same specific culture well which subjected to repeated retroviral transductions, 
it is possible that these lines are derivatives of single transduction event.  In this case, the n for 
each donor would be reduced to 1, reducing the power of our statistical inference.  Although we 
could prove by Southern blot that lines were independent, we cannot experimentally prove or 
falsify a lineal relationship between these lines.  However future studies could eliminate this 
possibility simply picking independent clones from the same donor from physically or 
temporally separate reprogramming cultures. 
We chose an unbiased and functional—ability to make a defined cell type—approach to 
characterizing the utility of pluripotent cell lines.  Our collaborators used this same test set and a 
larger set of ES lines to generate an unbiased predictive scorecard, based on several short-term 
experimental differentiations, to evaluate pluripotent cell lines (Bock, Kiskinis et al. 2011).  Our 
empirical results correlated very well with the predictions of this scorecard for the lineage 
represented by our terminal phenotype (ectoderm/neuroectoderm) and were not correlated with 
other lineages tested.  This result confirms the accuracy and utility of their expression profiling 
approach.  Conversely, it validates our empirical approach as well, and suggests that for disease 
models where only one particular cell type is of primary interest immediate differentiation of 




more directly relevant index of the behavior individual lines which is faster, cheaper, and 
accessible to any lab.   
 
Conclusion and Perspectives 
In summary, our data provide new confidence in the ability of iPSCs to give rise to functional 
differentiated cell types of disease interest with the same efficiency and fidelity as ESCs.  Our 
study provides the first analysis of the rate and nature of the potential pitfalls of defective lines 
and practical recommendations for how to handle them.  We also demonstrate that human 
genetic variation may be an important and previously underappreciated factor to consider when 
constructing iPSC line sets, for interpreting iPSC or ESC phenotypes, and for studying gene 
function.  Together this work establishes a strong empirical foundation and guidelines for 
launching disease-phenotype directed studies of ALS and other genetic diseases using iPSCs. 
The outstanding question for the field is whether iPSC motor neurons will show ALS disease 
phenotypes in vitro.  This was not addressed by our studies and will not be addressed within the 
scope of this thesis.  However, in addition to looking for pan-motor neuron ALS phenotypes, a 
complementary approach is to use the differential response of specific motor column and motor 
pool subtypes to search for disease phenotypes or disease modifying mechanisms.  We showed 
that iPS-MNs, like ES-MNs have dominantly cervical to brachial rostrocaudal identities.  This 
regional identity includes brachial LMC motor neurons which are typically affected first in 
disease.  Studying LMC motor neurons derived from ALS-iPS cells may reveal distinct or 
accelerated disease phenotypes in vitro.  However, two of the most disease resistant motor 






 sacral Onuf‘s nucleus motor neurons—and these are unlikely to have been generated 
in significant numbers in our population.   It will thus be critical to ask if more caudal motor 
neuron subtypes can be generated from human ESCs and iPSCs.  The question of caudal 




Figure 4.1   
 
 
Figure 4.1.  iPS cells can be established from patient fibroblasts after biopsy  
(A) Primary dermal fibroblasts (hFib, human fibroblasts) derived from an 82-year old female 
ALS patient, A29. (B) iPS cells produced from patient A29. (C and D) SSEA-4 and NANOG 












Figure 4.2. Patient-specific iPS cells are pluripotent  
(A) Schematic illustrating the spontaneous differentiation of iPSC in embryoid bodies (EBs) and 
subsequent adherent culture.  iPSCs were used to seed EBs and grown in suspension for 7-10 
days before attachment to tissue culture plastic and analysis for the production of cell types 
representative of the three embryonic germ layers. (B) Attached EBs contained cells 
characteristic of each of the three germ layers: endoderm (AFP), mesoderm (Desmin, alpha-




















Figure 4.3. ALS iPSC lines can be differentiated to motor neurons  
 (A) Schematic of protocol used to direct the differentiation of patient-specific iPSC to motor 
neurons. EBs derived from iPS cell line A29a were grown for 10 days before treatment with 
retinoic acid (RA) and a small molecule sonic hedgehog (SHH) signaling agonist. After two 
weeks of continued suspension culture in the presence of these inductive molecules, EBs were 




 cells is 
confirmed by the coexpression of HB9 and ISL1 (ISL), scale bar 75 µm (C and D) Neuronal 
identity of HB9
+
 cells is confirmed by (C) high-magnification image of HB9 and TuJ1 
coexpression in dissociated patient-specific motor neuron cultures, Scale bar 100 µm, and (D) 
abundant HB9
+

















Figure 4.4. ALS iPSC lines generate cells with astrocyte-like phenotypes  
(A) Cells expressing the astrocyte marker GFAP show radial glial morphology after 3 weeks of 
culture, scale bar 100 µm (B-D) after 120 days of continuous culture most cells show astrocytic 
morphology and express combinations of GFAP, the immature astrocyte marker CD44, and the 
glial progenitor marker Vimentin, and are costained for DAPI. (B) 450 µm field width (C and D) 
















Table 4.1. iPSC and ESC lines used for comparative studies 
Sixteen human iPSC lines were used for comparison with each other and with six ESC lines.  
iPSC lines include 14 newly generated three-factor lines from two ALS patients and five 
controls, and two previous four-factor lines from one ALS patient.  This cohort of human stem 
cell lines allows comparisons to be made between ESCs and iPSCs, between three-factor and 
four-factor iPSC lines, between male and female lines, between lines derived from the same 
donor and those derived from another donor, and between cells derived from ALS patients and 
























Figure 4.5. All test set iPSC lines pass standard assays of pluripotency  
(A) iPSC colonies were morphologically identical to ESC colonies and (B) expressed the 
pluripotency markers NANOG and TRA-1-60, unlike the patient fibroblasts (FB). Scale bars, 
200 μm. (C) iPSC lines‘ cell cycle profiles are similar to those of ESCs and different from 
parental fibroblasts.  T-test, ***P < 0.001, mean ±SD. (D and E) ESCs and iPSC lines generated 
cell types of all 3 embryonic germ layers (endoderm, AFP; mesoderm, α-SMA; ectoderm, TUJ1) 
in vitro from EBs, scale bars 100 μm, and when injected into mouse kidney capsules and allowed 
to form teratomas in vivo (E; scale bars 50 μm).  Representative images of H&E-stained sections 
are shown for lines 11b and 27e. Glands and goblet cells (endoderm), cartilage and muscle 
(mesoderm), pigmented neural epithelium and neural rosettes (ectoderm) are shown in the top 






























Figure 4.6.  iPSC lines show characteristic motor neuron differentiation efficiencies, but no 
global difference from ESC lines 
 (A) Protocol for directed differentiation of human stem cell lines into motor neurons. Cells were 
differentiated to motor neurons as described previously.  EBs were dissociated and single cells 
plated for adherent culture on day 29. On day 32 cultures were analyzed. (B) Representative 
immunostaining results for iPSC (18c) and ESC (HuES-6) cultures show many ISL1+ TUJ1+ 
motor neurons (scale bars 50 μm). (C) The percentage of all nuclei that were ISL1+ was 
quantified from differentiations performed independently in the Eggan and PALS laboratories. 
Data sets from lines differentiated in both laboratories are highly similar and lines have 
reproducible, characteristic % ISL1+ efficiencies.  29e and 27e did not differentiate efficiently in 
either laboratory.  Hu-13, HuES-13, Hu-3, HuES-3. (D)  Percent ISL1+ data from both 
laboratories were pooled for each iPSC and ESC line, and comparisons between lines showed 
that individual lines had different efficiencies and iPSC lines 11a and 11c were significantly 
different than 18c (p < 0.05). (E) The efficiency of IPSC lines as a group was not significantly 















Table 4.2. Statistical analysis of categorical variables on %ISL1 differentiation efficiency 
ANOVAs on %ISL1+ values show no difference between performance in Eggan vs. PALS 
Laboratories, iPSC vs. ESC lines, 3-factor vs. 4-factor vs. 0-factor (ESC) reprogramming, ALS 
vs. control vs. ESC, or normal vs. abnormal karyotype.  Day 32 differentiations were stained, 
imaged, and quantitated for mean % ISL1+ cells ( of all DAPI+ cells) per image field per line, 
and then mean %ISL1+ was compared for n different lines per grouping variable. Mean ±SEM is 













 cells varies by cell line  
Day 32 differentiations were stained, imaged, and quantitated for mean % ISL1+ cells (of total 
DAPI+ cells) per image field per experiment, and then mean % ISL1+ was compared for n 
different experiments per line. Mean +/-SEM is shown for each line. ANOVA revealed that there 
were significant differences based on line, and post hoc pairwise comparisons showed that lines 

















Figure 4.7. iPSC motor neuron cultures show phenotypes consistent with motor neuron 
identity 
 (A) Efficiency of motor neuron differentiation was also measured by the motor neuron marker 
HB9. (B) The percent of HB9+ nuclei were compared for a subset of iPSC lines and HuES-13. 
Although comparisons again suggest donor- and line-specific differences, iPSC lines were 
overall equally capable of generating HB9+ motor neurons as HuES-13 (n experiments shown 
under bars for mean ±SD). (C) Many ISL+ motor neurons were also ChAT+, indicating proper 
maturation toward a cholinergic transmitter phenotype.  (D) ISL1+ motor neurons are not 
dividing since they did not stain for  Ki67, as expected of post-mitotic cells, while PAX6+  neural 
progenitor cells were Ki67+. (E) The expression of motor neuron markers ISL1, ChAT, TUJ1, 
HB9, CHT1, and the motor neuron progenitor gene OLIG2 were assessed by qPCR.  iPS/ES 
represents the average expression level in undifferentiated HuES-3 Hb9:GFP and iPSC line 18c. 
The relative expression of these genes in undifferentiated HuES-3 Hb9:GFP is set as 1. (mean 


















Figure 4.8. iPS- and ES-MNs exhibit the same coherent cervical HOX phenotypes 
(A) Day 32 cultures were triple stained for ISL1, HOXA5, and HOXC8.  (B) 41% of IPS- and 
42% of ES- ISL1+ cells expressed HOXA5 (green) and 12% and 13% expressed HOXC8 (red) 
respectively.  The number of HOXA5 HOXC8 coexpressing cells (yellow) was extremely low 
(<5% of all HOXA5 or HOXC8 expressing cells) for iPS- as well as ES-MN.  Left panel, mean 
of 4 experiments on n=1 (RUES1) ESC line, and mean ±SEM of n=7 individual iPS lines tested 
(18a, 18c, 11a, 11b, 11c, 15b, 29A).  Right panel, individual percentages for representative lines 

































Figure 4.9.  iPSC- and ESC-derived neurons are physiologically active  
(A) Fura Red channel image of  iPSC 11a–derived neurons filled with Fura Red AM and Fluo-4 
AM dyes, same field as in (B-G). Activity of labeled cells is represented in (H) and (I). Scale bar, 
100 μm. (B) immunostaining shows ISL1+ (star) and ISL– neurons (arrow). (C) Spontaneous 
electrical activity in cultured iPSC-derived neurons visualized by a ‗subtracted image‘ that shows 
the difference in pixel intensities between two images acquired 1.7 s apart in the Fluo-4 channel. 
Higher gray values represent increased pixel intensity. (D–G) Identically exposed pseudocolored 
averages of ten Fluo-4 AM images taken during the control period (D), after treatment with 100 
μM KA (E), after KA washout (F) and after treatment with 50 μM KCl (G). Warmer colors 
represent increased fluorescence intensity. (H-K) Plots of Fluo-4/Fura Red intensity ratios  in the 
somata of (H) example ISL1+ (*) and ISL1-(arrow) cells show spontaneous activity in the ISL1+ 
cell, (I) both cells are activated by KA and KCl, (J) examples of spontaneous activity in cultures 
of ESC RUES1–, and iPSC 11a–, 18a–, 18c– and 27b–derived neurons as well as one example of 
a nonresponsive (NR), non-active cell for RUES1, and (K) KA and KCl response of cells from 

















Figure 4.10. iPSC- and ESC-derived neurons show voltage gated sodium channels and fire 
action potentials 
 (A–D) Sample voltage-clamp traces from ESC (A) and iPSC 18a–derived (B) neurons. (C) 
Blowup of an iPSC 27b–derived neuron recording reveals typical sodium currents (left), which 
are blocked by TTX (right). (D) Current-clamp recordings of single action potentials in ESC and 





















Figure 4.11. Persistent transgene expression in some iPSC lines does not inhibit MN 
differentiation  
(A-C) qPCR measurement of relative levels of transcript from endogenous ‗e‘ (blue) and viral  
―v‖ (red) reprogramming  factors (A) SOX2, (B) KLF4, and (C) OCT4 in undifferentiated iPSCs 
(left) and ESCs, and in day 32 neuron cultures (right). The expressed/silenced status of transgene 
is constant before or after differentiation. Relative levels in undifferentiated HuES-3 were set as 
1. FB, fibroblasts. (D) Day 32 motor neuron cultures were co-stained for ISL1 and OCT4. HuES-
3– and iPSC 17a–derived cultures, which do not express viral OCT4, did not stain for OCT4. 
However, iPSC 15b–derived cultures, which do express viral OCT4, contained many OCT4+ 




























Table 4.4. Some iPSC lines show abnormal karyotypes  
A number of iPSC lines are summarized including the percentage of normal cells as well as 
abnormalities detected. Passage number (p) and lab that cells were grown is indicated for each 
report. Bold fonts indicate normal lines. We have previously reported iPS cell line 29A as having 
a normal karyotype (Dimos, Rodolpha et al. 2008). Abnormalities found in only one of twenty 
metaphase spreads (5% of cells) are considered ―non-clonal‖ variants and were assumed to be 
technical artifacts.  Lines with >75% normal karyotype were considered normal. Of lines able to 
generate ISL1+ neurons under standard differentiation protocol 69% (9/13) had normal 
karyotypes; of ISL1-incompetent lines 33% (1/3) had continuous normal karyotypes: 27e was 























Figure 4.12.   2 of 16 iPSC lines display a defective EB and total cell number phenotype 
during motor neuron differentiation  
(A) During standard motor neuron differentiation, iPSC lines 27e and 29e showed abnormal 
embryoid body morphology and dissociated cell survival phenotype compared to all other iPSC 
and ESC lines (HuES-3, 29d, 27e shown), phase scale bar 500 μm; DNA scale bar 129 μm. (B) 
Total cell output was quantified for each line at day 32 of differentiation by averaging the total 
number of DAPI
+
 nuclei per image field and taking the mean of n experiments for each line (see 
Table 4.5) ±SEM.  Kruskal-Wallis One Way ANOVA on Ranks  showed a significant difference 
between lines (p=0.027) and Dunn‘s post-hoc tests showed that both 27e and 29e were 





















Table 4.5. Statistical analysis of mean total cells numbers per line after dissociated cell 
seeding identifies 2 defective iPS lines 
Kruskal-Wallis One Way ANOVA on Ranks for total cell number shows that the 2 of 16 iPSC 
lines with abnormal EB phenotype have significantly different total cell numbers. Day 32 
differentiations were stained, imaged, and quantitated for mean cells (DAPI
+
) per image field, 
and then compared for n different experiments per line. Mean ±SEM is shown for each line. The 
ANOVA showed a significant effect of line identity. All significant post hoc pairwise 









Figure 4.13.   1 of 14 iPSC lines shows a neuronal defect after standard motor neuron 
differentiation 
 (A) During standard motor neuron differentiation, iPSC line 11b had typical EB morphology 
and normal total cell numbers, but showed drastically reduced neuronal TuJ1 staining compared 
to all other lines (iPSC 11b, HuES-13, and iPSC 18a shown), scale bar 129 μm. (B) The 
percentage of TuJ1
+
 cells was quantified for n experiments (see Table 4.6) and the mean %TuJ1 
of all cells ±SEM is shown.    One Way ANOVA showed line identity significantly affected 
%TuJ1 (p=0.012) and Holm Sidak post-hoc pairwise comparisons showed 11b was significantly 






















Table 4.6. ANOVA for %TuJ1 showed line 11b had a significantly different phenotype. 
Day 32 differentiations were stained, imaged, and quantitated for mean %TUJ1
+
 cells (of DAPI
+ 
cells) per image field. The mean of n different experiments per line ±SEM is shown. All 








Figure 4.14. Pharmacological neuralization completely rescues all three defective-
phenotype iPSC lines 
(A) Dual inhibition of TGF-beta type I signaling rescues the defective EB and total cell number 
phenotype of both affected iPSC lines (27e not shown and 29e shown) and also rescues the Tuj1 
phenotype for line 11b, HUES-3 HB9:GFP shown as ES control.  Phase scale bars 500 μm, 
immunostaining scale bars 100 μm.  (B-D) Quantification of immunostaining for defective lines 
(11b, 27e, 29e) and ESC controls shows complete rescue for: (B) %TUJ1
+
 of all cells; (C); 
%ISL1
+
 of all cells; and (D) %HB9
+

















Figure 4.15.  Sources of variability in motor neuron differentiation between iPSC lines 
  (A-E) The mean of all experiments per line were averaged and the mean of n lines per category 
±SEM is shown. There was no significant difference (A) between control (Ctrl) and ALS lines or 
(B) between 3- and 4-factor reprogrammed lines.  (C) iPSC lines and (D) all stem cell lines from 
male donors showed a significantly different %ISL1 efficiency from female, (*p<0.05).  (E) lines 
from individual donors showed characteristic efficiencies and ANOVA showed that donor 
identity had a significant effect on %ISL1 (**, p=0.003), however no pairwise post-hoc tests 























Table 4.7. ANOVAs on %ISL1 show significant effects of donor identity and sex 
Mean %ISL
+
 of all cells (DAPI
+
 nuclei) per image field were averaged for all experiments per 
line and then the mean ±SEM of n different lines per sex, and n different lines for each donor 
were compared.  ANOVA indicated a significant effect of donor sex and donor identity, but no 












Figure 4.16. Southern blots show multiple lines from the same donor are independent lines 
(A) 6.5 μg BglII digested genomic DNA was separated by electrophoresis on an agarose gel, (B) 
Southern Blot and hybridization with DIG-labeled probe for SOX2 cDNA transcript showed a 
conserved SOX2+ restriction fragment at ~3800bp in the control ESC line and all iPSC lines, as 
well as a unique pattern of bands for each iPSC line demonstrating unique transgene insertion 
sites and therefore unique line identities. (C) Hybridization with OCT4 cDNA probe showed 
endogenous bands at ~6000bp in ESC control and iPSC lines, as well as unique MW species 

















Figure 4.17. Empirical measures of cell-line-specific motor neuron efficiency correlate with 
lineage scorecard predictions for germ layer and neuronal differentiation proclivity. 
Correlation between the lineage scorecard estimates for the neural lineage and three germ layers 
versus the cell-line-specific efficiency of directed differentiation into motor neurons (rp, 
Pearson‘s correlation coefficient; rs, Spearman‘s correlation coefficient). Motor neuron 
efficiencies were measured by the percentage of ISL1
+
 cells at the end point of a 32 day neural 
differentiation protocol.  Further details including biological replicates and standard errors are 






Chapter 5.  Controlling the rostrocaudal subtype diversity of human stem cell-derived 
motor neurons.  
 
Introduction 
While spinal motor neurons selectively degenerate and die in ALS, their susceptibility is not 
uniform.   Distal muscle-innervating motor neurons of LMC subtype for example are more 
typically the site of onset than proximal thoracic muscle innervating HMC/MMC motor neurons 
(Ravits, Paul et al. 2007).  On the other hand sympathetic chain innervating PGC motor neurons 
may be relatively preserved, and eye and pelvic sphincter innervating motor neurons are almost 
completely spared—oculomotor and Onuf‘s nuclei motor pools (Kanning, Kaplan et al. 2010).  If 
motor neuron subtypes with strong differential responses to ALS could be generated in vitro, 
their comparison could sharpen the resolution of in vitro disease phenotypes or molecular 
changes and allow direct investigation of the mechanisms underlying those differences.  
However as we have shown in Chapters 3 and 4, ES- and iPS-MNs are predominantly cervical, 
and therefore are unlikely to contain a robust cohort of either thoracic PGC or lumbar Onuf‘s 
nuclei motor neurons.  As we have discussed (Chapter 1 Part I) early rostrocaudal patterning 
events control the diversification of motor neurons into these and other subtypes.  In order to 
contemplate generating these more caudal motor neuron subtypes we would have to generate 
motor neurons with more caudal identities.  We therefore asked how more caudal motor neurons 
are generated during development of vertebrate model organisms—chick and mouse—and then 
sought to recapitulate these events in vitro at a timecourse appropriate to human development. 
During early spinal cord development the morphogens Wnt and FGF and later FGF and RA are 




first phase—from the mid-primitive streak stage to the 4-somite stage—Wnt from the paraxial 
mesoderm and FGFs from the primitive streak activate CDX gene expression which encodes 
caudal neural character in prospective hindbrain and spinal cord progenitor cells (Fig. 5.1A) 
(Nordstrom, Maier et al. 2006).  
In the second  phase—from the 4-somite to the 16-somite stage—FGFs secreted from the 
regressing node expose progressively more caudal prospective spinal cord progenitors to higher 
concentrations of FGF for longer durations while RA synthesized by the somites formed lateral 
to the neural tube in the rostral wake of the node exposes more rostral spinal progenitors to 
higher levels of RA (Fig. 5.1C) (Liu, Laufer et al. 2001; Nordstrom, Maier et al. 2006).  Spinal 
progenitor cells exposed to RA, RA and FGF, or FGF alone assume positional identities from 
caudal hindbrain to lumbar spinal cord as marked by the combinatorial expression of HOXB and 
HOXC cluster genes (Bel-Vialar, Itasaki et al. 2002; Nordstrom, Maier et al. 2006).  These 
rostrocaudal domains, with the additional influence of node derived GDFs on the prospective 
lumbar region, give rise to the code of HOXC protein expression which determines motor 
column identities (Liu, Laufer et al. 2001).   
While these patterning morphogens and CDX and HOX caudal identity genes are not described in 
human, a recent study has identified neural marker genes whose temporal expression profiles 
bracket the cognate phases of human embryonic development: late primitive streak to 16 somite 
stage.  PAX6 shows a novel expression pattern in early primate and human embryos, compared 
to mouse and chick, appearing as a selective marker of early neuroectoderm by the neural plate 
stage, day 18 (Zhang, Huang et al. 2010) (Fig. 5.2).  By day 26—the 19 somite stage—PAX6 no 
longer serves as a pan-neural marker, but is restricted to its role as an effector of dorsoventral 




in human embryos.  The molecular profile of human spinal neuroectodermal cells in vivo during 
the patterning period we inferred is therefore bracketed at the onset by the initiation of PAX6 
expression and at the end by the pan neural expression of SOX1.  These markers might therefore 
be used to correlate the developmental status of in vitro cultures with in vivo development during 
the time period of caudal patterning. 
If an appropriate time window for inducing more caudal neural pattern can be defined in vitro, 
we could then test the combinations of Wnt, FGF and RA which the vertebrate model predicts 
should determine rostrocaudal identity.  We would use the RA-only condition, which we 
previously described in Chapter 3, as a rostral spinal control and starting point.  The predicted 
outcomes of more caudalizing FGF-containing conditions are motor neuron populations with 
reduced cervical HOXA5
+
-, increased caudal brachial and thoracic HOXC8
+
-, and increased 
thoracic and lumbar HOXD9
+
-motor neuron subtypes.   
 
Results 
Inferring a time window for caudal neural patterning in human 
The events leading to caudal neural patterning and the graded expression of HOX genes in post-
mitotic motor neurons occur in two embryonic phases in chick.  In the first phase (primitive 
streak to 4 -somites) Wnt and FGF demarcate the caudal neural plate (prospective hindbrain and 
spinal cord) from more rostral neural tissues.  While the expression and activity of Wnt and FGF 
are not described in the human system, the human embryo passes through nearly identical stages 




day 15, and 4 somite stage at day 18; we therefore inferred that Wnt and FGF may be acting in 
the human embryo during this time (Fig. 5.1B).   
In the second phase (4 to 16 somites) RA and FGF gradients lead to the differentiation of caudal 
neural tissues into caudal hindbrain, rostral and caudal spinal cord.  Again, these morphogens are 
not described in the human embryo, but the human embryo reaches 17 somites by day 22 (Fig. 
5.1D).  These comparisons predict that Wnt and FGF act from day 15-18 and that FGF and RA 
act from day 18 -21 of human development to generate spinal positional identities (Fig. 5.1D).  
In order to translate this inferred patterning period to our in vitro system we made two final 
assumptions.  First, we assumed that in vitro development would proceed at an in vivo rate.  
Second, since human ES cells are derived from day 5 blastocysts, we subtracted 5 days of 
development from the inferred period of human in vivo caudal neural patterning to project an in 
vitro timing window of day 10-17. 
Molecular markers of neural lineage induction correlate in vitro timing with in vivo 
To monitor the transition away from pluripotency we quantified expression of the core 
pluripotency gene OCT4 (Nichols, Zevnik et al. 1998).  OCT4 mRNA levels were 95% of day 0 
(maximum) at day 6,  but reduced to 10% of maximal expression at day 10 and completely 
extinguished by day 17; this was confirmed at the protein level by immunostaining (Fig. 5.3A, 
B).  In order to confirm our assumption that the time course of neural differentiation in vitro 
would parallel that observed in vivo, and thereby validate the choice of days 10-17 for caudal 
patterning, we tested the expression of two key markers of neural identity, PAX6 and SOX1, 
whose expression profile in vivo (Zhang, Huang et al. 2010) (Fig 5.2) marks the same period we 




maximum) whereas SOX1 expression at the same stage was only 4% above baseline.  Both 
proteins however could be detected at low frequency in some EBs (Fig. 5.3B).  By day 17 
however, both PAX6 and SOX1 had reached peak expression levels.  Subsequently SOX1 
expression decreased slightly (to 80% of maximum), while PAX6 decreased substantially (to 
22% of maximum).    The decline of PAX6 after day 17 fits with its later in vivo function in 
dorsoventral patterning in vertebrates, since the increased concentration of SHH protein at day 
17 should ventralize cultures and inhibit PAX6 expression. We concluded from these data that in 
vitro differentiation matched the time course of in vivo development since days 10-17 in vitro 
showed a similar molecular profile to that observed over the corresponding period (day 15-26) in 
vivo.  Having inferred a patterning window in vivo, and then correlated in vitro marker 
expression with in vivo markers, we designed an experiment to test the effect of the relevant in 
vivo morphogens during this in vitro time window. 
Rostrocaudal patterning with Wnt, FGF, and RA 
The model of vertebrate rostrocaudal positional patterning reviewed above suggests that Wnt and 
FGF first define caudal neural identity, and then combinations of FGF and RA subdivide the 
hindbrain and spinal cord into hindbrain, rostral spinal cord, and caudal spinal cord.  Although 
node-derived GDFs are required for lumbosacral HOXC10 expression in chick (Liu, Laufer et al. 
2001), for simplicity we chose to focus on the initial two periods when caudal identities are 
determined and refined by Wnt, FGF and RA (Nordstrom, Maier et al. 2006) and to collapse 
these two patterning periods together.  We predicted that Wnt+RA, Wnt+RA+FGF, or Wnt+FGF 
if applied during the appropriate time window, would  generate progressively more caudal sets of 
spinal motor neurons, as they had been shown to do in chick explants (Nordstrom, Maier et al. 




window we identified (Fig 5.4).  The endpoint of this analysis was the HOX profile of post-
mitotic motor neurons.   
FGF treatment induces a caudal shift in HOX gene expression 
We first asked if FGF treatment induced a caudal shift in the expression of HOX genes in the 
whole culture (Fig. 5.5).  qPCR analysis of HOX gene mRNA expression showed that when FGF 
was added to RA there was a small decrease in HOXA5 (0.8 fold RA) and an increase in all 
caudal HOX genes tested (HOXC6, 4 fold; HOXC8, 17 fold; HOXD9, 4 fold; and HOXC10, 2 
fold), although this difference only reached significance for HOXC6 (t-test p=0.02) (Fig. 5.5A).   
When FGF was used in the absence of RA we observed a significant decrease in HOXA5 levels 
as compared to RA alone (0.2 fold), a significant decrease in HOXC6 and a large decrease in 
HOXC8, when compared to RA+FGF , suggesting a shift away from cervical through rostral 
thoracic spinal identities.  FGF alone compared to RA+FGF also showed unchanged HOXD9 
and increased HOXC10 suggesting stable caudal thoracic and increased lumbar gene expression.  
We concluded from these data that FGF, when added to RA, generated a more caudal positional 
profile of HOX gene expression, as shown by decreased HOXA5, and increases in all caudal 
HOX genes.  Notably the largest increases were in HOXC6 and HOXC8 which suggested 
brachial to mid-thoracic positional identities, although the increase in HOXD9 and HOXC10 was 
consistent with some mid-thoracic to lumbar gene expression as well.  We also concluded that 
FGF alone induced an even more caudal profile of HOX gene expression, based on the 
significant decrease in HOXA5 from RA and the trend decrease compared RA+FGF, the 
decreases in HOXC6 and HOXC8 compared to RA+FGF, the increase in HOXD9 compared to 




We then asked whether HOX proteins were affected by FGF treatment by staining cells for 
HOXA5, HOXC8, and HOXD9 (Fig. 5.5B, C).  We observed a trend decrease in the percent of 
total cells staining for HOXA5 when RA was compared to RA+FGF (11% vs. 5% respectively), 
a trend increase in HOXC8 (1% vs. 7% respectively), and a significant increase in HOXD9 (2% 
vs. 8% respectively, p<0.05).  FGF alone induced significantly fewer HOXA5
+
 cells compared to 
RA (2% vs. 11% respectively, p<0.05), and fewer than RA+FGF.  FGF alone also induced more 
HOXC8
+
 (3%) and HOXD9
+
 (3%) cells.  This was elevated as compared to RA alone but less 
than with the combination of RA+FGF, significantly so in the case of HOXD9 (p<0.05).  We 
concluded from these data that HOX protein expression showed a clear caudal shift in positional 
identity when FGF was added to RA.  When FGF was used alone we saw a stronger and 
significant decrease in HOXA5
+





 cells could supports the idea that FGF alone generated even more caudal 
positional identities than RA+FGF, but could also mean that cultures were less spinal in identity.   
FGF leads to a reduction in the number of neurons and motor neurons 
To determine whether FGF treatment affected the efficiency of neuronal or motor neuronal 
differentiation we stained cultures for the neuronal marker TuJ1, and the motor neuron markers 
HB9 and ISL1 (Fig. 5.6A,B,C).  The percent of total cells positive for TuJ1 was slightly but 
significantly decreased when RA was compared to RA+FGF (65% vs. 56%, p<0.05), and was 
further decreased when FGF was used without RA (53%, p<0.05 vs. RA).  We concluded from 
these data that FGF significantly decreased the percentage of differentiated neurons present in 
culture, although the magnitude of this change was relatively small (-9% for RA FGF vs. RA and 




the result of increases in the numbers of undifferentiated neural progenitor cells or the 
preferential specification of non-neuronal cell types.  
Because FGF reduced the percentage of differentiated neurons, we next wanted to determine 
whether the efficiency of motor neuron induction was decreased and if the pattern of motor 
neuron marker expression was changed.  It was also important to establish that the motor neuron 
markers HB9 and ISL1 were still expressed exclusively by neurons and not by non-neural cells 
which also express these markers in vivo.  We therefore stained cultures for HB9, ISL1, and 




 cells co-expressed TuJ1, and there was no 





 cells were neurons under all conditions tested.  The percent of cells expressing 
HB9 however was significantly decreased under RA+FGF conditions vs. RA (8% vs. 13% 
respectively, p<0.05), and was significantly decreased with FGF-only compared to RA+FGF or 
RA (4%, p<0.05)  (Fig. 5.7C).  The percent of ISL1
+
 cells was also significantly decreased with 
FGF-only (5%, p<0.05) compared to either RA (11%) or RA+FGF (9%)   (Fig 5.6C).  The 
degree of HB9 and ISL1 coexpression however, was not significantly changed by either 
treatment (Fig. 5.6C).  We concluded from these data that FGF treatment reduced the efficiency 





generated in these conditions remained predominantly neuronal and their pattern of ISL1/HB9 
co-expression continued to match that described in vivo.  We could therefore use these motor 






FGF induced caudal motor neuron subtypes at the expense of rostral 
To determine whether FGF affected the positional identity of motor neurons specifically we 
costained cultures for HB9 or ISL1, and HOXA5, HOXC8, or HOXD9 (Fig. 5.7A).  The percent 
of HB9
+
 cells expressing HOXA5 was significantly decreased from RA (34%) under both 
RA+FGF (18%, p<0.05) and FGF-only (9%, p<0.05) conditions.  The percent of HB9
+
 cells 
expressing HOXC8 or HOXD9 was also increased from RA (13% HOXC8, 7% HOXD9) under 
RA+FGF treatment (34% HOXC8, 24% HOXD9) but this difference was only significant for 
HOXD9 (p<0.05).  When FGF alone was used, the fraction of HOXC8 (37%) and HOXD9 
(29%) of HB9
+
 cells was further increased and significantly different from RA alone (p<0.05) 
(Fig. 5.7B).  When the shift in HOX expression was gated for ISL1
+
 cells, the results were 
virtually identical (not shown).  We concluded from these data that FGF induced a caudal shift in 
ES-MN positional identity.  When FGF was used in the absence of RA, the trend toward even 
lower HOXA5, and higher HOXC8 and HOXD9, compared to RA+FGF suggested an even more 
caudal positional identity.  
ES-MN HOX protein expression is mutually exclusive even in more caudal populations 
Because we now observed substantial numbers of motor neurons expressing more caudal HOX 
proteins we asked whether caudalized ES-MNs would adopt coherent positional identities 
characterized by mutually exclusive HOX protein expression as reported in vivo (Chapter 1) and 
for predominantly rostral ES- and iPS-MNs (Chapter 2 and Chapter 3).  Because of the strongly 
reduced total motor neuron numbers in the FGF-only condition, and the clearly caudalized 
identities observed in the RA+FGF condition, we restricted these analyses to the RA and 




HOXC8 or HOXA5 and HOXD9 (Fig. 5.8A, B) we found that under rostral or caudal conditions 
fewer than 5% of HB9
+
 cells expressing either HOX protein coexpressed the other (Fig. 5.8C, 
D).  We concluded from these data that ES-MNs were successfully able to interpret competing 
patterning cues, RA and FGF, and resolve coherent, mutually-exclusive HOX identities.  We 
next wanted to ask if the caudal shift in rostrocaudal identity coincided with any change in the 
distribution of columnar subtypes. 
Caudalization does not change motor column subtype distribution 
In order to determine whether the caudal shift in HOX expression would lead to a shift in motor 
column identity, we stained caudalized and control (RA) cultures for markers of LMC (FOXP1) 
and MMC (LHX3) identities (Fig. 5.9A).  We found that the percentage expression profile of 
LHX3 and FOXP1 for HB9
+
 motor neurons was not significantly different in caudal cultures 







 motor column subtypes, because each of these HOX genes is expressed 
by motor neurons in nearly equal proportions of limb and non-limb innervating spinal regions in 
vivo and therefore includes, MMC, HMC, PGC, and LMC columnar subtypes in relatively equal 
proportions.  Therefore taking away motor neurons positive for any one of these HOX genes, and 
adding any another would not be predicted to substantially change the motor column profile.   
HOX and column marker staining more precisely classifies potential subtype identities 
To more precisely classify in vitro-generated ES-MNs using in vivo expression patterns, we 
stained control and caudalized cultures for HB9 or ISL1, a positional marker (HOXA5, HOXC8, 
or HOXD9), and the LMC column marker FOXP1, the marker for LMC/PGC motor column 








these in vitro combinatorial expression patterns were matched to in vivo correlates (Fig. 5.10B) 
the range matched all motor neuron staining profiles found in the spinal cord between cervical 
and mid lumbar levels in vivo (Fig. 5.10C).  Because each marker combination we measured was 
consistent with more than one in vivo motor neuron subtype, in vitro staining combinations 
yielded several potential identities.   We therefore list the possible in vivo identities based on our 
evidence.  We concluded however that the rostrocaudal and columnar range of potential subtypes 
included several with differential responses to ALS in vivo: LMC vs. thoracic HMC/MMC, and 
thoracic PGC. 
 
Testing caudal patterning on accelerated protocol differentiations and iPS cells 
In order to search for motor neuron-intrinsic subtype-selective ALS phenotypes, these specific 
subtypes must be differentiated from stem cells with ALS genotypes.  We showed in Chapter 3 
that iPS cells generate the same range of predominantly cervical motor neuron subtypes in vitro.  
In order to study ALS-refractory thoracic or lumbar subtypes, iPS cells must be competent to 
generate these more caudal subtypes as well.  We therefore next tested whether iPS cells would 
respond similarly to the rational approach for generating caudal motor neurons we developed 
using ES cells.   
As discussed in Chapter 2, recent developments in pharmacological control of neural induction 
led us to establish an Accelerated Protocol (Fig. 3.4A) which more than doubled motor neuron 
differentiation efficiency.  This technical development may prove to be a superior strategy for 
generating motor neurons for disease studies and may be useful for studies of development as 




especially temporal, we wanted to ask how amenable it would be to our developmentally based 
patterning approach.   
Accelerated cultures show early expression of neuroectodermal markers 
To target a developmental time window in accelerated cultures that was similar to that used for 
Standard Protocol patterning experiments above, we reasoned that the same early neural lineage 
markers, PAX6 and SOX1 could again be used to define an appropriate patterning window.  
Colleagues in the lab (Mackenzie Amoroso, Andrew Brunswick, Laurent Roybon, unpublished) 
found that by day 10 accelerated cultures showed the same widespread expression of PAX6 and 
SOX1 observed at day 17 under Standard Protocol conditions (not shown) indicating an 
acceleration of at least 7 days.  These result corroborated previously published findings showing 
that neural induction may be largely complete by day 5 under similar conditions (Chambers, 
Fasano et al. 2009), which suggested an acceleration of at least 5 days.  Finally we had observed 
that the onset of HB9-driven GFP expression was accelerated by 10 days (Chapter 2).  This 
suggested that the only acceleration was in the early phase of neural induction and that 
subsequent development proceeded in parallel with Standard Protocol differentiations.  We 
therefore shifted the patterning window for Wnt3a and FGF exposure backwards to day 5-12. 
Accelerated Protocol cultures generate comparable motor neuron populations  
We first wanted to test whether FGF-treated accelerated differentiations would generate a 
comparable spectrum of motor neurons.  Both iPSC lines and ESC control generated abundant 
HB9
+
 and or ISL1
+
 neurons with RA, and slightly fewer motor neurons with FGF treatment 




 of total cells under 




pattern of HB9 and ISL1 overlap was very similar between iPS lines and RUES1 control, 
although it appeared there was more overlap and fewer HB9
HIGH
-only cells compared to 
Standard Protocol conditions (Fig. 5.11B).  We concluded that using the Accelerated Protocol 
with iPS and ES cells generated motor neurons with similar profiles of pan-motor neuron marker 
expression and at similar efficiencies. 
iPS-MNs respond to caudal patterning similarly to ES-MNs 
We next asked if iPS cells would be competent to respond to FGF and generate caudal motor 
neurons.  When we stained iPS- and ES-MNs for HOXA5 and HOXC8, we observed that for 
iPSC as well as ESC lines, only under caudalizing conditions were many HB9
+
 cells stained with 
HOXC8 (Fig. 5.11C).  Both iPS lines showed a decrease in the percent of HOXA5
+
 motor 
neurons, and an increase in the percent of HOXC8
+
 motor neurons, similar to the RUES1 control 
(Fig. 5.11D).  We concluded from these data that differentiating iPS cells responded to 
developmental mechanisms to generate more caudal motor neuron subtypes in a fashion 
comparable to ES cells.  We also concluded that the Accelerated Protocol, and accelerated 




FGF induces more caudal motor neuron subtypes 
Vertebrate embryos use rostrocaudal patterning as a means to specify a diversity of motor 




This model of development predicts that controlling rostrocaudal identity is necessary and 
sufficient to generate specific functional motor neuron subtypes at the level of both motor 
column and pool.  In accord with the predictions of this model, we found that FGF, when added 
to RA, or used alone, generated a group of motor neurons with significantly more caudal 
positional identities.  This shows that human spinal neuroepithelial cells can operate by the 
developmental rules defined in model systems.  This finding also supports, though cannot not 
directly test, the idea that human motor neuron diversification in vivo is enacted by the same 
mechanisms as model vertebrates.  Importantly these findings act as a proof of principle that 
complex developmental events defined in model systems can be translated to rational approaches 
for engineering the differentiation of highly specific cellular subtype of intellectual and disease 
relevance from human ES and iPS cells. 
 The profile of motor neurons was most rostral with RA alone, was caudalized by FGF addition 
in the presence of RA, and was the most caudal with FGF in the absence of RA.  Generating 
specific cell types from stem cells is crucial to their use for studies of development and cellular 
function in health and disease.  Therefore our results have broad implications for 
developmentally-based approaches to generating specific and hitherto unavailable cell types 
from human stem cells.  Most specifically our findings render rostral and caudal motor neuron 
subtypes available for functional and disease-related studies.   
A broad diversity of coherent subtypes generated across conditions 
When we used the three HOX genes and two positive markers of motor column identity for 
which we had previously defined in vivo expression patterns we could assign a set of potential 




potential identities spanned each motor column residing in spinal regions from cervical to mid-
lumbar human spinal cord.  However, because the HOX proteins we tested each span limb and 
non-limb-innervating territories, because FOXP1 is expressed by both LMC and PGC cells, and 
because we could not identify a human-reactive antibody for the HMC marker ER81, most of the 
transcription factor expression combinations we identified could potentially be assigned to 
several potential identities.  Resolving these ambiguities is a major unsolved task looking 
forward since motor column-specific disease phenotypes can only be studied if motor column 
identities can be definitively monitored.  
In cases where it was possible to test, we found a striking coherence of cellular identities at the 
level of transcription factor expression.  For example, the mutual exclusion of HOXA5 and 
HOXC8 or HOXD9 matches the pattern found in vivo.  Importantly under caudalizing conditions 
when a large percent of motor neurons expressed HOXC8 or HOXD9, these proteins were still 
expressed exclusively.  This result shows that even in the context of competing positional 
information, differentiating ES cells are able to interpret these cues to resolve coherent identities.  
Furthermore, since the elaboration of motor pool subtype identity at the forelimb level depends 
on cross repressive interactions between many HOX genes, including HOXA5-HOXC8 pair, our 
results suggest that ES- and iPS-derived motor neurons manifest an intact network of functional 
HOX responses which is required for coherent motor pool identities. 
The interpretation of ES-MN identity based on column marker expression was less clear cut.  
The majority of motor neurons in vivo expressed the motor column markers LHX3 (MMC) and 
FOXP1 (LMC/PGC) mutually exclusively (Chapter 2).  This was the case for most in vitro ES-
MNs as well (Chapter 3).  However a subset of cells inappropriately coexpressed these markers.  




cells match the novel brachial LMC putative motor pool identified in human fetuses in vivo.  
Alternatively, as seen in mouse ES-MN differentiation LHX3 expressed inappropriately 
according to mouse in vivo expectations, i.e., appears it is coexpressed by some FOXP1
+
 motor 
neurons ((Peljto, Dasen et al. 2010) and Mackenzie Amoroso unpublished observations).  This 
expression pattern may therefore be an in vitro artifact which could be interpreted as cells with 
confused molecular identities.  The shift to dominant FOXP1 expression in matured cultures and 
loss of LHX3 expression, which we describe in Chapter 3, supports the interpretation that this 
cellular confusion is transient, and resolves in favor of clean LMC identities however.  In either 
case this is small subset of cells, but future studies are needed to address its significance.   
iPS cells are similarly responsive to caudal patterning 
Finally we found that iPS cells showed the same response to caudal patterning as ES cells.  
Importantly, this result shows that human iPS cells regain the ability to execute specific 
developmental pathways when they are reprogrammed.  This result is also critical for the larger 
goal of these studies: to generate ALS motor neuron subtypes in vitro which show differential 
disease responses in vivo.  Identifying motor neurons which show unambiguous expression of 
thoracic and rostral lumbar HOX markers puts several of these subtypes in reach.  The full 
rostrocaudal diversity of brachial LMC subtypes is likely represented by these cultures which 
will allow investigation of the mechanisms of heightened sensitivity of distal, limb projecting 
motor neurons to degeneration in comparison with proximal projecting motor neurons.  Thoracic 
motor neurons (HOXC8 or HOXD9) that express no or low-level FOXP1 are consistent with 
either HMC/MMC or PGC identities respectively, and represent disease-delayed and disease-
resistant populations.  It will therefore be of great interest to determine if these motor neuron 




Conclusions and Perspectives 
Motor neuron functional and subtype-specific ALS phenotypes 
As discussed above, the assignment of subtype identity based on combinatorial expression of the 
markers we validated in vivo lead to a set of several possible in vivo cognate identities for each 
combination.  Disambiguation could be achieved in the future by several means.  First, reagents 
to monitor expression of purely thoracic (HOXC9) or purely limb-level (HOXC6: brachial and 
HOXC10: lumbar) motor neurons would help to eliminate or support specific identities for in 
vitro cells.  Since these genes also play functional roles in limiting and enabling position-specific 
columnar identities it is critical that their expression patterns be defined in human in vivo and in 
vitro.  Their functional roles in determining motor column identity also make them crucial 
candidates to test using gain and loss of function strategies in vitro with motor column identity as 
the endpoint.  Additional markers of subtype identity like RALDH2 (LMC), ER81 (HMC), and 
nNOS and pSMAD (PGC) would greatly add to the certainty of specific assignments.  
Furthermore, markers for individual motor pools are needed to investigate the biology of these 
specific subtypes. 
The ultimate proof of identity however, no matter how precise the assemblage of correctly 
overlapping markers, will be to define functional phenotypes which are specific to motor 
columns and pools.  These phenotypes could consist of column or pool-specific behavior in 
xenotransplantation assays (motor column settling position and axonal pathfinding) or in vitro 
assays which mimic aspects of these or other phenotypes defined in vivo.  In addition, motor 
pools which show defined gene expression and functional responses to exogenous target derived 




GDNF in CM/LD and followed by cell body settling position and endplate arborization for 
CM/LD motor neurons) will be attractive targets to test the functionality of human stem cell-
derived motor neurons. 
Establishing bona fide functional motor column and motor pool identities, and reliable markers 
and functional assays for ES-derived motor neurons are important goals to study the specific 
biology of these cell types in human development.  However these are equally important from a 
translational perspective.  ES- or iPS-MN subtypes must be identifiable and should reproduce 
functional phenotypes in order to increase their relevance to in vivo subtypes and therefore 
increase the chances of success in searching for differential disease phenotypes.  This imperative 
is relevant at the level of both motor column and motor pool.  LMC neurons are typically 
affected first in clinical presentation, whereas thoracic columns are less quickly affected and 
PGC motor neurons may show some resistance.  Oculomotor and Onuf‘s nucleus motor neurons 
show strong resilience even at end stages of disease both clinically and in animal models.  Future 
work to establish unambiguous and functional columnar identities, as well as to generate specific 
affected and resistant motor pools would allow direct investigation of the pathways contributing 

















Figure 5.1. Comparison of chick and human embryos during the period of caudal neural 
patterning 
(A) In the model of caudal neural patterning defined in chick Wnt and FGF activity from the 
paraxial mesoderm and primitive streak are required from primitive streak to the 4 somite stage, 
HH stages shown.  (B) Human embryos at matched developmental stages, Carnegie stages 
shown, in vivo developmental day, and assumed in vitro cognate (in vivo -5 days) shown.  (C)  
RA and FGF secreted from somites and the node between 4 somite and 16 somite stages refine 
and subdivide caudal neural identity, chick HH stage 12 shown.  (D) Human matched equivalent 
is ~CS 10.5 (CS 11 shown) and in vivo and in vitro days of human development.  Model and 
cartoon adapted from Nordstrom, Maier et al. 2006; and Liu, Laufer et al. 2001; chick embryo 
pictures from Hamburger and Hamilton 1956; human embryo pictures from UNSW embryology 




















Figure 5.2. Transition to PAX6 marks the beginning and SOX1 the end of inferred 
patterning window 
PAX6 expression is initiated at low levels in human embryos in the neuroectoderm during late 
primitive streak stage (embryonic day 15), is upregulated as the first selective marker of neural 
plate by day 21, and subsequently serves as a restricted marker of dorsoventral positional identity 
as it does in mouse and chick.  SOX1 is expressed in all neuroectodermal cells of the neural tube 
by embryonic day 26.  Embryonic day -5 = assumed in vitro ES cell day of development are 
shown.  Human protein expression data from Zhang, Huang et al. 2010; human embryo pictures 

















Figure 5.3. In vivo markers of human neural plate to neural tube stages define cognate 
developmental stages in vitro 
(A) qPCR for pluripotency gene OCT4 and neuroectodermal markers PAX6 and SOX1 shows 
neural induction initiated around by day 10, and consolidated by day 17.  Mean ±SEM of n=4 
experiments. (B) Immunostaining of representative cryosections of EBs for OCT4, PAX6, and 
SOX1 confirms qPCR data showing transition to definitive neuroectoderm by day 17 in vitro, 



















Figure 5.4. Design of caudal patterning ES-MN differentiation experiment 
 Motor neuron differentiations were conducted as described previously (Chapter 3 Fig3.1).  The 
in vivo caudal morphogen FGF-4 (100ng/ml) was used alone or in combination with RA during 
the putative patterning window, in vitro day 10-17.  As described previously, all EBs were 
dissociated to single cells at day 31, analyzed for HOX gene mRNA expression, and seeded at a 
fixed density for fixation and immunostaining for HOX markers of positional identity.  Our 
hypothesis was that combinations of RA and FGF-4 would generate progressively more caudal 













Figure 5.5. FGF induces a caudal shift in HOX expression 
 (A) qPCR for HOXA5, HOXC6, HOXC8, HOXD9, and HOXC10 shows a caudal shift in HOX 
gene expression when FGF-4 is added to RA. Mean ±SEM from n experiments (HOXA5, 
HOXC6, and HOXD9: RA n=5; RA+FGF and FGF n=4; HOXC8: n=3; HOXC10: RA n=5; 
RA+FGF n=4; FGF n=1.  HOX gene expression was normalized to GAPDH and expressed as 
fold change from RA control. All significant comparisons from paired 2-tailed t-tests are 
indicated, * p<0.05.  (B) Immunostaining for HOXA5, HOXC8, and HOXD9 proteins confirmed 
a caudal shift in HOX protein expression with FGF. (C) % of total cells expressing HOX 
proteins, mean ±SEM, n=4 experiments. One Way Repeated Measures ANOVA indicated that 
treatments affected HOXA5, HOXC8, and HOXD9 (p= 0.010, 0.042, 0.021 respectively).           





















Figure 5.6. FGF treatment reduces the percent of neurons and motor neurons, without 
affecting their phenotype and MN-marker profile  
(A) Immunostaining of representative fields for TuJ1 and HB9 (left columns), or HB9, ISL1, and 
TuJ1 (right columns). (B) % Tuj1
+
 of total cells (black bars) and % of HB9
+
 cells expressing 
TuJ1 (grey bars), mean ±SEM of n=4 experiments. Significant differences (p<0.05) in paired 
two-tailed t-test, * = RA vs. RA+FGF, and RA vs. FGF.   There were no significant differences 
between %Tuj1 of HB9.  (C) % of total cells expressing only high level HB9 (green), only high 
level ISL1 (red), or both (yellow), mean ±SEM, n=5 experiments. Significant differences 
(p<0.05) in paired two-tailed t-test for ISL1 (black bars at left) or HB9 (black bars at right), * = 













Figure 5.7. FGF induces caudal motor neuron subtypes at the expense of rostral 
(A) Immunostaining for HB9 and HOXA5, HOXC8, or HOXD9 proteins shows a caudal shift in 
motor neuron HOX-subtype with FGF treatments. (B) % of all HB9+ cells coexpressing 
HOXA5, HOXC8, or HOXD9, mean ±SEM, n=5 experiments.  Repeated Measures ANOVA 
showed significant differences between treatments for HOXA5 (p= 0.008), HOXC8 (p= 0.026), 
HOXD9 (p= 0.012).  All pairwise Holm-Sidak post-hoc tests showing significant (p< 0.05) 























Figure 5.8. HOX protein expression is mutually exclusive in caudalized ES-MNs.  
(A, C) Triple immunocytochemistry for HOXA5 (green) and HOXC8 (red, A) or HOXD9 (red, 
C) and HB9 (not shown) shows these HOX pairs are mutually exclusive. (B, D)  Quantitation of 
HOX expression by HB9
+
 MNs shows most ES-MNs expressed HOXA5 (green) and HOXC8 
(red) or HOXD (blue)  mutually exclusively, with less than 5 % of all MNs (yellow (B) or aqua 















Figure 5.9. Motor column diversity preserved in caudal ES-MNs   
(A) immunostaining for HB9 (green) and LHX3 (left, red) or FOXP1(right, red) (B) When HB9 
LHX3 and FOXP1 were stained simultaneously, the %of all HB9+ cells expressing all 
combinations of markers and their putative columnar identities could be assessed: LHX3 
alone(red: MMC), FOXP1 alone (green: LMC), both LHX3 and FOXP1 (yellow: novel brachial 
LMC pool?) or neither (white: HMC).  There was no significant difference between control (RA) 
and caudalizing (RA+FGF) conditions for any scoring category (paired 2-tailed t-tests p>0.05) 






























Figure 5.10. HOX proteins and column markers jointly classify more precise ES-MN 
subtypes 
(A) RA and RA+FGF treated differentiations were stained with FOXP1 and either HB9 or ISL 
and either HOXA5, HOXC8, or HOXD9.  Mean of n=4 experiments ±SEM are shown for cells 
expressing marker combinations.  Black bars show FOXP1- staining combinations, white bars 
show FOXP1 positive expression profiles (B) The set of in vivo human MNs (Chapter 2) which 
matches each of the expression profiles graphed at left. (C) Summary diagram of potential 
































Figure 5.11. FGF induces more caudal motor neuron subtypes from iPS and ES cells   
(A) iPS cells stain for motor neuron markers HB9 and ISL1 after Accelerated differentiation with 
rostral or caudal patterning treatment. Scale bar 10 um (B) iPS and ES cells generate similar 
distribution of HB9 and ISL1-expressing MNs under Ra or RA+FGF conditions, mean +/-SEM, 
n=3 experiments  (C)  FGF treatment induces HOXC8+ MNs (HB9+ neurons) from iPS lines, 
scale bar 10 um.  (D) FGF treatment (grey box label below) decreased rostral ( %HOXA5+ 
(white bars)) and increased caudal (%HOXC8+ (black bars))  MNs derived from both ES 









Chapter 6.  General Discussion: Conclusion and Perspectives 
 
ALS is an intractable and fatal neurodegenerative disease with poorly understood causes and 
mechanisms resulting in cell loss.  Principal and most obvious among the human cell types lost 
are the spinal motor neurons which directly innervate muscles, however this human cell type has 
been historically unavailable for direct study.  This has changed since human ES and iPS cells 
have been differentiated to motor neurons.  Recently, attention has become more focused on the 
diversity of responses to ALS among motor neuron subtypes.  Motor neuron subtypes 
innervating specific categories of muscles (motor columns), muscle fiber-types (fast vs. slow), 
and specific individual muscles (eye and pelvic sphincters) show differential vulnerability or 
resistance to degeneration in ALS (Kanning, Kaplan et al. 2010).  It was the aim of this thesis to 
set the stage for modeling ALS in vitro using specific motor neuron subtypes differentiated from 
ALS-patient iPS cells.   
To study human motor neuron subtypes we first needed to translate the rich understanding of 
chick and mouse motor neuron diversity into the human system.  To this end we characterized 
the subtype diversity of human embryonic motor neurons in vivo at the molecular level.  These 
studies defined a set of antibodies that label human spinal motor neurons and their subtypes, and 
established that human motor neuron subtype diversity and organization are overwhelmingly 
similar to vertebrate models.  Practically, they also provide validated tools to identify human 
motor neuron subtypes in vitro.  The similarity of human motor neuron diversity to chick and 
mouse at the molecular level also provides confidence that in vitro directed differentiation 
strategies based on developmental mechanisms in chick and mouse may be highly applicable to 




In order to quantitatively characterize motor neuron subtypes and generate cell preparations 
compatible with high throughput studies of ALS in vitro, we developed robust protocols for the 
differentiation of motor neurons from human ES and iPS cells.  We then used the in vivo 
categories we defined to systematically categorize the diversity of motor neuron subtypes 
generated in vitro from human stem cells for the first time.  First, we showed that the traditional 
in vitro perspective that motor neurons are defined by coexpression of HB9 and ISL1 is 
inadequate to describe the diversity of motor neurons present in vivo or in vitro, and provided a 
detailed profile of their combinatorial expression.  Then we showed that ES and iPS derived 
motor neurons are predominantly cervical and brachial but contain cells matching all motor 
column subtypes.    Because of the broad diversity of motor neuron subtypes in vivo, and their 
differential responses to ALS, it is critical to be able to account for the diversity of stem cell 
derived motor neuron subtypes that would potentially be used for disease modeling and drug 
screening. 
In order to make more relevant models of ALS in vitro we anticipated the need to generate 
mature motor neurons which better match the cells affected in vivo.  We therefore developed 
assays to characterize the rapid morphological and electrophysiological maturation of ES-MNs.  
We showed that ES-MNs rapidly acquired large size and mature morphologies, and that this was 
accompanied by a functional maturation of electrophysiological activity.  Since both cellular size 
and electrical activity are implicated in ALS pathology, defining them in vitro should improve 
the prospects for disease modeling.  The electrical activity we defined also mimicked key 
features of in vivo motor neuron physiology thought to underpin their circuit properties.  These 




vivo similarity which makes ES-MNs a favorable tool to model the disease affecting their in vivo 
correlates. 
One of the most promising new approaches to modeling human disease is to derive iPS cells 
from patients with defined familial forms of disease, generate the relevant cell types, and identify 
disease relevant defects and phenotypes that manifest in vitro.  In order to access motor neuron 
subtypes with ALS genotypes we participated in a collaboration to generate a large collection 
iPS cells from ALS patients and unaffected controls.  We then used these cells to demonstrate 
the equivalence of iPS and ES cells for making functional motor neurons, classify their subtypes,  
and establish that they assumed coherent in vivo-like identities.  Since maturation and activity 
may be important for modeling ALS, we also demonstrated that ALS-iPS motor neurons 
achieved functional electrical activity comparable to ES-derived motor neurons. 
Finally, in order to generate thoracic and lumbar motor neuron subtypes that show differential 
susceptibility or resistance to ALS we needed to first control the rostrocaudal identity of 
differentiating ES and iPS cells to generate more caudal motor neurons.  We developed a rational 
approach, based on developmental patterning mechanisms, to recapitulate the rostrocaudal 
patterning which orchestrates motor neuron diversification in vivo.  We then used this approach 
to generate motor neuron populations with more caudal subtype identities in vitro.  The rostral 
and caudal populations we describe collectively span the length of the spinal cord from cervical 
to mid-lumbar (Fig. 5.10).  We generated cells that match the profile of several motor columns 
with potential differential responses to disease (LMC vs. MMC vs. PGC), and defined 
caudalizing conditions that might lead to specification of a key ALS-resistant motor pool (Onuf‘s 
nucleus).  These findings theoretically put several motor neuron subtypes with differential ALS 




able to resolve competing patterning signals (RA and FGF) into coherent positional identities 
characterized by mutually exclusive HOX protein expression as do motor neurons in vivo.  Since 
HOX cross-repression is a fundamental mechanism for resolving motor column and motor pool 
identity this finding suggests that stem cell derived motor neurons are following the in vivo 
developmental path leading to defined columnar and motor pool identities. 
As intended this work moves the field closer to making novel and highly specific models of ALS 
using motor neuron subtypes.  However in the light of what we now know several major 
questions remain to be resolved.  First, how can we more definitively identify specific motor 
neuron subtypes?  Second, can we develop rational means to more precisely control the subtypes 
of motor neurons?  Third, how might these subtypes actually be used to model disease? 
Definitive identification of specific motor neuron subtypes 
While we have generated motor neurons with individual expression profiles matching those in 
vivo from cervical to mid-lumbar spinal cord and including all motor columns, each of these in 
vitro motor neurons could match several in vivo subtypes.  For example, because HOXC8 
expression in vivo straddles brachial LMC and thoracic regions, and because FOXP1 is 




 ES-MNs are a 
transcriptional match for both caudal brachial LMC and thoracic PGC motor neurons (Fig. 5.10).   
Although FOXP1 expression levels, especially if coupled with anatomic position, can easily 
distinguish between these identities in vivo, expression level does not translate well as a marker 
of identity in the in vitro setting.   Indeed, like other markers tested in vitro there is a smooth 
continuum of staining intensity and no objective, unambiguous, or most importantly, verifiable 




LMC identity.  And while the high level expression of FOXP1 in all ES-MNs we scored as 
positive strongly suggests they are LMC rather than PGC, and while we can easily identify lower 






 cells consistent with PGC identity, we 
have no reliable way to positively identify disease-refractory PGC motor neurons.  In order to 
study the behavior of specific motor column or motor pool subtypes for basic or disease 
modeling purposes it will therefore be crucial to push the resolution and certainty with which we 
can identify these cells at least one step further. 
One approach to resolving this ambiguity would be to generate human reactive antibodies for 
more definitive markers.  HOXC6 vs. HOXC9, if these prove in human spinal cords to match 
chick and mouse expression patterns, would cleanly discriminate between LMC and PGC 





 expressing cells in favor of lumbar LMC or thoracic PGC.  These reagents would also 
be extremely useful for determining if the system of HOXC6, C9, and C10 cross repression 
controls limb vs. non limb motor column identities in human as it does in chick and mouse (see 
below).  In addition to resolving ambiguous identities, we noted that almost 40% of ES-MNs did 
not stain for either of the HOX markers we profiled.  It is therefore important that in addition to 
HOXC9 and HOXC10, which should account for some of these unlabeled cells, that antibodies 
be developed and validated for hindbrain and cervical motor neurons HOX1-4, and for HOX 
negative midbrain motor neurons like the disease relevant oculomotor motor neurons.  While 
HOX markers will be crucial for assigning identities to ambiguous or unlabeled cells, there will 
be no substitute for generating more direct markers of motor column identity.  Reagents to detect 
the known markers of LMC (RALDH2), HMC (ER81), and PGC (nNOS) need to be developed 




Another approach would be to identify new markers for these columnar identities.  Laser capture 
microdissection (LCM) on motor columns from new fresh-frozen human spinal cords, or even 
from the current tissue resource described above (Table 2.1) followed by microarray expression 
profiling or deep sequencing, could identify differentially expressed genes, which could then be 
validated on human samples and serve as new specific markers.  Validated markers could be 
used for immunostaining and potentially for MACS or FACS sorting on endogenous surface 
epitopes.  Indeed the LCM-microarray approach has already been used to great effect to isolate 
gene expression profiles for oculomotor and Onuf‘s nucleus motor neurons (Artem Kaplan, 
unpublished findings) which have shed light on novel mechanisms of disease resistance and 
susceptibility, and additionally provided gene expression profiles including candidate marker 
genes which could be screened against human samples in vivo and in vitro.  
If more specific columnar identities can be definitively established in vitro for ES/iPS-MNs, will 
these show functional phenotypes?  The pilot studies we performed suggesting a FOXP1 specific 
outgrowth phenotype are suggestive of an LMC-specific functional phenotype, which can be 
rationalized since LMC cells must extend longer axons to reach peripheral targets.  While this 
study was far from conclusive it is a proof of principle for searching for biologically interesting 
phenotypes for human motor neuron subtypes in our preparations in vitro.  Furthermore, the 
evidence from chick in vivo experiments (Dasen, Liu et al. 2003; Dasen, Tice et al. 2005; Jung, 
Lacombe et al. 2010)  and mouse ES-MN studies suggests that if cells express a coherent profile 
of HOX genes and column markers then functional phenotypes will follow.  When mouse ES-









)  (Soundararajan, Miles et al. 2006)  identities and xenotransplanted to chick embryos, 




We have shown that xenotransplantation of hES-MNs to chick is feasible and that axons 
extended millimeters into the periphery along endogenous spinal motor nerve paths.  These early 
pilot studies were complicated by the presence of very large quantities of cycling human neural 
progenitors, low motor neuron yields, limited trials, and a transplant technique which was a work 
in progress.  Since we can now generate robust populations of high purity FOXP1
+
 GFP labeled 
human ES-derived motor neurons, in the absence of mitotic progenitors, the question of whether 
these human motor neurons can interpret cell body settling position and axon guidance cues in 
the chick xenotransplantation assay, according to their column identity, is begging to be asked.  





human motor neurons that we describe, which contains a balanced mix of HOXA5 and HOXC8 
expressing subtypes, might be able rescue the functional phenotype of the FOXP1 knockout 
mouse (Dasen, De Camilli et al. 2008), at least in the forelimb, if transplanted in utero to the 
spinal cord of these animals. 
Other functional phenotypes can be examined for specific motor columns and motor pools.  For 
example pSMAD marks the PGC motor column and PEA3 marks the CM/LD motor pool.  Since 
these subtype markers depend on peripheral cues (BMP5, Ed Laufer, personal communication, 
and GDNF (Haase, Dessaud et al. 2002; Livet, Sigrist et al. 2002) respectively) their expression 
in hES-MNs in response to these ligands would itself constitute functional column- or pool-
specific phenotypes respectively.  Pilot experiments using BMP5 and GDNF in attempt to elicit 











 putative brachial LMC motor neurons, either in dissociated 
cultures or in EBs, failed to show any specific staining for either pSMAD or PEA3.  It remains to 




specific pool or columnar identities, or functional divergence between human and non-human 
spinal motor neurons.   
More precise control of motor neuron subtype identity and purity 
We have shown that we can inflect the distribution of motor neuron rostrocaudal identity from 
largely rostral to largely caudal, however these populations are still each composed of a very 
broad rostrocaudal range of identities.  Furthermore, while we detected lumbar (HOXC10) gene 
expression we did not have reagents to show that ES-MNs expressed this marker.  Because 
Onuf‘s nucleus motor neurons are lumbosacral HOXC10-expressing cells, we need to be able to 
generate higher purity lumbar cultures in an effort to isolate this disease refractory population. 
In order to exert more precise control over rostrocaudal identity and thereby generate more 
focused lumbar MN populations, we suggest a return to the in vivo veritas approach, the success 
of which we report in Chapter 5.  In this case, the aim would be to one, better understand the 
mechanisms of human development in vitro, and two, better mimic in vivo mechanisms in vitro.  
The first approach would be to use genetic gain and loss of function strategies to test the 
sufficiency and requirement of HOXC genes in controlling motor column subtypes as has been 
done so fruitfully in the chick.  Overexpression studies and dominant negative constructs or 
RNAi for HOXC6, HOXC9, and HOXC10 could be transiently transfected into differentiating 
human EBs and motor column identity would serve as the readout.  Understanding whether 
human motor column diversity is controlled by the interaction of these genes will be of basic 
interest but also critical to designing strategies to differentiate, for example, high purity cultures 
of limb level or thoracic motor neurons.  Additionally, recent success in transcription factor 




this type of gain of function expression approach could serve as an alternate means to program 
motor neuron columnar or other subtype identities in order to isolate and study those columnar 
subtypes for disease or basic purposes.  Applying this strategy to ES-derived cell types which 
already possess correct lineage, region, and generic cell type identity could only increase the 
chances of success and the potential relevance and in vivo similitude of resulting cells. 
The second approach would be to return again to what is known about embryonic development.  
Our approach in Chapter 5 was to crudely approximate the timing of 3 overlapping positional 
cues.  However for simplicity we made several sacrifices of fidelity to in vivo events.  First, we 
collapsed the earlier developmental phase of Wnt/FGF pan-spinal caudal patterning with the 
subsequent FGF/RA phase which subdivides spinal identity.  Second, we did not account for the 
importance of concentrations of patterning factors.  And third, we could not, in the scope of these 
studies, account for the spatio-temporally dynamic nature of rostrocaudal patterning and motor 
neurogenesis.  The pursuit of more fine grained approximations of developmental events should 
therefore include separating the early period of Wnt/FGF patterning from the subsequent 
RA/FGF patterning period.  Additionally, since FGF is thought to act in a concentration 
dependent manner, the effect of different doses of this and other morphogens should be tested 
with HOX protein expression as endpoints.  In addition, the spinal cord is patterned by FGF and 
RA over a long time period acting on different rostrocaudal regions at different times from initial 
somite stages until 16-17 somite stages when FGFs and GDFs act on the prospective lumbar 
spinal cord.  A series of experiments should therefore be done to present cues in a temporally 
dynamic and combinatorial fashion to better approximate the embryonic events leading to motor 
neuron diversification in vivo.  Finally, node-derived GDFs are necessary for the proper 
elaboration of HOXC10
+




experiment showed that GDF11, when added to FGF treatment, substantially increased HOXC10 
transcription (data not shown).  Therefore future studies should incorporate this cue at a 
developmentally relevant timepoint: that is, towards the end of the patterning period we defined 
here.   
Refining the rostro-caudal patterning of ES-MNs should provide better access to defined 
clinically relevant motor neuron subtypes.  The pools of greatest interest in the context of disease 
resistance, oculomotor and Onuf‘s, are midbrain HOX- and sacral HOX10+, respectively.  The 
oculomotor motor neurons are rostral to the region on which we have focused.  Alternative 
differentiation strategies, based on rhombomeric segmentation mechanisms in vivo should 
therefore be designed for this target population.  The targeted strategies we suggest above should 
help to refine differentiation conditions to increase the abundance of these lumbar and midbrain 
regional subtypes.  Pool specific markers can then be validated in vivo and screened in vitro so 
differentiation conditions can be optimized to support their differentiation and survival. 
Differentiation strategies alone however are unlikely to produce target cell types of interest at 
high purity.  It is more likely that the cells will acquire a positionally appropriate range of motor 
neuron subtypes as seen in our experiments and in mouse ES-MNs (Peljto, Dasen et al. 2010).  
Therefore, means to purify cells are clearly needed for subtype-specific disease modeling studies.  
One approach is the identification of endogenous surface markers that could be used for FACS 
or MACS sorting.  Alternatively appropriate marker genes and their regulatory sequences could 
be harnessed to generate transgenic fluorescent and/or surface marker reporter cell lines, which 
would allow sorting of relevant MN populations to purity.  FOXP1, LHX3, or ER81 and nNOS 
genetic elements, if validated in human, could potentially be used to purify LMC, MMC, HMC 




Towards disease phenotype assays 
How can the populations we have described, or those achieved by the approaches discussed 
above, be used to model ALS?  While in vitro disease phenotypes do not necessarily have to 
mimic the disease pathology in vivo in order to generate useful insights, the most parsimonious 
approach is to first attempt to recapitulate in vivo pathology in vitro.  Prima facie, the survival of 
motor neurons would then be the most relevant assay.  Since we have generated and cultured a 
population of almost pure FOXP1
+
 presumably limb innervating motor neurons which show high 
sensitivity to ALS in vivo, simply following the survival of ALS and control FOXP1
+
 motor 
neurons might be a useful strategy.  If these could be compared to more resistant non limb 
innervating motor neurons at the level of survival, gene expression changes, morphology, or 
biochemical endpoints this would significantly increase the power, sensitivity and relevance of 
the assays.  Hopefully, more disease refractory populations of human MNs can be generated 
using the approaches discussed above. 
The only clear in vitro phenotype identified in ALS is the motor neuron selective toxicity of ALS 
astrocytes (Di Giorgio, Carrasco et al. 2007; Nagai, Re et al. 2007; Di Giorgio, Boulting et al. 
2008), or organophosphate treated astrocytes (Marine Prisette and Derek Oakley, unpublished).  
Whether control or ALS motor neurons respond differentially to this challenge remains a matter 
of controversy (Di Giorgio, Carrasco et al. 2007; Nagai, Re et al. 2007), raising the possibility 
that the degree of motor neuron degeneration might depend on MN subtype identity.  It is 
therefore our high priority to test human ALS-motor neurons in these assays and to determine 
whether the presence of predominantly FOXP1
+
 LMC-like motor neurons in matured mitotically 
inhibited cultures might reveal ALS dependent differences in motor neuron survival.  Indeed, a 




human genetic background of the cells may reveal aspects not mimicked by mouse cells or 
animal models. 
In summary much work remains to be done to leverage the specificity of ES-and iPS-derived 
motor neuron subtypes into a useful tool for modeling ALS.  The challenge of defining 
screenable phenotypes for an adult onset disease like ALS is considerable and is outside the 
scope of these studies and discussion.   However the ability to define human motor neuron 
subtypes and control their rostrocaudal identities are first steps towards building more specific 
and targeted models of disease.  It is our hope that in the future these cell types will show 
differential responses to ALS in vitro as they do in vivo.  In turn these differential responses 
should be manipulated into screenable phenotypes which could identify therapeutic compounds 
and illuminate novel mechanisms of disease vulnerability and resistance, leading to new 















Chapter 7. Experimental Procedures 
Embryos 
Anonymized postmortem embryos from voluntary terminations were obtained with informed 
consent and in accordance with IRB guidelines within 10 minutes after clinical procedures, and 
staged by collaborating physicians using last menstrual period and or crown rump length 
ultrasound.  Post-mortem analysis of embryological features was used to confirm and adjust a 
developmental stage for embryos using Carnegie categories.  Spinal cords were dissected intact 
and then fixed. 
ES and iPS cell culture. 
ES cell lines used: RUES1(James, Noggle et al. 2006), HBG1 (plasmid HB9:GFP motor neuron 
reporter) (Di Giorgio, Carrasco et al. 2007)); HBG47 (BAC-HB9:GFP motor neuron reporter) 
(Placantonakis, Tomishima et al. 2009).  iPS and ES cell lines for used for iPS comparison study:  
see Table 4.1.  All stem cell lines grown under standard pluripotency maintenance conditions: on 
irradiated CF-1 mouse embryonic fibroblast feeder cells (0.015 M cells/cm
2
, Globalstem) on 
gelatinized (Millipore) TC plastic, fed daily with DMEM/F:12 (Invitrogen) with 20% KSR 
(Invitrogen), 110 uM BME (Sigma), L-Glutamine and NEAA (Invitrogen), and 20ng/ml bFGF 
(Invitrogen) added to medium just prior to feeding. Cultures were passaged weekly using dispase 
50 ug/ml for 20 min (Invitrogen) followed by manual trituration.  Parallel passages of ES cells 
were karyotyped at passage number subsequent to passages used for experiments and found 
normal, with the exception of abnormal karyotypes reported for iPS lines (Chapter 4).  ES and 
iPS cells and motor neurons were cryopreserved by gradual dilution (dropwise addition of 1:1 
volume, with gentle agitation, over 1-2 minutes) of single cell suspensions or colonies with ice 




chambers, stored overnight at -80ºC, then transferred to liquid nitrogen.  All cells were thawed 
by immersion in 37ºC water bath until only a few crystals remained, then immediate dropwise 
dilution with ES-medium for ES cells, or Neurobasal+B27 for ES/iPS-MNs over the course of 
~2 minutes, with gentle agitation until 10mls was reached.  Cells were pelleted at 400G for MNs, 
or settled for intact ES colonies.  ES colonies were washed 3x with ES-medium, then plated.  ES-
MNs were resuspended in 1ml fresh Neurobasal+B27, then brought to 11mls, underlaid with a 
4% BSA cushion, and spun at 400G for 5 minutes with no brake, to float cell debris. 
Standard Protocol motor neuron differentiation 
After a normal passage, washed ES or iPS cell colonies were incubated for 1 hour in ES medium 





trypsinized (0.5% trypsin with EDTA) to a single cell suspension and seeded in suspension at 0.4 
M cells/ml in human ES medium with 20 ng/ml bFGF, 10 µM ROCK inhibitor, and 300 ng/ml 
recombinant mouse Noggin (R&D) to inhibit non-neural differentiation.  Fresh ROCK inhibitor, 
FGF, and Noggin were added daily for 6 days.  EBs were pelleted at 100 G on day 4 and 
resuspended in Neural Induction Medium (NIM: DMEM/F12 plus N2 supplement(Invitrogen), 
NEAA, L-Glutamine, 2 µg/ml Heparin (Sigma)) with ROCK inhibitor, FGF, and Noggin.  EBs 
were pelleted and fed with fresh medium every other day, and ROCK inhibitor was discontinued 
after day 6.  FGF was discontinued at day10, and 1:100 dilution of Wnt3a-Lcells conditioned 
medium (ATCC, source and protocol), all-trans retinoic acid (RA, 100 nM in DMSO, Sigma), 
Ascorbic Acid (0.4 µg/ml, Sigma), db-cAMP (1 µM, Sigma), and 100 ng/ml active-mutant 
recombinant mouse SHH protein (SHH-C25II, R&D) and 100 ng/ml recombinant human FGF-4 
(R&D) were added.  On Day 18, Wnt3a conditioned medium was removed, SHH increased to 




was switch to Neural Differentiation Medium (Neurobasal with N2 and B27 (Invitrogen), L-
Glutamine, NEAA, Ascorbic Acid, db-cAMP, with 10 ng/ml each recombinant human BDNF, 
GDNF, IGF-1, and CNTF (R&D), 200 ng/ml SHH, and 100 nM RA). 
EB‘s were dissociated using trypsin on day 31, and cryopreserved using 2x freezing medium 
(Millipore, for ES cells) for future analysis.  Separate vials were thawed for electrophysiology 
and immunocytochemistry time series in Neurobasal with B27 and seeded on Poly-
ornithine/laminin coated glass coverslips, in complete day 25 Neural Differentiation medium, as 
above, with the addition of 1 µg/ml mouse laminin (Invitrogen), Beta-Mercaptoethanol (25 µM, 
Sigma), Glutamate (25 uM, Sigma), Forskolin (20 uM, Sigma) IBMX (100 µM, Fisher) at 0.25 
M cells per 35 mm coverslip or 0.046 M cells per 15 mm coverslip and ½ medium was changed 
every 4 days.  For labeling of dividing cells and inhibition of cell division, ClickIt EdU (0.5 µM, 
Invitrogen) was included in culture medium for morphometry studies after seeding, and 
refreshed with media changes.  EdU was processed for immunocytochemistry following 
manufacturer‘s instructions (Invitrogen) 
Accelerated Protocol MN differentiations 
Performed according to Standard Protocol with the following modifications.  ES/iPS colonies 
were not trypsinized at passage, rather trituration with a p1000 tip, 8 passes until colony 
fragments were just below visible size. Then seeded by eye at density comparable to single cell 
motor neuron seeding density (0.4 M cells/ml) in the same medium described above with all 
supplements except noggin, instead LDN-193189, (0.2 µM) and SB-431542 (10 µM) were used.  
FGF and ROCK inhibitor were refreshed at day 2 and more medium was added if medium was 




all previous supplements. At day 4 Rock inhibitor was not added nor subsequently. At day 5 
patterning factors were added (Wnt3a-CM 1:10, RA, +/-FGF-4), this was the last day of LDN-
193189/SB-431542 and FGF2 was not added, and 200ng/ml SHH protein was added.  Medium 
was changed every other day and patterning treatments were last added on day 11.  BDNF was 
added at day 13, and on day 15 culture were switched to NDM with all supplements as described 
above. EBs were dissociated at day 21 and fixed for acute analysis at day 23, or cultured longer 
for maturational analyses. 
Trituration 





-free plus 25mM Glucose, 0.1% dialyzed BSA, MgCl
2
 2mM, EDTA 2mM, 2.5% FBS, 
and N2 and B27 supplements for day 31 or day 23 EB dissociation) with a p1000 tip (12 passes, 
at 1 Hz for EBs, ~6 passes for ES colonies), plus freshly added DNAse (1:50-1:500 from 
100mg/ml stock in 0.1%dialyzed BSA in 1xPBS stock). 
4% dialyzed BSA 
Fraction V BSA was dissolved at 4% weight/volume in  was dissolved in and dialyzed against 
L15 with phenol red, using Pierce Slide-a-lyzer 10,000MW cutoff large volume dialysis 
cassettes, over 4-5 days with stirring at 4 degrees, with daily medium changes, until solution was 
claret colored and pH~7.5, filtered, then frozen for future use. 
Fetal spinal cord astrocytes were purchased from ScienCel Research Laboratories and cultured 
with manufacturers medium and supplements on gelatin, passaged every 5 days at confluence 
and cryopreserved as described above.  For motor neuron co-cultures they were seeded at 0.02 M 




pressure 20PSI using a large 100 µM nozzle under single cell mode with purity mask, at either 
the Herbert Irving Cancer Center Flow Cytometry Facility by Kristi Gordon, or New York Stem 
Cell Foundation by David J Kahler. 
Fixation Cryosectioning and Immunocytochemistry 
Spinal Cords and EBs 
Spinal cords were fixed for 1.25 hrs on ice (for GW7 ), or 2.5hrs at room temperature (for one  
GW8 sample), and 1 hour for EBs in 4% PFA in 1x PBS, washed several times with PBS then 
incubated overnight at 4°C.  Cords were then photographed and divided into sections <6 mm to 
facilitate sectioning. 4%PFA was prepared by dilution of sealed ampules of 32% liquid PFA 
(Electron Microscopy Sciences) with filtered water and 10x PBS, to  8%PFA, 2x PBS stock. 8% 
PFA was stored light protected at 4°C for one week, and dilution to 4% was performed 
immediately before use. 
 Cords and EBs were cyroprotected by equilibration with 30% sucrose, embedded in OCT. and 
serially sectioned at 12µM on a Hacker cryostat. Slides were stored at -80ºC for subsequent 
analysis. 
Fixation of motor neuron cultures 
Culture medium was removed from coverslips and multiwell chambers, replaced with cold 4% 
PFA and incubated for 30 minutes on ice (or 4 ºC), washed 3x in PBS then handled as per Post-





Motor neurons cultures were seeded on Poly-lysine/laminin pre-coated 8-well glass 
chamberslides (Invitrogen) or on German glass (Fisher) coverslips coated with 1mg/ml poly-
ornithine in 0.1M boric acid coated, washed 3x with water, then coated overnight with laminin 
10ug/ml in L-15 with bicarbonate. 
Post-fixation and Immunostaining 
All samples were permeabilized for 15 minutes at room temperature (RT) with Wash 
(PBS+0.1%Triton-X ) + 100mM Glycine, incubated with Block (Wash+10% normal donkey 
serum +0.1%NaAzide for 0.5hr at room temperature, then with primary antibody (diluted in 
Block) for 2 hours at RT, or overnight at 4°C, washed, incubated with  secondary antibodies for 
one hour at RT, washed, counterstained with DAPI and coverslipped using Fluoromount-G.  
Primary antibodies are described in Table 7.1.  All secondary antibodies used were highly cross 
adsorbed Donkey anti-species whole IgG coupled to DyLight 488, 549, or 647 (Jackson 
ImmunoResearch). Samples were counterstained with DAPI (Invitrogen) 
RNA, cDNA, qPCR 
Dissociated day 31 motor neurons, or various timepoints of EBs, or dispase passaged ES 
colonies were lysed in Trizol or Trizol LS (Invitrogen), homogenized and sheared with a 21 
gauge needle, and RNA was purified using RNEasy columns (Qiagen) following manufacturers‘ 
instructions.  Superscript III RT was used to prepare cDNA following manufacturer‘s 
instructions (Invitrogen).  qPCR primers were designed to produce 50-100 bp intron-spanning 
amplicons using Primer3 software, or were used from previous publications.  All thermal cycling 
reactions used the following parameters: 10min, 95; (30sec, 95;1min, 55; 45sec, 72)x45 




2x Master Mix following manufacturer‘s instructions on a MX300 Light Cycler (Stratagene). 
PCR products were checked for single melting curve peaks; where ambiguous, reaction products 
were separated on an agarose gel, evaluated for appropriate size, and sequenced using 
amplification primers, confirming amplification of target sequence.  
Southern Blot 
Genomic DNA was prepared using Qiagen genomic DNA kit, followed by separation on agarose 
gel, denaturation, and neutral capillary transfer.  Easy Hyb DIG labeled probes were synthesized 
and detected as described in (Boulting, Kiskinis et al. 2011). 
Microscopy 
Images were acquired using a Zeiss AxioObserver with14-bit Coolsnap HQ2 grayscale camera at 
10x, 20x, or 40x.  For quantitative experiments, 8-12 randomly placed fields were acquired 
manually per sample at 10x or 20x or by using an automated stage with fixed positions/well and 
autofocus on DAPI. Representative photos were acquired at 4x, 10x, 20x, or 40x, using Apotome 
structured illumination for optical sectioning where indicated.  Image intensity look up tables 
were adjusted to accentuate salient signal to noise details and some images were brightened in 
Photoshop for better signal visibility in print. 
Image analysis 
14bit grayscale images were analyzed in Metamorph (Molecular Devices) using 
Multiwavelength Cell Scoring or Neurite Outgrowth modules.  Threshold fluorescent intensities 
were determined and adjusted for each staining (>~2000-16000 grey levels over local 




field for day 33 MN phenotype analysis.  Coexpression was automatically scored based on above 
threshold staining intensities for DAPI and up to 3 other stains simultaneously. 
Statistical Analyses 
Statistical analyses were performed using SigmaPlot 11, or Excel as indicated in text and figure 
legends.  Paired 2-tailed T-tests were used where two conditions were compared.  ANOVA was 
used for comparisons of more than 2 groups, or ANOVA on ranks where unequal variance was 
found with appropriate post hoc comparisons as indicated in text.  Population histograms were 
constructed in Excel or Sigmaplot. 
 
Figures were prepared in Adobe InDesign or Powerpoint. 
 
Experiments reported and not performed by myself: 
Electrophysiological studies of GFP human ES-MNs (Chapter 2) were performed by Tomonori 
Takazawa (Amy B. MacDermott laboratory) following standard practices for patch clamp 
recording. 
See methods from (Dimos, Rodolfa et al. 2008; Bock, Kiskinis et al. 2011; Boulting, Kiskinis et 
al. 2011) for experiments not performed by myself, as described in general Statement of 












Table 7.2 qPCR primers.  Primers for qPCR were designed in house for qPCR with the 
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